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Abstract	
 
Chronic kidney disease (CKD) is a common disease of elderly cats characterized by a 
progressive course and a high mortality rate. The development and the progression of 
CKD depend on the presence of complications such as proteinuria and hypertension. 
Hence, a correct staging of the disease based to these latter pathologic states together 
with serum creatinine, as suggested by the International Renal Interest Society (IRIS) 
guidelines, is recommended to properly treat affected cats. In this regard, hypertension is 
often difficult to confirm given the high frequency of white-coat hypertension in this specie. 
Moreover, although decisive progresses have been achieved in the last years, an early 
diagnosis of CKD or of hypertension and proteinuria associated with CKD is still 
challenging in cats. Early identification of ongoing kidney injury may allow veterinarians to 
prevent worsening of the disease and ultimately to improve the quality of life of affected 
feline patients.  
The first part of this thesis was focused on a preliminary evaluation of preanalytical and 
analytical variability of parameters used in IRIS staging of CKD: preanalytical and 
analytical variability of urinary protein-to-creatinine (UPC) ratio (study 1); the effect of 
hematuria and pyuria on UPC (study 2); and the physiologic concentration of the novel 
biomarker of glomerular filtration rate symmetric dimethylarginine (SDMA) in Holy Birman 
cats (study 3). 
The second main part of this thesis was aimed to assess how biomarkers such as serum 
big endothelin-1 (big-ET1), homocysteine (Hcy), aldosterone and urinary big-ET1, alpha-1 
microglobulin (A1MG) and the presence of tubular proteins in urine (evaluated with sodium 
dodecyl sulfate-agarose gel electrophoresis, SDS-AGE) may allow an early diagnosis of 
CKD, may identify cats at risk of severe worsening of the disease, or may be a predictor of 
hypertension (study 4). To this aim, privately owned cats (i.e. clinically healthy cats at risk 
to develop CKD and cats affected with CKD) were prospectively enrolled and sampled 
over time. 
The results of study 1 demonstrated that proteinuria was stable up to to 6 hours at room 
temperature, 1 week at refrigeration temperature, four freeze-thaw cycles and 4 weeks at 
−20°C, whereas the use of different analytical methods resulted in inaccuracy and 
suboptimal concordance in classifying samples according to IRIS substaging, that in turn 
can potentially affect clinical decisions, make questionable the comparison of UPC results 
between different laboratories, and have significant impact in substaging cats affected by 
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CKD. Study 2 showed that hematuria could affect proteinuria, suggesting that diagnosis 
and staging of renal proteinuria should be avoided or interpreted with caution in samples 
with high hematuria. Study 3 highlighted that SDMA may be a better marker of CKD than 
creatinine in Birman cats and the analysis of both creatinine and SDMA could help prevent 
errors in diagnosing and staging CKD in Birman cats.  
In study 4, different results were found with the different biomarkers. Big-ET1 did not give 
satisfying results in serum, whereas in urine the ELISA method yielded satisfying 
validation results, supporting its introduction in this specie. Urinary big-ET1 was associated 
with the severity of CKD and proteinuria, revealing that it could be a promising aid in 
nephropatic cats and could shed light on the pathogenesis of tubulo-interstitial and 
glomerular damage in cats with CKD. The method to measure Hcy can be considered 
reliable in cats according to the validation tests. Serum Hcy increased progressively with 
the progressive increase in severity of CKD and the detection of high Hcy in some non-
azotemic patients with CKD could add this new marker to those currently available for the 
identification and staging of the kidney disease of the cat. Conversely, no direct 
relationship was found between Hcy and hypertension. Aldosterone was not associated 
with severity of CKD, proteinuria and SBP. Therefore, neither Hcy nor aldosterone can be 
considered an indicator of hypertension in cats affected with CKD. The ELISA kit used for 
A1MG measurement failed all the validation tests and results were considered 
unacceptable; further studies are therefore needed to investigate the presence of A1MG in 
cats with CKD and tubular damage. SDS-AGE showed the consistent presence of bands 
with high molecular weight in healthy cats, suggesting that this pattern is normal in this 
specie and has to be taken into account while evaluating proteinuria in cats; tubular bands 
were frequent in patients with CKD at any stage, confirming the predominant tubule-
interstitial damage of this disease in cats and suggesting that SDS-AGE can be 
considered a valuable aid in diagnostic approach to feline CKD. 
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Abstract	(Italian	version)	
 
La patologia renale cronica (CKD) è una malattia comune nei gatti anziani, caratterizzata 
da un decorso progressivo e da un elevato tasso di mortalità. Lo sviluppo e la 
progressione della CKD dipendono dalla presenza di fattori complicanti, quali proteinuria e 
ipertensione. Pertanto, per una corretta gestione terapeutica, è necessario stadiare la 
patologia in base a questi due stati patologici, contestualmente ai livelli di creatinina 
sierica, come raccomandato dalle linee guida della International Renal Interest Society 
(IRIS). A questo proposito, nel gatto l'ipertensione è spesso difficile da confermare data 
l'elevata frequenza dell'ipertensione da “camice bianco”.  
Inoltre, anche se negli ultimi anni sono stati conseguiti importanti progressi nell’approccio 
diagnostico della CKD felina, la diagnosi precoce di CKD o di ipertensione e proteinuria 
associate alla CKD è ancora problematica in questa specie. L'identificazione precoce del 
danno renale cronico attivo potrebbe consentire al veterinario di attuare gli accorgimenti 
terapeutici necessari a rallentare la progressione della malattia e, in ultima analisi, 
migliorare la qualità della vita dei pazienti nefropatici felini. 
La prima parte di questa tesi si è focalizzata sulla valutazione preliminare della variabilità 
preanalitica e analitica di alcuni parametri utilizzati nella stadiazione del gatto nefropatico:  
la variabilità preanalitica e analitica del rapporto proteine urinarie su creatinina urinaria 
(UPC) (studio 1); l'effetto dell’ematuria e della piuria sulla UPC (studio 2); e la 
concentrazione fisiologica del nuovo biomarker di filtrazione glomerulare dimetilarginina 
simmetrica (SDMA) nei gatti Holy Birman (studio 3). 
La seconda parte di questa tesi si è orientata sulla valutazione dell’utilità di biomarker 
sierici e urinari nella diagnosi precoce di CKD, nella identificazione dei gatti a rischio di 
peggioramento della malattia, e nell’identificazione dell’ipertensione (studio 4). In 
particolare sono stati presi in esame big endothelin-1 (big-ET1), omocisteina (Hcy) e 
aldosterone nel siero, e big-ET1, alfa-1 microglobulina (A1MG) e bande di proteine 
tubulari (rilevate con sodium dodecyl sulfate-agarose gel electrophoresis ,SDS-AGE) nelle 
urine. A tal fine, gatti clinicamente sani a rischio di sviluppare CKD e gatti affetti da CKD 
sono stati inseriti nello studio prospettivamente e campionati nel tempo. 
I risultati dello studio 1 hanno dimostrato che la proteinuria è stabile fino a 6 ore a 
temperatura ambiente, fino 1 settimana a temperature di refrigerazione, dopo 4 cicli di 
congelamento-disgelo e fino 4 settimane a -20° C, mentre l'utilizzo di diversi metodi 
analitici ha evidenziato la mancata accuratezza e la concordanza non ottimale nella 
classificazione dei pazienti secondo la stadiazione IRIS, suggerendo come queste 
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variabilità possano potenzialmente influenzare le decisioni cliniche, rendere discutibile il 
confronto dei risultati di UPC tra diversi laboratori, e incidere in modo significativo sulla 
suddivisione in stadi dei gatti colpiti da CKD. Lo studio 2 ha mostrato che l'ematuria 
potrebbe influenzare la proteinuria, indicando che la diagnosi e la stadiazione della 
proteinuria renale dovrebbero essere evitati o interpretati con cautela nei campioni con 
ematuria elevata. Lo studio 3 ha evidenziato che SDMA potrebbe essere un biomarker di 
CKD migliore rispetto alla creatinina nei gatti di Birmania e l'analisi contemporanea di 
creatinina e SDMA potrebbe aiutare a prevenire gli errori nella diagnosi e nella stadiazione 
di CKD nei gatti di Birmania. 
Nello studio 4, la big-ET1 non ha dato risultati soddisfacenti nel siero, mentre nell'urina 
con il metodo ELISA sono stati ottenuti buoni risultati di validazione, supportando la sua 
applicazione in questa specie animale. Inoltre, la big-ET1 urinaria è risultata essere 
associata alla gravità della CKD e della proteinuria, rivelando una possibile utilità in ambito 
diagnostico in gatti nefropatici e gettando luce sulla patogenesi della nefropatia tubulo-
interstiziali e dei danno glomerulare nei gatti con CKD. Considerati i buoni risultati della 
validazione, anche il metodo per la misurazione della Hcy potrebbe essere considerato 
affidabile nei gatti. Dato l’incremento progressivo della concentrazione di Hcy con 
l’aggravarsi della nefropatia e la presenza di alcuni pazienti non iperazotemici con Hcy 
elevata evidenziati nel nostro studio, questo nuovo biomarker potrebbe aggiungersi a 
quelli attualmente disponibili per l'identificazione e la stadiazione della malattia renale. 
Nonostante questi buoni risultati, la relazione tra la Hcy e ipertensione è risultata assente.  
L’aldosterone non è risultato associato alla gravità di CKD, proteinuria e ipertensione. 
Pertanto, l'aldosterone sierico, come la Hcy sierica, non sembrano essere utili nell’indicare 
presenza di ipertensione nei gatti colpiti da CKD. Il kit ELISA utilizzato per la 
quantificazione urinaria di A1MG ha fallito tutti i test di validazione e, pertanto, i risultati 
ottenuti sono stati considerati inattendibili, suggerendo ulteriori studi per esaminare la 
presenza di A1MG nei gatti con CKD e danno tubulare. La SDS-AGE ha mostrato la 
presenza di bande ad alto peso molecolare nei gatti sani, indicando che la loro presenza 
sia normale in questa specie ed esortando a tenere in considerazione questo pattern nella 
valutazione della proteinuria nei gatti; inoltre, le bande tubulari sono risultate frequenti in 
pazienti nefropatici a tutti gli stadi, confermando il prevalente danno tubulo-interstiziale 
nella CKD felina e suggerendo che l’SDS-AGE può essere considerata un valido aiuto 
nell’approccio diagnostico di questa patologia. 
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Introduction	
 
Chronic kidney disease (CKD) is usually defined as structural and/or functional 
abnormalities of one or both kidneys that have been present for a period of 2-3 months or 
longer (Reynolds and Lefebvre, 2013).  
CKD is common in cats and the prevalence increases with age. Early studies suggested 
that up to 15% to 30% of cats older than 15 years of age show evidence of CKD 
(Reynolds and Lefebvre, 2013) but more recent studies suggest that the prevalence of 
CKD is much higher, estimating that 80% of cats greater than 15 years old may have renal 
impairment (Jepson, 2016). 
Irrespective of the different triggering causes, CKD is characterized by the progressive and 
irreversible loss of nephrons. The rate of progression could be variable and depends on 
many factors but it is generally slow and not common (Chakrabarti et al., 2012). 
The current view of the pathogenesis of CKD is that one (or more) initiation factor(s) 
precedes a phase in which progression factors perpetuate the kidney injury (Brown et al., 
2016).  
Among the initiation factors, the well-defined diseases that can trigger CKD are: 
• Amyloidosis  
• Renal dysplasia 
• Polycystic kidney disease 
• Pyelonephritis (bacterial) 
• Nephrolithiasis 
• Chronic viral infections: feline immunodeficiency virus (FIV), feline leukemia virus 
(FeLV), feline infection peritonitis (FIP), feline morbillivirus (FmoPV)  
• Immune complex glomerulonephritis  
• Acute kidney injury 
• Chronic feeding of unbalanced diets 
• Lymphoma 
 
These diseases could initiate CKD by injuring feline kidney in different ways, some 
localizing to a particular region of the kidney and some affecting the whole nephron and 
kidney, and the specific mechanisms are discussed elsewhere (*).xx 
* Glick et al., 1978; Boyce et al., 1984; DiBartola et al., 1987; DiBartola et al., 1993; Lyons et al., 2004; Kyles et al., 2005; Aresu et al., 
2009; Baxter et al., 2012; Poli et al., 2012; Pedersen, 2014, Sieg et al., 2015 
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When one of these diseases is diagnosed concurrently to the chronic renal impairment, it 
could be considered the cause of CKD. Conversely to human and dogs, in the majority of 
cats with CKD a specific primary disease could not be identified and the nephropathy is 
therefore termed idiopathic. In these cases, it seems likely that a combination of intrinsic 
factors, repeated acute insults and environmental factors act synergistically as initiating 
factors. The recognized and suspected initiation factors are: ageing, comorbidities, AKI, 
vaccinations, stress and chronic hypoxia (Brown et al., 2016). There are no evidences that 
these factors alone could initiate CKD, therefore it is currently accepted that only the 
combination of two or more of these factors and their persistent and repeated action over 
time during the life explain the development of the form of CKD that is recognized as 
idiopathic. These factors are discussed in an excellent recent review (Brown et al. 2016). 
 
The main pathological feature of feline CKD, especially idiopathic CKD, is the chronic 
tubule-interstitial inflammation. Inflammatory infiltrate is mainly represented by 
lymphocytes that are present at any stage of the disease (McLeland et al., 2015). 
Interstitial fibrosis and scarring occur as consequence of chronic cellular injuries and 
inflammatory stimuli and it’s considered an irreversible damage of the kidney. Collagen 
deposition correlates with the degree of CKD and is the lesion that best correlated with 
severity of azotemia (Chakrabarti et al., 2012).  
 
A plethora of other pathologic alteration affecting other part of the kidney and the nephron 
could occur during the progression of disease: tubular degeneration comes together to 
interstitial inflammation and fibrosis, and is more severe in later stages; also 
glomerulosclerosis progressively worsened with stage progression but it’s deemed 
secondary to adaptive changes due to the loss of nephrons; vascular alterations such as 
hyperplastic arteriolosclerosis, fibrointimal hyperplasia, or other lesions could be present 
(McLeland et al., 2015). 
 
Beyond the different mechanisms that are able to trigger the kidney injury, the progressive 
loss of nephrons lead to numerous sequelae that self-perpetuate the chronic kidney injury 
and/or are able to cause other systemic injuries by its self. The progression factors are: 
proteinuria, hypertension (systemic and glomerular), renin-angiotension-aldosterone 
system activation, phosphorous intake, sodium intake, anemia and tubular hypoxia.  
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Azotemia, electrolyte abnormalities, acid-base disorders (metabolic acidosis), dehydration, 
loss of muscle mass are other common  
Most of them are also prognostic factors and they need to be investigated and specific 
treatment instituted in order to slow the progression of CKD. Azotemia, proteinuria and 
hypertension are discussed below. 
 
Azotemia. The progressive structural and functional loss of the nephrons leads to a global 
reduction of the glomerular filtration rate (GFR). The retention of endogenous substances 
that otherwise are filtered and excreted by the kidney is the direct effect of the decreased 
GFR. Among these substances (mainly between 500 and 12.000 KDa) are present amino 
acids, nitrogenous substances, cytokines and hormones and other molecules that are the 
final metabolites of various metabolic pathways.  
Their increasing concentration leads to direct or indirect toxic effect on different cells types 
and organs and causes the clinical appearance of a group of signs defined “uremic 
syndrome”. It is generally accepted that clinical signs associated to azotemia occur when 
at least 75% of functional mass is lost (Brown et al., 1997). However, a recent study found 
that some mildly azotemic cats had only 25-50% of altered parenchyma, pointing out that 
even a mild degree of lesions (less than 75%) could have functional significance 
(McLeland et al., 2015). 
 
Proteinuria. In CKD, proteins could be classically lost in urine by the increased amount of 
filtered protein by the injured glomerulus and/or by the impairment reabsorption from 
tubular cells.  
Proteinuria can contribute directly to chronic kidney injury mainly in case of primary 
glomerular injury. In this scenario, tubular cells are overloaded by the proteins and as a 
consequence, can degenerate, degrade for apoptosis and secrete inflammatory cytokines, 
contributing to and accelerating chronic interstitial inflammation (D'amico and Bazzi, 2003; 
Chakrabarti, 2013). Primary glomerular injury is not common in cats and is reported to be 
the leading cause of CKD in certain kidney disease such as familiar amyloidosis (Boyce et 
al., 1984) and FIV infection, in which both glomerular amyloidosis and presumed immune 
complex glomerulonephritis have been described (Poli et al., 2012). 
Accordingly, cats with immunodeficiency virus (FIV) had higher proteinuria compared to 
non–infected cats in two studies (Baxter et al., 2012; Taffin et al., 2017) and moderate to 
severe proteinuria was found in cats with familiar amyloidosis (White et al., 2008; 
 12 
Paltrinieri et al., 2015). Primary hypertension is considered an other cause of increase 
filtration of proteins by glomerulus in human (Obialo et al., 2002) whereas in cats it is 
unclear whether CKD-associated hypertension contribute to the magnitude of proteinuria 
or not, since discordant results were found: an earlier study showed that cats with 
hypertension were more proteinuric than normotensive cats with equivalent stage of CKD 
(Syme et al., 2006) whereas a recent study found no influence of hypertension on 
proteinuria in cats (Bijsmans et al., 2017). 
The majority of cats with chronic kidney disease are affected by the idiopathic form, and 
proteinuria is mild and more common at late stages in this case (Syme, 2006), suggesting 
that it is mainly a consequence rather than a cause of kidney injury. (Chakrabarti et al., 
2013) Accordingly, it was associated with increased severity of tubular degeneration, 
inflammation and fibrosis in a study (McLeland et al., 2015).  
Nevertheless persistent proteinuria is a sign of kidney damage and also a strong indicator 
for progression (Chakrabarti et al., 2012; Lees 2005; Syme 2009; Jepson 2009) and 
mortality (Syme et al., 2006; King et al., 2007) of CKD. However, although both ACEi and 
ARB significantly reduce the magnitude of proteinuria, the benefit in terms of slowing 
progression of CKD and improve survival has yet to be demonstrated (King et al., 2006; 
Sent et al., 2015). 
 
Hypertension. Systemic hypertension (HT) is considered to be both a cause and a 
consequence of CKD (Syme, 2011). HT is an important potential complicating factor of 
CKD (Syme, 2011) and is common in cats with this disease. Depending on the population 
studied and the cut-off used to define HT, prevalence could range from 19.4% (Syme et 
al., 2002a) until 61% (Kobayashi et al., 1990). Also, CKD is the most common disease 
associated with HT and cats (Brown et al., 2007) since approximately 3/4 of HT patients 
were reported to be also azotemic in a study (Taylor et al., 2017).  
The persistence of high SBP can lead to severe clinical consequences due to target organ 
damage (TOD), affecting the eyes, heart, brain and the kidney itself (Sansom et al., 2004) 
(Taylor et al., 2017). On the kidney, HT can lead to glomerular lesions such as 
hyperplastic arteriolosclerosis, fibrointimal hyperplasia, or other vascular lesions 
(Chakrabarti et al., 2013) but, in contrast to people, in cats are generally mild. On this 
regard, hyperplastic arteriolosclerosis, a feature of systemic hypertension thought to be 
due to microvascular injury, was found in 48% of normotensive cats with CKD. This may 
indicate that systemic blood pressure does not adequately represent local renal 
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hemodynamics in cats (McLeland et al., 2015). Accordingly, the evidence for systemic 
hypertension contributing to the development or progression of feline CKD is unclear since 
SBP was not identified as a risk factor (Syme et al., 2006; Jepson et al., 2009; Chakrabarti 
et al, 2012). However, in these studies all the cats were treated with antihypertensive 
drugs and it could be considered a confounding factor.  
The mechanisms beyond the regulation of SBP HT is very complex and multiple 
molecules and receptors are simultaneously involved (Syme, 2011). Therefore, in cats as 
in other species, no single cause is recognized to be predominant in the pathogenesis of 
CKD-associated HT (Syme, 2011).  
The renin-angiotensin-aldosterone system (RAAS) is particularly important as a modulator 
of blood pressure and fluid balance. Since the kidney contains all the necessary 
components for local RAAS activation, systemic activation of this mechanism could not 
reflect the renal RAAS.  
Angiotensin II and aldosterone are the two final effectors of this system. It is generally 
accepted that during the CKD progression, the loss of nephrons leads to increase renin 
production by the underperfused nephrons, which in turn cause increase angiotensin II 
and aldosterone synthesis (hyperaldosteronism) and HT (Syme, 2011). 
Nephropathic cats with hypertension actually tend to have higher aldosterone 
concentration compared to normotensive cats with CKD (Syme et al., 2002b) and healthy 
cats (Jensen et al., 1997). However, it was shown that renin concentration was normal or 
also low during CKD (Jensen et al., 1997) and (Hogan et al., 1999). This result was in 
accordance with another study in which was showed that, in cats with CKD and HT, 
aldosterone and renin concentrations did not change in response to ACEi (Syme et al., 
2002b). Moreover, also SBP was not affected after ACEi and ARB administration (Syme et 
al., 2002b; Sent et al., 2015). 
These results highlights that the activation of the RAAS seems to be less important in the 
development CKD-associated hyperaldosteronism and HT in this specie. The increase of 
aldosterone secretion is probably independent (or only partly dependent) by the renin 
secretion and increased angiotensin II synthesis by injured nephrons.  
Interestingly, in a study was shown that some cats presented with signs of hypertension 
had extensive micronodular hyperplasia of the zona glomerulosa at the histologic 
examination of their adrenal glands (Javadi et al., 2005). However, no different 
adrenocortical histopathologic findings were found between hypertensive and 
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normotensive cats with CKD, although the majority of cats of both groups had 
adrenocortical hyperplasia (Keele et al., 2009). 
Salt intake was show to affect hypertension in human but it seems to have minor effect on 
hypertension in cats with or without CKD (Luckschander et al., 2004; Buranakarl et al., 
2004; Kirk et al., 2006) although in end stage kidney disease the capacity of the kidney to 
excrete sodium may decrease.  
 
Diagnosis	and	staging	of	feline	CKD	
 
The diagnostic process in patients suspected to have CKD requires the interpretation and 
integration of multiple tests, because most of the clinical and laboratory alterations 
associated with CKD are also typical of many other systemic diseases. Moreover, since 
the kidney have different functions and could be affected in different part in naturally 
occurring disease, different pattern of abnormality could occur and a wide panel of test are 
almost always necessary. 
Given the high compensatory capacity of the kidney, clinical signs typically occur when 
most of the kidney is injured. They have been the subject of a recent review (Bartges, 
2012) and most common are anorexia, polyuria, polydipsia, weight loss, lethargy, halitosis, 
vomit and diarrhea.  
Collection and analysis of blood and urinary samples are mandatory to confirm the 
diagnosis of CKD. The primary goals of the laboratory tests are to evaluate the different 
renal functions and detect which of them are compromised. The maintenance of the GFR, 
the capacity to concentrate or dilute the urine and the retention of molecules such as 
proteins by the glomerulus are the main altered functions during CKD progression. GFR 
can be measured by injection of exogenous substances such as (inulin, creatinine and 
iohexol) to detect the rate of reduction in blood, or indirectly estimated by the 
measurement of endogenous substances excreted only by glomerular filtration such as 
creatinine and symmetric dimethylarginine (SDMA) (Yerramilli et al., 2016). The capacity 
to concentrate or dilute the urine is commonly estimated by the evaluation of urine specific 
gravity (USG) by the means of a refractometer and in cats values lower than 1035 are 
suggestive of reduction of concentration ability (Reppas and Foster, 2016).  
A second goal is to evaluate other complications that could be present at any stage and 
need specific treatment. The most common are hyperphosphatemia, anemia, metabolic 
acidosis, dehydration, hypokalemia and hypo/hypercalcemia. As already described above, 
most of them are also prognostic factors (Bartges, 2012). Excess of protein in urine can be 
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screened with rapid tests (such as dipstick) and more accurately quantified with wet 
biochemistry, and suggests glomerular impairment or tubular reabsorption defects 
(Littman, 2011; Vaden and Elliot, 2016). 
A third but not less important goal to perform blood and urine collection and analysis is to 
stage the disease, in order to properly treat a patient and have an estimation of the 
prognosis. In the last decade the International Interest Society (IRIS) has published and 
updated worldwide accepted guidelines to stage feline patients affected by CKD (Elliott 
and Watson, 2016). The staging has the aim to aid clinicians to facilitate both choice of 
appropriate treatment and monitoring of the patient. This staging system is based primarily 
on serum creatinine and, after an update in 2015, on serum SDMA. Moreover, it is also 
based on proteinuria and SBP as sub-staging. Below these parameter are described and 
discussed. 
 
Measurement of GFR 
 
CREATININE. Creatinine is the product of the nonenzymatic dehydration from creatine 
and the conversion occurs almost at constant rate (Braun et al., 2003). After the release in 
blood, creatinine is freely filtered by the glomerulus and no secretion in renal proximal 
tubules is demonstrated in cats. Therefore, measurement of endogenous serum or plasma 
creatinine concentration allows an indirect extimation of GFR (Yerramilli et al., 2016). 
Is generally accepted that the increase of creatinine over the reference interval of 
normality occurs when at least 75% of functional mass is lost (Brown et al., 1997) 
However, a recent study found that some cats with mild azotemia had only 25-50% of 
altered parenchyma, pointing out that even a mild degree of lesions could have functional 
significance (McLeland et al., 2015). 
Beyond the kidney function, muscle mass is an important endogenous determinant of the 
serum creatinine concentration. On this regard, at late stages of CKD sarcopenia could 
occur. Hence serum creatinine could loss sensitivity for disease progression as the CKD 
advance. Moreover, some feline breeds, such as Siberian, Holy Birman cats and, to a 
lesser extent, Siamese and Somali cats, have a physiologically high concentration of 
serum creatinine (and urea) compared with the feline general population (Reynolds et al., 
2010; Paltrinieri et al., 2014). Therefore, the presence of renal disease risks to be 
overestimated in these breeds.  
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IRIS staging based on creatinine requires at least two samples collected in two occasions 
in the stable patient and is shown in Table 1. 
 
Table 1 IRIS staging based on serum creatinine 
Stage Blood creatinine 
mg/dl 
Comments 
At risk <1.6 
History suggests the animal is at increased risk of developing 
CKD in the future because of a number of factors (such as, 
exposure to nephrotoxic drugs, breed, high prevalence of 
infectious disease in the area, or old age). 
1 <1.6 
Nonazotemic. Some other renal abnormality present (such as, 
inadequate urinary concentrating ability without identifiable 
nonrenal cause, abnormal renal palpation or renal imaging 
findings, proteinuria of renal origin, abnormal renal biopsy results, 
increasing blood creatinine concentrations in samples collected 
serially). 
2 1.6-2.8 
Mild renal azotemia (lower end of the range lies within reference 
ranges for many laboratories, but the insensitivity of creatinine 
concentration as a screening test means that animals with 
creatinine values close to the upper reference limit often have 
excretory failure). Clinical signs usually mild or absent. 
3 2.8-5 Moderate renal azotemia. Many extrarenal clinical signs may be 
present. 
4 >5 Increasing risk of systemic clinical signs and uraemic crises 
 
 
SDMA. SDMA is the methylated form of the amino acid arginine, which is released into the 
circulation during the normal catabolism of body proteins. (Fleck et al., 2003) Similarly to 
creatinine, SDMA is excreted primarily by the kidneys (>90%) and therefore its serum 
concentration increases when the glomerular filtration rate decreases, as it occurs during 
CKD in cats. (Jepson et al., 2008) SDMA is not affected by body mass in dogs (Hall et al., 
2015) and it is likely that this occur also in cats. 
The increase of CKD in patients affected by CKD seems to be earlier than the increase of 
creatinine in cats (Hall et al., 2014a). Therefore, SDMA has been proposed as a novel 
marker for the early diagnosis of CKD and it is recently added to the IRIS Staging 
Guidelines for CKD (Elliot and Watson, 2016). As for creatinine, re-evaluation within two 
weeks in stable patients is necessary in case of abnormal results. 
IRIS guideline suggests to measure SDMA together to creatinine and, according to results, 
the refining of the staging or treatment recommendations is carried out, as shown in Table 
2. 
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Table 2 IRIS staging refinement recommendation based on blood SDMA 
Creatinine Blood SDMA Recommendation 
 
<1.4 mg/dL (dogs) or  
<1.6 mg/dl (cats) 
 
Persistent SDMA 
>14 µg/dl 
Stage the dog or cat  
as IRIS CKD Stage 1 
IRIS CKD Stage 2 
+ low BCS 
 
SDMA ≥25 µg/dl 
 
Treatment recommendations listed under 
IRIS CKD Stage 3 for this patient. 
IRIS CKD Stage 3 
+ low BCS 
 
SDMA ≥45 µg/dl 
 
Treatment recommendations listed under 
IRIS CKD Stage 4 for this patient. 
BCS: body condition score 
 
 
Measurement of Proteinuria 
 
Proteinuria can be routinely assessed via semi-quantitative methods such as urine dipstick 
colorimentric test and/or SSA.  
Dipsticks (or dry reagent test strips) are rapid and inexpensive methods that allow, along 
with other urinary physico-chemical or cytological parameters, a first evaluation of the 
presence or absence of proteins in urine in a point-of-care setting (Stockham and Scott, 
2008). 
When proteins (mainly albumin) are present, the reaction with the pad yields a variable 
color change whose intensity is proportional to the protein concentration. Results are then 
expressed semi-quantitatively, usually as negative, trace or 1+ to 4+ (corresponding, for 
most of the commercially available dipsticks to 15 to 2000 mg/dL of proteins), comparing 
the pad against the chart on the side of the dipstick package or, alternatively, loading the 
strip in an automated spectrophotometric reader. 
In cats, the sensitivity and specificity of the dipstick (≥ trace reaction) for albumins in urine 
were reported to be 90% and 11%, respectively (Lyon et al., 2010) 
 
Urinary protein concentration dependes not only to pathologic states but also to the hour-
to-hour or day-to-day urine dilution. Therefore, dipstick results should be interpreted 
together to USG in order to estimate the grade of proteinuria.  
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In a previous study (Zatelli et al, 2010) a scheme of interpretation of dipstick results in 
conjunction with USG values was suggested in dogs (Table 3) and a similar approach 
should be carried out in cats. 
 
Table 3 Scheme of interpretation of dipstick in dogs. Samples with negative dipstick are likely non proteinuric 
(NP), samples with 2+ or more are likely proteinuric and samples with 1+ may or may not be proteinuric 
depending on the USG (modified by Zatelli et al, 2010). UPC: urinary protein-to-creatinine ratio; USG: urine 
specific gravity. 
 Dipstick results 
 0+ 1+ ≥2+ 
 USG ≤1012 NP 
UPC necessary to 
confirm diagnosis 
UPC necessary to 
grading 
USG  
>1012 and <1030 
NP NP 
UPC necessary to 
grading 
 USG ≥1030 NP NP 
UPC necessary to 
grading 
 
Although the evaluation of protein excretion using the dipstick is considered a screening 
test, pre-analytical and analytical variables could affect clinical decisions. Alkaline urine, 
quaternary ammonium salts and chlorexidine could falsely increase protein results, and 
also the presence of abnormal pigments could interfere with the reagent pad color and 
reading (Stockham and Scott, 2008). 
 
Some laboratories confirm the positivity of the dipstick with the sulphosalicylic acid (SSA) 
turbidometric test, especially in case of trace or 1+ results. SSA test is based on the 
denaturation of the proteins by the acid solution to form a precipitate that is detected as 
increased turbidity. It could be affected by false positivity due to some drugs and false 
negative due to alkaline urine. Compared to dipstick, it was shown to have higher 
specificity (25%) for the detection of albumins. (Lyon et al., 2010) Therefore, when applied 
as confirmation test after dipstick, SSA should be used in series instead of in parallel, in 
order to improve the specificity.  
 
Dipstick and SSA allow an estimation of proteinuria and are not accurate for quantitative 
evaluation. Although the gold standard for an accurate quantification (and detection) of 
proteinuria is the measurements of proteins in a 24 hours urine collection (Monroe et al., 
1989), in veterinary medicine this approach is impractical in clinical settings. Currently, the 
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quantification of proteinuria with the urinary protein-to-creatinine (UPC) ratio in spot urine 
sample is considered a reliable estimation of the daily protein excretion in cats (Adams et 
al., 1992). 
Since creatinine is constantly filtered by glomerulus, the ratio of urinary protein with urinary 
creatinine allows the normalization with the hour-by-hour urinary dilution. 
 
Concentration of urinary proteins is quantified by the means of automated biochemical 
analyzers in laboratories and different specific reagents are commercially available. 
Among these reagents, dye-binding methods are easy to use, relatively rapid and 
inexpensive. The most used are Pyrogallol red molybdate (PRM) and Coomassie brilliant 
blue (CBB). (Adams et al., 1992; Kuwahara et al., 2008; Williamset al.,  2016; Fiorina et 
al., 2001; Martin et al., 2011). Other methods are based on protein precipitation and could 
be used as well (McDowell, 1985).  
Urinary creatinine is measured with the same analytical methods used for serum creatinine 
(Stockham and Scott, 2008). However, in order to obtain accurate results, to measure 
urinary creatinine it is necessary to dilute urinary supernatants to low the concentration 
within the range of linearity of the method. In dogs it was demonstrated that the best 
dilution is 1:20 (Rossi et al., 2012). 
 
IRIS staging based on proteinuria suggests 3 stages (Table 4) and the evaluation should 
be ideally done on the basis of at least two urine samples collected over a period of two 
weeks. Patients that are persistently borderline proteinuric should be re-evaluated within 2 
months. IRIS and the ACVIM consensus statement recommends therapeutic intervention 
with antiproteinuric drugs when UPC ≥0.4 in cats with CKD (Lees 2005; Elliott and Watson, 
2016). 
 
Table 4 IRIS staging based on proteinuria 
UPC value Substage 
<0.2 Non-proteinuric 
0.2 – 0.4 Borderline proteinuric 
>0.4 Proteinuric 
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Since the clinical decisions concerning proteinuria are currently based on quantification of 
urinary proteins with UPC ratio, it is of extreme importance to know and take into account 
all the possible source of biological and analytical variability, discussed below.  
 
URINARY TRACT DISEASE. In the diagnostic approach to proteinuria in CKD it is 
mandatory to exclude pre-renal and post-renal causes of proteinuria. Urinary tract 
inflammation and hemorrhage are the main causes of post-renal increase of protein 
excretion (Grauer, 2011) and are possible concurrent finding in CKD in cats (Martinez-
Ruzafa et al., 2012). In dogs UPC significantly increased only in case of macroscopic 
hematuria and was more likely to be high with concurrent hematuria and pyuria, according 
to a study (Vaden et al., 2004). Despite this, it is still recommended to role out post-renal 
inflammation before to interpret UPC values in CKD patients (Lees et al., 2005; Grauer, 
2016). In cats, few information is available about the effect of hematuria and pyuria on 
UPC ratio but similar results are expected and similar approach is warranted. Interestingly, 
a recent study in cats highlighted mean UPC values of 0.70 ±0.19 in idiopathic cystitis 
yielding active urinary sediment (Panboon et al., 2017). 
 
BIOLOGICAL VARIABILITY. In dogs, quantification of UPC in consecutive days is 
necessary when UPC is higher than 5, in order to determine a mean value representative 
of the actual value given a day-to-day variation of UPC (Nabity et al., 2007). However, in 
cats these values are rarely reached (Syme et al., 2006) and no information is available 
about this variability in cats. If necessary, it is possible to determine the mean value 
between consecutive samples on a pool of urine samples, in order to reduce the number 
of tests and the expense for the owner (LeVine et al., 2010). In dogs, a recent study 
demonstrated that intact male dogs could present persistent borderline proteinuria (UPC 
between 0.2 and 0.5) that after castration, tended to low at non-proteinuric range 
(UPC<0.2) (Bertieri et al., 2015). No information is available about the effect of neutering 
status on UPC in cats, but it is deemed that intact male could have higher urinary protein 
content, given the more abundant cauxin proteins in urine (Miyazaki et al., 2006). 
Moreover, urine collected at the clinical setting yielded UPC ratio higher compared to UPC 
measured in urine collected at home, suggesting an influence of stress on proteinuria 
(Duffy et al., 2015). However, it is not known whether also in cats the site of collection 
affect UPC. On the other hand it is known that in cats, UPC did not differ between samples 
 21 
collected with cystocentesis and samples collected by manual compression of the bladder 
(Vihena et al., 2015). 
 
ANALYTICAL VARIABILITY. In dogs it was shown that different pre-analytical and 
analytical procedures could affect UPC quantification, such as storage conditions, urine 
predilution to measure urinary creatinine and intra-assay variability (Rossi et al., 2012). 
Another recent study in dogs showed biases between the two most common dye-binding 
methods for quantification of urinary proteins and one of two (PRM) the latter tended to 
underestimate protein concentration (Rossi et al., 2016). Also in cats there are reports 
demonstrating disagreements between analytical methods different to PRM and CBB. 
(Fernandes et al., 2005; Heeley, 2016). In dogs, disagreements was recently 
demonstrated between different labs also using the same reagent (PRM) but different 
biochemical analyzer and standard operative procedures (Rossi et al., 2015) and it is likely 
that this variability exist also for feline urinary proteins. 
Hence, the UPC ratio can be affected by different assays principles and as a consequence 
cats with kidney diseases can be incorrectly sub-staged applying the IRIS guidelines. 
 
Hypertension 
 
Systolic blood pressure could be routinely assessed by indirect methods such as 
oscillometry and doppler ultrasonography. To obtain reliable values in the measurement of 
BP, it is important that a trained operator follow a standard protocol as described in a 
previous published guideline (Brown et al., 2007). Similar to any other analytical methods, 
the instrument should be validated for the cat and checked at leas annually (Brown et al., 
2007). The patient should be acclimatized to the measurement condition in order to avoid 
the so called white-coat hypertension (WcHT). In animals WcHT is defined as the increase 
of SBP measured in clinical setting not detected at home or in general in case of stressful 
environment. Although the physiologic cause of the white-coat effect is not precisely 
known, it is deemed to be caused by the temporary sympatheic stimulation that could 
occur during the stressful clinical consultation (Zimmerman and Frohlich, 1990). In cats, 
this stress could occur during the transportation to the clinic and/or could occur due to the 
unfamiliar and relatively invasive procedures performed during the clinical visit (Belew et 
al., 1999). SBP could rise on average 30 mmHg above the actual value (both in healthy 
cats and in cats affected by CKD) and until 70 mmHg higher than baseline value (Belew et 
al., 1999). Hence WcHT is of concern in veterinary medicine since it interferes with the 
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SBP evaluation and a false diagnose of HT could occur. Moreover, this condition it’s 
difficult to manage since the repeated measurement in clinical setting could reduce but not 
delete the WcHT. Although there is some evidence that the presence of white-coat 
hypertension in normotensive people is a risk factor for subsequent hypertensive damage, 
(Karter et al., 2003) there is no justification for treating white-coat hypertension in cats 
(Brown et al., 2007). Repeated measurements over time are therefore necessary to 
confirm the presence HT.  
 
IRIS suggest a substaging of HT according to the degree of risk of target organ damage 
and whether there is evidences of target organ damage or complications (tables 5).  
 
Table 5 IRIS sub-staging according to systolic blood pressure (SBP) 
SBP (mmHg) Sub-stage Acronym Risk of future target organ damage 
<150 Normotensive AP0 Minimal 
150-159 Borderline hypertensive AP1 Low 
160-179 Hypertensive AP2 Moderate 
>180 Severely hypertensive AP3 High 
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General	aims	
 
The first general aim of this thesis was the preliminary evaluation of pre-analytical and 
analytical variability of some laboratory parameters used in International Interest Society 
(IRIS) staging of feline chronic kidney disease (CKD). Specifically, to evaluate: 
- whether the pre-analytical and analytical variability of urinary protein-to-creatinine (UPC) 
ratio (such as storage conditions, effect of creatinine predilution, and imprecision and 
method-dependent difference) could affect proteinuria interpretation in clinical practice 
(study 1);  
- whether the presence of hematuria or pyuria affects the urinary protein concentration and 
UPC ratio in feline urine (study 2); 
- whether the serum concentration of symmetric dimethylarginine (SDMA) in Birman cats, 
which have higher physiological serum creatinine, could be a better biomarker to estimate 
theglomerular filtration rate (study 3) 
Then, this thesis was aimed to assess the usefulness of novel biomarkers of hypertension 
and proteinuria in cats with CKD in order to define the pattern typical of each IRIS stage 
and the role of these biomarker as prognostic factors (study 4). Specifically, serum 
biomarkers that in other species increase in hypertension and CKD, such as big 
endothelin-1 (study 4.1) homocysteine (study 4.2), aldosterone (study 4.3) or biomarkers 
such as big endothelin-1 (study 4.1), alpha-1 microglobulin (study 4.4) and tubular proteins 
(study 4.5) increase also in cats with CKD and may therefore work as early biomarkers for 
diagnosis or prognosis of CKD or as ancillary tests to preliminary select cats potentially 
affected by hypertension, avoiding procedures to measure blood pressure in normotensive 
cats. Our hypothesis is that both serum biomarkers increase and urinary protein patterns 
change in cats with CKD, as happens in humans and dogs.  
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Description	of	the	studies	
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1.	Evaluation	of	pre-analytic	and	analytic	variability	of	urine	
protein-to-creatinine	ratio	in	cats	
 
Introduction	and	aims	
 
The quantification of proteinuria with the urinary protein-to-creatinine (UPC) ratio in spot 
urine sample is considered a reliable estimation of the daily protein excretion in cats 
(Monroe er al., 1989; Adams et al., 1992) and it’s mandatory in diagnostic approach of 
CKD and staging according to the International Interest Renal Society (IRIS) guidelines 
(Elliot and Watson, 2016). 
In human medicine it was shown that different methods for urinary protein quantification 
yielded discordant results (Chambers et al., 1989; Dube et al., 2005) and efforts were 
made to improve agreement (Wimsatt and Lott, 1987; Marshall and Williams, 2000). 
Similarly, in dogs, the UPC ratio can be affected by different assays principles and as a 
consequence dogs with kidney diseases can be incorrectly sub-staged applying the IRIS 
guidelines. A recent study in dogs showed biases between CBB and PRM in quantification 
of urinary protein in canine urine and the latter tended to underestimate protein 
concentration (Rossi et al., 2016). Moreover, also in cats there are reports demonstrating 
disagreements between analytical methods different to PRM and CBB (Fernandes et al., 
2005; Heeley, 2016). On this regard, it’s important to highlight that the IRIS guidelines do 
not specify which method should be used to assess the thresholds proposed in sub-
staging feline patients with CKD.  
Other factors, such as different pre-analytical procedure in different laboratories, storage of 
supernatants or pre-dilution for urinary creatinine quantification have been shown to 
influence the quantification of urinary protein in dogs (Rossi et al., 2012; Rossi et al., 
2015). 
To our knowledge there is no information available about pre-analytical and analytical 
factors that may affect the measurement of proteinuria. 
Therefore, the aims of this study were to determine whether preanalytic and analytic 
factors affect the evaluation of the UPC ratio in cats. Specifically, the influence of 
preanalytic dilution for creatinine quantification, the intra-assay repeatability of UPC ratio 
measurement and the effect of storage at different temperatures and times were 
evaluated. In addition, agreement between two dye-binding methods (PRM and CBB 
methods) for measurement of total protein in feline urine was determined. 
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Material	and	methods	
 
Animals	and	sample	collection	
 
One hundred seventy-four urine samples were prospectively collected from client-owned 
cats presented for routine diagnostic investigations  
Samples were collected from January 2015 to February 2016 at the Internal Medicine Unit 
of the Department of Veterinary Medicine (University of Milan) and at a private clinical 
practice in Milan (Ospedale Veterinario Città di Pavia) during routine health screen, under 
informed consent signed by the owners. According to the ethical committee statements of 
the University of Milan (number 2/2016), biological samples collected in this setting could 
be used also for research purposes. 
Due to the analytical nature of this study, cats were enrolled irrespective of age, sex and 
breed or underlining disease and also cats with diseases that could affect urine 
composition (e.g. CKD, lower urinary tract inflammation, neoplasia, etc.) were included.  
Eight to 10 mL of urine samples were collected from each cat by ultrasonographically-
guided cystocentesis. Samples were sent within the syringe to the respective internal 
clinical pathology laboratories (labelled as “Lab 1” for university of Milan and “Lab 2” for 
Ospedale Veterinario “Città di Pavia”). 
 
Urinalysis	
 
Five millilitres of urine were transferred from the syringe to a sterile conical tube and were 
macroscopically evaluated for physical properties (color and turbidity) and assayed with 
dipstick for a semi-quantitative chemical analysis (Combur 10 test, Roche diagnostics, 
Risch-Rotkreuz, Switzerland). Urine specific gravity (USG) was determined by a handheld 
refractometerd calibrated daily with distilled water (Clinical Refractometer, model 105, 
Sper Scientific, Scottsdale, AZ, USA).  
In order to perform sediment evaluation and supernatant collection, tubes were centrifuged 
at 1250 rpm for 5 minutes (450G) (Hermle Z300, Labnet international, Edison, NJ, USA). 
Then, 4.75 mL of supernatant was removed and transferred in other tubes for subsequent 
diagnostic biochemical analysis and for study purposes (see below). Supernatants were 
removed by suction using a dispensable pipette according to current guidelines (ECLM, 
2000) in order to avoid loss of sediment and supernatant contamination by elements of the 
sediment. 
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Sediments were resuspended in the remaining 0,25 mL supernatant and 50 µL were 
placed on a slide, covered with a microscope coverslip (24x32 mm) and evaluated 
microscopically al 100x (low power field, LPF) and 400x (high power field, HPF) 
magnifications. 
Bacteriuria, spermaturia, lipiduria, and the presence of epithelial cells, casts, and crystals 
were recorded according to a semiquantitative scale (rare, moderate, abundant, or very 
abundant) whereas erythrocytes and leukocytes were quantified as the mean on 10 HPF. 
Sediments were classified as active on the basis of the presence of one or more of the 
following findings: >5 RBCs /HPF, >5 WBCs /HPF or both. Samples without any of these 
listed findings were classified as inactive.  
Supernatants enrolled in “Lab 1” were used fresh for the analytical procedures described 
below. Supernatants collected at “Lab 2” were aliquoted (approximately 2 mL each 
sample) and stored at −20° within 2 hours from collection. Then, aliquots were shipped in 
batch under controlled temperature to “Lab 1” for inclusion in method comparison study 
(see below). 
 
Analytical	methods	
 
Two commercially available colorimetric test kits were used for protein quantification on 
urine supernatants in “Lab 1”, one based on PRM (Urine proteins, Sentinel diagnostics, 
Milan, Italy) and the other based on CBB (Total protein coomassie urine, Far Diagnostics, 
Pescantina (VR), Italy). The concentration of urinary protein was expressed in mg/dL 
either for PRM (UPPRM) or for CBB (UPCBB). Both methods were performed according to 
manufacturer’s instructions and were calibrated with the standards provided by the 
manufacturers. Specifically, PRM standard was stated to be “urinary protein” with no 
specification of the particular nature of the protein content whereas CBB standard was 
bovine serum albumin. The protein concentration of the PRM standards provided with the 
different lots used during the study period ranged from 109 to 122 mg/dL whereas the 
concentration of CBB standards was 100 mg/dL in all the lots used.  
Preliminary assays run in our lab demonstrated that PRM method was linear up to 210 
mg/dL as reported by the manufacturer whereas CBB method, independently on the limit 
of linearity indicated by the producer, loses linearity at concentration higher than 120 
mg/dL. Therefore, when CBB yielded values higher than 120 mg/dL, supernatants were 
diluted 1:5 with distilled water; then, samples were re-run with both PRM and CBB and the 
actual values were calculated based on the dilution factor. 
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Urinary creatinine concentration (UC) was measured with the modified Jaffè method 
(Creatinina, Real-Time Diagnostics, Viterbo, Italy) and was expressed as mg/dL.  
When CBB method was applied in a session of work, PRM and Jaffe methods were run 
first, due to the peculiarity of CBB reagent to stain the reagent needle of the automated 
analyser and the theoretical possibility of contamination and interference of Coomassie 
dye in the subsequent reaction. Then, an automated cleaning of the needle at the end of 
the session was performed. 
Because urinary creatinine concentration frequently exceeds the range of linearity of the 
method, supernatants were diluted 1:20 with distilled water in order to measure urinary 
creatinine and then the actual values were calculated. 
Except when differently specified, biochemical tests were performed in triplicate and the 
mean values were used for data analysis. 
All tests were performed with an automated biochemical analyser in Lab1 (Cobas Mira, 
Roche Diagnostics, Basel, Switzerland) and all methods were daily controlled with a 
solution known protein concentration (70.6 mg/dL, level 3 calibration solution, Siemens 
Dimension® UCFP calibrator, Muenchen, Germany) and calibrated if necessary. 
UPC ratios obtained with PRM (UPCPRM) and, UPC ratios obtained with CBB (UPCCBB) 
were calculated for each method. 
 
Experimental	procedures	
 
The flow of the study design with the different analysis performed and described below is 
shown in Figure 1.  
 
Effect of predilution of urine samples— Three aliquots of 25 fresh urine supernatants were 
diluted 1:10, 1:20, and 1:100 and assayed for creatinine concentration. Protein 
concentration was also determined with PRM, and the UPC ratio corresponding to each 
creatinine dilution was calculated.  
 
Intra-assay repeatability— The intra-assay imprecision was assessed on twenty fresh 
urine supernatants, testing samples 20 consecutive times in the same run for protein 
concentration (with both PRM and CBB methods) and for creatinine concentration and the 
UPC ratio was calculated. Mean, SD and CV (calculated as CV = SD/mean X 100) for 
UPPRM, UPCBB, UC and thus UPC ratio for each method were calculated first on the whole 
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set of samples and then considering separately the results from samples with active and 
inactive sediment. 
 
Figure 1 Flow chart of this study. A preliminary evaluation of the best supernatant dilution for creatinine 
measurement was performed and intra-assay and inter-assay variability was evaluated. Then, the effect of 
different storage conditions was assessed. In the meanwhile, method comparison study on the fresh urine 
samples included in those evaluations was carried out. After results of storage at -20°C, samples form Lab2 
were included in method comparison study 
 
 
Inter-assay repeatability— The inter-assay imprecision was assessed in 15 samples, 
immediately aliquoted after sampling and stored at -20°C. Each sample was measured on 
5 consecutive working days. Urine proteins were measured with both methods (PRM and 
CBB), urine creatinine was also measured to calculate the UPC ratio with each method. 
Mean, SD and CV (calculated as CV = SD/mean X 100) were calculated for UPPRM, UPCBB, 
UC and thus UPC ratio for each method. 
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Effect of storage duration and temperature— Fresh urinary supernatants were included in 
this evaluation. To assess short-term stability at room temperature (20°C), 40 samples (20 
using PRM and 20 using CBB) were assayed within 2 hours from collection (T0) and 
aliquoted in 3 tubes (300 µL); aliquots were left in closed tubes on the working desk of the 
lab and they were assayed at 2, 4 and 6 hours from T0;  
To assess the effect of refrigeration, 40 samples (20 using PRM and 20 using CBB) were 
assayed at T0, then seven aliquots (300µL) were stored at 4°C and analyzed 24, 48, and 
72 hours and 1 week after storage. 
To assess the effect of repeated thawing-freezing cycles was evaluated in 40 samples (20 
using PRM and 20 using CBB): 1 aliquot of 1 mL was stored at -20°C and was thawed, 
analysed and frozen again at 24, 48 and 72 hours and 1 week after collection (4 thaw-
freeze cycles). 
To assess stability at freezing temperature, 28 samples were tested at T0, then 6 aliquots 
(300 µL) were stored at –20°C and analysed 1, 2, 3, 4, 8 and 12 weeks after storage, 
using PRM for protein quantification at each checkpoint. Twenty-five supernatants were 
assayed at T0 for UPCBB and UC, were immediately stored in one aliquot (300 µL) at −20°C 
and evaluated again at 1 month. Stability at 3 months were evaluated on further 28 
samples (different from those included in the previous evaluation) at T0 and 3 months for 
UPCBB and UC. 
In all the tests previously described, refrigerated or frozen samples were allowed to gently 
warm or thaw at room temperature and subsequently vortexed. 
 
Method comparison study— Forty samples from “Lab1” and 80 samples from “Lab2” were 
included. Supernatants sent to “Lab1” were analysed fresh within 3 hours from collection, 
while supernatants from “Lab2” have been stored no longer than 4 weeks at -20°C before 
the assay. 
Urine protein concentration was measured using both PRM and CBB methods, creatinine 
concentration was measured to allow the calculation of UPC ratios for each method.  
UPC ratios obtained with both methods (PRM and CBB) were classified as NP, BP or P 
according to the IRIS staging system. 
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Statistical	Analysis	
 
A commercially available software (MedCalc® Statistical Software, version 16.8.4, Ostend, 
Belgium) was used. A P value <0.05 was considered statistically significant. Normality of 
variables was assessed by Kolmogorov-Smirnov test. 
For the evaluation focused on the effect of predilution of urine supernatants, creatinine 
concentrations, measured by use of the three dilutions and the corresponding UPC ratios, 
were compared with Friedman test, followed by Wilcoxon signed rank test to compare the 
results between single dilutions; the agreement between results was tested with Bland-
Altman and Passing-Bablok tests; concordance in classify sample according to IRIS 
guidelines for proteinuria (NP, BP, P) in cats was tested with Cohen k test (see below for 
further details).  
For the evaluation focused on the intra-assay variability, the possible correlation between 
intra-assay CV of urinary protein concentration, urinary creatinine concentration or UPC 
ratio, and the actual values of each of these variables, was investigated with Spearman 
correlation test. Mann-Whitney U test was applied to investigate difference in UP, UC and 
UPC ratios between samples with active and inactive sediment. 
For the evaluation focused on the influence of different storage conditions on UP, UC and 
UPC ratios, results obtained at different checkpoint were analyzed using Friedman test 
followed by multiple comparisons using the Wilcoxon signed rank test adjusted with the 
Bonferroni correction in case of >2 checkpoint (i.e. room temperature, 4°C, repeated 
freeze-thaw cycles and –20°C using PRM). Wilcoxon signed rank test was also used for 
samples stored at –20°C and assayed with CBB. These tests were performed on the 
whole set of samples and on the data grouped according to the presence or absence of an 
active sediment. In order to assess the clinical relevance of the variation due to the 
storage conditions, at each checkpoint, UPC results were considered clinically different 
whenever the mean value was outside the range determined applying the inter-assay CV 
to the respective mean T0 values. To this aim, the inter-assay CV values found in this 
study were used (see Results). 
For the method comparison study, the UP values obtained with PRM and CBB were 
compared to each other with Wilcoxon signed rank test to assess difference and assayed 
for correlation with the Spearman test. The same analysis has been run to compare the 
UPC ratios calculated using the PRM and the CBB method. The agreement between the 
two methods was assessed by Passing-Bablok and Bland–Altman tests. 
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The concordance of the two methods in classifying samples according to IRIS staging of 
proteinuria was assayed with the Cohen’s kappa (k) concordance test. The Cohen’s k 
coefficient was used to define concordance as “very good” (k = 0.8–1), “good” (k = 0.6–
0.8), moderate (k = 0.4–0.6), “fair” (k = 0.2–0.4), “poor” (k = 0.0–0.2) or “absent” (k <0) 
(Landis and Koch, 1977). Method comparison study tests were performed for the whole 
set of data and for the sub-sets of samples grouped according to the presence or absence 
of active sediment. 
Results	
 
Effect	of	predilution	of	urine	samples	
 
Median of UC concentration measured at 1:10, 1:20 and 1:100 dilutions were 191.4 mg/dL 
(mean ± SD: 225.2 ± 117.0 mg/dL), 188.1 mg/dL (mean ± SD: 227.2 ± 126.4 mg/dL) and 
180.3 mg/dL (mean ± SD: 219.1 ± 123.8 mg/dL) respectively. 
Median UPC ratios measured at 1:10, 1:20 and 1:100 dilutions were 0.16 (mean ± SD: 
0.23 ± 0.24), 0.17 (mean ± SD: 0.24 ± 0.24) and 0.16 (mean ± SD: 0.24 ± 0.26), 
respectively. No significant differences were found between the three dilutions for both UC 
(P = 0,468) and UPC (P = 0.540). 
Comparing dilutions with Bland-Altman and Passing-Bablok tests, only a constant error 
between UPC calculated at 1:20 dilution and UPC calculated at 1:100 dilution was found 
(Figure 2 and 3). 
Agreement in classifying samples according to IRIS stages was defined “very good” in all 
the three comparisons (1:20 vs 1:10, k = 0.83; 1:20 vs 1:100, k = 1; 1:10 vs 1:100, k = 
0.83). Only two samples yielded different IRIS stage when measured using 1:10 compared 
to other dilutions (one NP instead of BP and one BP instead of NP). 
 
Intra-	and	inter-assay	variability	
 
Descriptive statistics of the samples included in intra-assay and inter-assay evaluation and 
the respective CVs with regard of UPPRM, UPCBB, UC, UPCPRM and UPCCBB are shown in 
Table X. Test for normality revealed a non-Gaussian distribution for both UP, UC and thus 
for UPC. 
The CV was lower for the UC than for UP (and UPC ratio) measured with both PRM and 
CBB. CBB method appeared more precise than the PRM method. The effect of this 
variability on sub-staging of sample according to IRIS guidelines was assessed on 4 urine 
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samples that had UPC ratios close to the threshold values (i.e. 0.2 and 0.4) and is shown 
in Table 6. 
No significant differences were found between mean values of UPPRM, UPCBB, UC, UPCPRM 
and UPCCBB between samples with active and inactive sediment. 
No significant correlations were found comparing intra-assay CV and mean values of 
UPPRM (r = –0.08; P = 0.72), UPCBB (r = –0.29; P = 0.220), UC (r = –0.01; P = 0.95), 
UPCPRM (r = –0.23; P = 0.33) and UPCCBB (r = –0.19; P = 0.42).  
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Figure 2 Passing Bablok (left) and Bland-Altman (right) plots regarding the comparison of urinary creatinine 
(UC) concentration between dilutions 1:20 vs. 1:100 (A), 1:20 vs. 1:10 (B) and 1:100 vs. 1:10 (C), obtained from 25 
samples. In Passing Bablok plots, the blue line is the correlation, the gray line shows best fit and the blue dotted 
lines 95% CI. In Bland–Altman plots, X axes represent the average between the two dilutions, and the Y axes the 
indicate the difference between dilutions; the grey line shows the zero bias, the blue solid with the dashed blue 
lines represent the bias and 95% confidence interval (CI), respectively; the light blue dashed lines are the limits 
of agreement and the red dotted line is the regression line. 
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Figure 3 Passing Bablok (left) and Bland-Altman (right) plots regarding the comparison of urinary protein-to-
creatinine (UPC) ratio between dilutions 1:20 vs. 1:100 (A), 1:20 vs. 1:10 (B) and 1:100 vs. 1:10 (C), obtained from 
25 samples. In Passing Bablok plots, the blue line is the correlation, the gray line shows best fit and the blue 
dotted lines 95% CI. In Bland–Altman plots, X axes represent the average between the two dilutions, and the Y 
axes the indicate the difference between dilutions; the grey line shows the zero bias, the blue solid with the 
dashed blue lines represent the bias and 95% confidence interval (CI), respectively; the light blue dashed lines 
are the limits of agreement and the red dotted line is the regression line. 
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Table 1 Precision tests of protein concentration measured with PRM and CBB, creatinine concentration and urinary protein-to-creatinine ratio calculated with both 
methods. Intra-assay repeatability was evaluated in 20 samples (11 with active and 9 with inactive sediment) tested 20 consecutive times. Inter-assay repeatability was 
evaluated in 15 samples tested in 5 consecutive days. UP, UC and UPC values are described as median and range in brackets; CV values are described as mean ± SD. 
 UPPRM UPCBB UC UPCPRM UPCCBB 
 
UP 
concentration 
(mg/dL) 
CV 
(%) 
UP 
concentration 
(mg/dL) 
CV 
(%) 
UC 
concentration 
(mg/dL) 
CV 
(%) 
UPC ratio 
CV 
(%) 
UPC ratio 
CV 
(%) 
Intra-assay 
all samples 
61.6 
(22.8-858.6) 
8.4 ±5.2 
87.2 
(33.4-614.8) 
5.6 ±2.6 
152.9 
(35.3-517.7) 
3.4 
±2.5 
0.32 
(0.05-
24.32) 
9.5 ±4.8 
0.62 
(0.15-17.41) 
7.2 ±2.6 
Intra-assay 
active sediment 
56.5 
(22.8-455.6) 
9.3 ±6.8 
82.8 
(43.4-595.0) 
5.5 ±2.1 
152.8 
(70.0-468.5) 
3.7 
±2.8 
0.32 
(0.04-6.6) 
10.4 ±6.4 
0.61 
(0.16-7.06) 
7.1 ±2.5 
Intra-assay 
inactive 
sediment 
45.1 
(23,9-78.1) 
7.9 ±0.8 
57.5 
(33.4-101.7) 
7.3 ±1.4 
184.6 
(93.9-374.4) 
3.8 
±2.4 
0.19 
(0.16-0.27) 
8.2 ±1.1 
0.29 
(0.15-0.41) 
8.3 ±1.9 
Inter-assay 
all samples 
27.4 
(9.8-518.4) 
10.8 ±3.2 
51.6 
(18.2-314.6) 
10.9 ±4.5 
176.3 
(59.3-426.8) 
6.6 
±2.7 
0.15 
(0.06-6.59) 
16.4 ±9.4 
0.26 
(0.07-3.98) 
17.8 ±3.1 
UP, urinary protein; UPPRM, urinary protein measured with pyrogallol red-molybdate; UPCBB, urinary protein measured with Coomassie brilliant blue; 
UC, urinary creatinine, UPC, urinary protein-to-creatinine ratio; UPCPRM urinary protein-to-creatinine ratio measured with pyrogallol red-molybdate;  
UPCCBB urinary protein-to-creatinine ratio measured with coomassie brilliant blue 
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Table 7 Frequency of misclassification of 4 feline urines with UPC ratios close to IRIS 
thresholds. When tested with PRM, 2 samples yielded UPC values close to the two IRIS 
cut-off (0.2 and 0.4). Similarly, two other different samples yielded UPC values close to 
the same two cut-off when tested with CBB. Number (and percentage) of shifts of IRIS 
stage out of the 20 repeated measurements in these samples were countered. 
  UPC same 
stage 
UPC different 
stage 
UPCPRM BP (UPC =0.22) 17 (85%) 3 (15%) NP 
 P (UPC =0.42) 13 (65%) 7 (35%) BP 
UPCCBB BP (UPC =0.22) 18 (90%) 2 (10%) NP 
 P (UPC =0.41) 11 (55%) 9 (45%) BP 
UPC, urinary protein-to-creatinine ratio; UPCPRM urinary protein-to-creatinine ratio 
measured with pyrogallol red-molybdate;  UPCCBB urinary protein-to-creatinine ratio 
measured with coomassie brilliant blue; BP, borderline proteinuric; P, proteinuric 
 
Storage	
 
No significant differences were found for UP, UC and UPC using both PRM and CBB 
when stored at room temperature for 6 hours, at +4°C for 1 week and after four thaw-
freeze cycles within 1 week (Figure 4). When stored at -20°C (Figure 5), UPPRM did not 
change during 12 weeks of storage in the whole set of samples and in the inactive 
sediment, whereas in active sediment set of samples was significant different (P = 0.002) 
highlighting higher values at 3rd week compared to T0, 4th and 12th weeks according to the 
post-hoc analysis. UC significantly differed in the whole caseload (P = 0.047) but no 
differences were found in the active and inactive subsets. UPCPRM significantly differed in 
the whole caseload (lower values at 8th week compared to T0, 1st and 2nd weeks and lower 
values at 12th compared to 2nd week), and in the sets of active (higher values at 3rd week 
compared to T0, 4th, 8th and 12th weeks) and inactive sediment (lower values at 8th week 
compared to T0 and 2nd weeks). When storage stability at -20°C was tested with CBB 
(Figure 5), at 4 weeks UPCBB and UPCCBB did not significantly differed in any of the sets of 
samples. At 12 weeks (Figure 5) mean UPCBB significantly differed (P = 0.046) in the whole 
set of samples, highlighting lower values at 12th week, whereas active and inactive sets 
did not. Conversely UPCCBB did not significantly change in any of the sets of samples. All 
the previous UPC mean values at any checkpoint (including those significantly different) 
were within the range determined by the inter-assay variability applied to the respective 
UPC mean value at T0 showing no clinical relevance of the statistical variation.  
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Figure 1 Effect of storage at room temperature within 6 hours (upper row), at +4°C for 1 week (middle row) and at thaw-freeze cycles for four cycles (lower row) for 
UPPRM (A), UPCPRM(B), UC (C), UPCBB (D) and UPCCBB(E). Box plots represent the interquartile range (IQR), and the horizontal line represents the median value of each 
group. Whiskers extend to the furthest observations within ± 1.5 IQRs of the first or third quartile 
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Figure 5 Effect of storage at -20°C for UPPRM (upper row), urinary creatinine (middle row) and UPCPRM (lower row). A: All 
samples (n = 28). B: Samples with active sediment (n = 11). C: Samples with inactive sediment (n = 17). Box plots 
represent the interquartile range (IQR), and the horizontal line represents the median value of each group. Whiskers 
extend to the furthest observations within ± 1.5 IQRs of the first or third quartile. 
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Figure 6 Effect of storage at -20°C for UPCBB (upper row) and UPCCBB (bottom row) after 4 weeks (T4w). A— All samples (n = 25). B— Samples with active sediment (n = 
11). C— Samples with inactive sediment (n = 14). Box plots represent the interquartile range (IQR), and the horizontal line represents the median value of each group. 
Whiskers extend to the furthest observations within ± 1.5 IQRs of the first or third quartile 
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Figure 7 Effect of storage at -20°C for UPCBB (upper row) and UPCCBB (bottom row) after 12 weeks. A— All samples (n = 28). B— Samples with active sediment (n = 13). 
C— Samples with inactive sediment (n = 15). Box plots represent the interquartile range (IQR), and the horizontal line represents the median value of each group. 
Whiskers extend to the furthest observations within ± 1.5 IQRs of the first or third quartile. 
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Method	comparison	study	
 
Data referred to the whole caseload or to samples with inactive or active sediment are 
reported in Table 7. 
Forty-one (38.7%) urinary samples had an active sediment, while 65 (61.3%) had an 
inactive sediment. The most common sediment alteration was hematuria (68.3%), followed 
by leukocyturia (24.4%) and hematuria and leukocyturia (7.3%). 
Using PRM, 66, 17 and 37 samples were classified as N, BP and P, respectively, whereas 
using CBB were 45, 25 and 50, respectively. 
CBB yielded constantly higher UP and UPC ratios compared to PRM and the difference 
was significant (P <0.0001) in all sets of samples. 
Urinary protein (PRM: P = 0.0146, CBB: P = 0.0104) and UPC ratio (PRM: P = 0.0035, 
CBB: P = 0.0087) were significantly different between samples with active and inactive 
sediment. 
Correlations between UPPRM and UPCBB, and between UPCPRM and UPCPRM were highly 
significant (P <0.0001) in all groups of samples. In the whole set of samples correlation 
coefficients were 0.82 and 0.91 for urinary proteins and for UPC, respectively; coefficients 
in the samples with active sediments were 0.96 for both proteinuria and UPC; in the 
samples with inactive sediments coefficients were 0.78 and 0.96 for protein and for UPC, 
respectively.  
Statistical results of the method comparison study (including intercept and slope with 95% 
confidence intervals) obtained by Passing-Bablok regression analysis, and Bland-Altman 
biases with 95% limits of agreement obtained from UP and UPC ratio in the whole set of 
sample, in samples with active and with inactive sediments were shown in Table 8 and 
graphically displayed in Figures 8 and 9. Constant and proportional errors were found in all 
sets of samples, with the exception of UPC in inactive sediment set that yielded no 
constant bias. 
The agreement in staging samples according to IRIS guidelines (Table 4) was defined as 
“good” in the whole set of samples (k coefficient =0.62), “moderate” for both active and 
inactive groups of samples (0.59 and 0.56 respectively). 
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Table 1 Median and range of UP, UC and UPC of the 120 samples included in the method comparison. Data of 
the whole caseload and of samples with inactive or active sediment are shown. 
 All samples Active sediment Inactive sediment 
UPPRM (mg/dL) 28.9 (0.9-919.7) 40.3 (2.3-919.7)a 25.5 (0.9-345.3) 
UPCBB (mg/dL) 56.6 (2.8-614.8) 74.2 (8.9-595.0)a 48.2 (2.8-286.3) 
UC (mg/dL) 162.0 (23.9-234.2) 152.9 (23.9-632.6) 158.2 (28.2-520.7) 
UPCPRM 0.17 (0.01-24.32) 0.28 (0.02-12.92)b 0.15 (0.01-6.97) 
UPCCBB 0.31 (0.03-17.41) 0.42 (0.09-14.95)c 0.22 (0.03-5.78) 
UPPRM, urinary protein measured with pyrogallol red-molybdate; UPCBB, urinary protein measured with 
Coomassie brilliant blue; UC, urinary creatinine; UPCPRM urinary protein-to-creatinine ratio measured with 
pyrogallol red-molybdate;  UPCCBB urinary protein-to-creatinine ratio measured with coomassie brilliant blue. 
Letters  indicate  which  P  value  refer to  comparison  between  samples  with  active  sediment  vs  inactive 
sediment: a <0.05, b P <0.005, c P <0.01. 
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Table 1 Intercept and slope of Passing-Bablok tests and bias recorded in Bland–Altman tests (showed in Figure 8 and 9) of UP and UPC ratios measured with both 
methods for the whole set of sample and for active and inactive sets of samples. Cohen’s k coefficients describing the concordance in classify samples according to 
International Renal Interest Society (IRIS) are also showed. 
UP, urinary protein; UPC, urinary protein-to-creatinine ratio 
 
 
  Passing-Bablok Bland-Altman Cohen 
  Intercept (95% CI) Slope (95% CI) Bias (95% CI) K coefficients 
All UP 
10.70 
(6.67 to 14.91) 
1.21 
(1.10 to 1.33) 
-17,82 
(-7.50 to -28.14) 
 
 UPC 
0.03 
(0.02 to 0.05) 
1.27 
(1.18 to 1.43) 
-0.11 
(0.02 to -0.25) 
0.62 
Active UP 
13.01 
(5.27 to 20.77) 
1.14 
(1.01 to 1.27) 
-19.61 
(4.72 to -43.95) 
 
 UPC 
0.07 
(0.03 to 0.10) 
1.15 
(1.04 to 1.30) 
-0.2 
(-0.06 to -0.34) 
0.59 
Inactive UP 
7.6 
(0.39 to 15.44) 
1.29 
(1.05 to 1.61) 
-17.68 
(-12.6 to -22.77) 
 
 UPC 
0.01 
(-0.02 to 0.04) 
1.49 
(1.26 to 1.83) 
-0.14 
(-0.05 to -0.23) 
0.56 
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Figure 8 Passing-Bablok (left) and Bland-Altman plots (right) showing the comparison of urinary protein (UP) 
between Pyrogallol red molybdate (PRM) and Coomassie brilliant blue (CBB) obtained from 120 cats in whole 
set of sample (A) and for active (B) and inactive sets (C) of samples. In Passing-Bablok plots, the blue line is the 
correlation, the gray line shows best fit and the blue dotted lines represent 95% CI. In Bland–Altman plots, X 
axes represent the average between the two methods, and the Y axes the indicate the difference between PRM 
and CBB; the grey line shows the zero bias, the blue solid with the dashed blue lines represent the bias and 95% 
confidence interval (CI), respectively, the light blue dashed lines are the limits of agreement and the red dotted 
line is the regression line.  
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Figure 9 Passing-Bablok (left) and Bland-Altman plots (right) showing the comparison of urinary protein-to-
creatinine (UPC) ratio between Pyrogallol red molybdate (PRM) and Coomassie brilliant blue (CBB) obtained 
from 120 cats in whole set of sample (A) and for active (B) and inactive (C) sets of samples. In Passing-Bablok 
plots, the blue line is the correlation, the gray line shows best fit and the blue dotted lines 95% CI. In Bland–
Altman plots, X axes represent the average between the two methods, and the Y axes the indicate the difference 
between PRM and CBB; the grey line shows the zero bias, the blue solid with the dashed blue lines represent 
the bias and 95% confidence interval (CI), respectively, the light blue dashed lines are the limits of agreement 
and the red dotted line is the regression line. 
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Discussion	
 
In this study, pre-analytical and analytical variables in quantification of feline urinary 
proteins and UPC ratio were evaluated in order to determine their potential effect on 
clinical decisions. 
The dilution of urinary supernatants that is performed to measure urinary creatinine was 
shown to be a source of variability in dogs (Rossi et al., 2012).  
In this study, although the range of linearity of the Jaffe method (0-20 mg/dL) was 
exceeded in many cases with 1:10 dilution, no difference was found between the three 
dilutions for urinary creatinine measurement or UPC ratios.  
Feline urines generally have higher creatinine concentration (compared to dogs) due to 
the higher concentration capacity. Hence, the lower supernatants predilution (1:10) was 
expected to dilute urine not enough to lower creatinine concentration within the range of 
linearity of the methods. Interestingly, among the 25 samples, in two cases the 1:10 
dilution yielded different IRIS stage when compared to the other two (1:20 and 1:100). 
According to these results, all the 3 dilutions could be used for quantification of urinary 
creatinine in feline urine in order to obtain reliable UPC results. Therefore, in all the other 
test performed in this study, 1:20 dilution was chosen in order to adhere to the internal 
standard operative procedure. 
The two methods for urinary protein quantification yielded CV values similarly to what 
already found in dogs (Rossi et al., 2012). A higher value was found with PRM for the 
sample with protein concentration close to the lower limit of the range of linearity (20 
mg/dL) of the method. It’s worth to note that the magnitude of CV of this sample could 
dramatically affect clinical decisions because it could potentially cause shift of the IRIS 
sub-stage for CKD. However, BP or P samples with low UP and UC are rare (3/120 cases 
in this study); therefore, the influence of high CVs at low protein concentration is 
negligible. The CBB method has the advantage to yield on average lower CV values 
compared to PRM but from a practical standpoint similar numbers of misclassifications 
were found in samples with UPC close to the two IRIS cut-off. Due to the magnitude of the 
intra-assay variability, in samples with UPC close to 0.2 and 0.4 it’s advisable to interpret 
results with caution and to repeat measures of UPC over time in order to properly sub-
stage feline patients affected by CKD. The inter-assay CVs found in this study were higher 
than the most common biochemical analytes (Harr et al., 2013) and could affect clinical 
decisions even more than intra-assay variability. However, because information about 
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biological variability of proteinuria in cats is not available, it’s not known whether these 
inter-assay CV values could be considered acceptable.  
The lack of statistical differences in storage at room and refrigerator temperatures and in 
repeated freezing-thawing cycles during the periods evaluated in this study suggested that 
measurement of the UP in cats may provide reliable results in these settings. 
Some statistical differences were found storing samples at -20°C. UPPRM tended to be 
higher at an intermediate checkpoint (T3w) in active sediment subset. UPCPRM tended to 
be lower at late checkpoints in the whole and inactive sets of samples whereas tended to 
be higher at T3w in active sediment subset in a fashion similar to UPPRM. These 
differences are difficult to explain from a biochemical point of view. A combination of 
sample dehydration (Rossi et al., 2012) and protein degradation (Kania et al., 2010) over 
time could theoretically have produced these peculiar patterns. Accordingly, urine 
supernatant evaporation was suspected to affect protein concentration in stored canine 
urines (Rossi et al., 2012) and proteins were shown to reduce in stored human urine 
samples (Osberg et al., 1990) (Schultz et al., 2000). Moreover, in a previous study in 
human urines it was shown that fragments of albumin were less able to react with wet 
biochemistry methods (Eppel et al., 2000). The different pattern in active and inactive sets 
could reflect the different content of proteases and protein substrates and fragments. 
Further studies using higher number of samples with active and inactive sediment and 
samples with known concentration of specific proteins are needed to confirm these 
hypothesis. 
Differently to UPPRM but similarly to UPCPRM, UPCBB yielded mild lower values at the late 
checkpoint (T12w) albeit the respective UPC values resulted stable. This different variation 
of UP at 12 weeks detected with CBB compared to PRM was not the result of different 
samples included in the two analytical evaluations. This could be stated because no 
significant difference was found between UP values at T0 of the two different analysis 
(both measured with CBB; data not shown). One possible explanation of the decrease of 
UP detected with only CBB could be that the possible denaturation or degradation of 
proteins during long period storage could produce less reactivity with CBB reagent 
(compared to PRM dye). This could be in accordance to previous results in human 
medicine (Eppel et al., 2000). Whether these processes are present and analytically 
significant in feline urine need further research. Another possible cause of the difference at 
3 months between the two methods could be the presence in some samples of the 
freezing-induced sediments. This kind of sediment was demonstrated to generate in 
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urinary supernatants after freezing mainly in presence of higher urinary calcium 
concentration and acid urine, and it was shown to lower the protein concentration (Saetun 
et al., 2009). However, in this study samples were vortexed after thawing and therefore the 
effect of such sediment on these results was probably unlikely.  
Taken together, differences at -20°C found in this study were more important from a 
statistical standpoint than from an practical point of view because at all checkpoints, sets 
of samples and method used UPC values were within the inter-assay CV. Therefore, 
results could be considered stable in all the cases from a clinical point of view. 
Among the several commercially available automated methods for measurement of urinary 
proteins, the two most used dye-binding methods were evaluated in this study. Constant 
and proportional errors were demonstrated in the whole set of samples and agreement did 
not improve neither in samples with inactive sediment, where UPC values gain clinical 
significance. Similar results have been previously reported in a smaller group of feline 
samples, comparing different analytical assays (specifically, colorimetric pyrocatechol 
violet dye-binding says and turbidimetric benzethonium chloride assay) (Fernandes et al., 
2005). In this study, CBB yielded higher protein concentration and in turn UPC ratios when 
compared to PRM. Similar positive bias of CBB was demonstrated in dogs for 
quantification of urinary proteins (Rossi et al., 2016) and total protein in cerebrospinal fluid 
(Riond et al., 2014). Conversely, in human urine CBB tended to yield lower protein 
concentration when compared to PRM (Marshall and Williams, 2000). One important 
cause of discrepancy between these two methods was shown to be the different 
responses of dyes to different types of proteins. For example, both methods were shown 
to constantly underestimate globulin when compared to albumin (Marshall and Williams, 
2000; Riond et al., 2014; Nishi et al., 1985; Watanabe et al., 1986). Samples included in 
this study probably presented a large variability of protein types due to the different 
underlying diseases and this variability could persist also within the inactive and active 
sets of samples. This heterogeneity reflected the actual variability of protein patterns in 
samples commonly assayed in diagnostic laboratories and allowed to quantify analytical 
variability from a practical point of view. Analysis of the protein content of urine samples 
was beyond the aim of this study and whether the agreement between methods is different 
in specific diseases or protein patterns need further research. Because of the different 
response to different proteins, the use of the same standard for calibration of different 
methods and the use of mixed proteins instead of a single protein (such as albumin) as 
standard solution were proven to improve the agreement between methods (Marshall and 
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Williams, 2000). The two methods evaluated in this study were calibrated with the 
standards provided by the manufactures. The use of the original standards had the aim to 
evaluate the actual variability that could be found between laboratories. Further studies 
are needed in order to evaluate whether the agreement improves using the same 
standard, possibly composed by mixed proteins or feline urinary proteins. 
The concordance in classifying samples according to the IRIS staging was never in the 
higher category of classification according to the Cohen’s k coefficients (i.e. “very good”). 
Although concordance in active and inactive subsets of samples was defined moderate 
and lower than that found in whole set of samples, k coefficients were very close in 
magnitude and concordance in the three sets of samples could be considered similar. It 
can be stated that these low concordances were the results of the tendency of CBB to 
misclassify samples in higher stages, as discussed above. On this regard, it’s worth to 
note that in some cases the magnitude of the bias was so high that samples were graded 
as non proteinuric with PRM and proteinuric with CBB. These patients would experience 
different diagnostic approaches and possibly different therapies. Taken together, the 
results of the method comparison study pointed out that the use of the same laboratory 
and the same method should be recommended in monitoring patients over time and the 
comparison of results between different laboratories should be avoided. Moreover, the use 
of external reference intervals (as determined by IRIS) could enhance the clinical effect of 
analytical variability. Therefore, according to these results, the use of laboratory specific 
reference interval, as suggested in human medicine (Dube et al., 2005), or the 
improvement of the IRIS cut-off in relation to the different methods (Jefferey, 2017) should 
be advocated.  
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Conclusion		
 
In conclusion, UPC can be considered relievable when stored up to 6 hours at room 
temperature or 1 week at refrigeration temperature; moreover, no effect of 4 freeze-thaw 
cycles was found but, when frozen samples are used, UPC should be interpret with 
caution in case of storage longer than 4 weeks, given the tendency to reduce in 
magnitude. Dilution of urine to quantify creatininuria did not appear to affect UPC and a 
dilution between 1:10 and 1:100 could be used. 
Both PRM and CBB methods were precise but samples with UPC close to the cut-off of 
IRIS substaging should be carefully interpreted to avoid misclassification. Intrinsic 
difference between analytical methods resulted in inaccuracy and suboptimal concordance 
in classifying samples according to IRIS substaging. This disagreement could affect 
clinical decisions, make questionable the comparison of UPC results between different 
laboratories, and have significant impact in substaging cats affected by CKD, given the 
strict cut-off recommended in published guidelines in which the method of choice is not 
indicated. 
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2.	Effects	of	hematuria	and	pyuria	on	feline	proteinuria	
 
Introduction	and	aims	
 
The interpretation of proteinuria in cats with CKD requires the exclusion of extra-renal 
source of protein (Lee et al., 2005). 
Urinary tract inflammation and hemorrhage are the main causes of post-renal proteinuria 
(Grauer, 2011) and are possible concurrent finding in CKD (Martinez-Ruzafa et al., 2012). 
In dogs, proteinuria significantly increased only in case of macroscopic hematuria and was 
more likely to be high with concurrent hematuria and pyuria. (Vaden et al., 2004) 
No information is available about the effect of such conditions on UPC in feline urinary 
samples. Therefore, the aim of this study was to determine whether the presence of 
hematuria or pyuria affects the urinary protein concentration and UPC ratio in feline urine 
The aim of this study was to determine whether the presence of hematuria or pyuria 
affects the urinary protein concentration and UPC ratio in feline urine. 
 
Materials	and	Methods		
 
Data	collection	
 
The electronic database of the internal medicine unit of Veterinary Teaching Hospital was 
retrospectively searched for urinalysis of feline patients collected between January 2013 
until May 2017.  
Each record of the database corresponds to a sample obtained from client owned cats 
presented at our institution for routine health screening.  
Records of patients without measurement of serum creatinine the same day of urinalysis 
or the day after were excluded. 
Records with incomplete urinalysis data, samples lacking UPC ratio measurement and 
samples with unspecified method of collection or whose method of collection was different 
from cystocentesis and spontaneous micturition after manual collection (Vihena et al. 
2015) were excluded. In the event that a patient had one or more urine samples collected 
within 1 month, only the first record was included and the other record (or records) was 
excluded. 
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For each sample, serum creatinine, UP, UPC ratio, USG, and semiquantitative evaluation 
of urinary red blood cells (RBC) and white blood cells (WBC) were recorded and used for 
analysis.  
 
Analytical	procedures	
 
During the study period, the same standard operative procedures (SOPs) for urinalysis 
were performed in our lab, between 3 and 5 hours after collection. Specifically, urine 
specific gravity (USG) was determined by a handheld refractometer (Clinical 
Refractometer, model 105, Sper Scientific, Scottsdale, AZ, USA). In order to perform 
sediment examination, five mL of urine were transferred from the syringe or the urine 
container to a sterile conical tube). Tubes were than centrifuged at 1250 rpm for 5 minutes 
(450G) (Hermle Z300, Labnet international, Edison, NJ, USA) and 4.75 mL of supernatant 
was removed by suction using a dispensable pipette according to current guidelines 
(ECLM, 2000) in order to avoid loss of sediment and supernatant contamination by 
elements of the sediment and it was transferred in another tube.  
Sediments were resuspended in the remaining supernatant and 50 µL were placed on a 
slide, covered with a microscope coverslip (24x32 mm) and evaluated microscopically al 
100x (low power field, LPF) and 400x (high power field, HPF) magnifications. Urinary RBC 
and WBC were countered and reported as estimation of the mean number per high power 
field (HPF, 400x). 
Hematuria and pyuria were defined as >5 RBC/HPF and >5 WBC/HPF, respectively 
(Callen et al., 2016). Samples with both <5 urinary RBC and WBC/HPF were classified as 
inactive.  
On the suctioned supernatant, UP was measured using Pyrogallol red molybdate (PRM) 
method and UC were measured with modified Jaffe method using an automated 
biochemical analyzer (Cobas Mira, Roche Diagnostics, Basel, Switzerland). Serum 
creatinine was measured with the same biochemical method. 
 
Study	design	
 
To the study purposes, a case-control study was performed separately for both hematuria 
and pyuria. Case-control comparison was applied in order to normalize the effect of other 
factors affecting proteinuria such as renal diseases, or pyuria on samples with hematuria 
and hematuria on samples with pyuria, 
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Concerning hematuria, all samples with >5 RBC/HPF were grouped together (group 
“RBC”) and each sample was matched with an other sample having <5 RBC/HPF, to form 
the control group labeled “control-RBC”. The match were based on serum creatinine (both 
samples with lower or higher 1.6 mg/dL, corresponding to the upper limit of reference 
interval of our laboratory), USG (both samples with lower or higher 1035, considered the 
limit of the concentration ability in cats) (Reppas and Foster, 2016) and pyuria (both 
samples with lower or higher 5 WBC/HPF) 
Concerning pyuria, all samples with >5 WBC/ HPF were grouped together (group “WBC”) 
and the control group (group “control-WBC”) was similarly created matching each sample 
of the former group to an other sample having <5 WBC/HPF, on the basis of serum 
creatinine, USG and hematuria (categorized as higher or lower 5 RBC/HPF). 
 
A second evaluation was performed only on the subset of samples with USG >1035 and 
serum creatinine <1.6 mg/dL. These patients were considered to present adequate renal 
function and therefore kidney disease and renal proteinuria were deemed less likely. 
Samples without pyuria (<5 WBC/HPF) were grouped according to the level of RBC/HPF 
as follow: <5 RBC/ HPF, 5-20 RBC/HPF and >20 RBC/HPF. A similar analysis on samples 
without hematuria (<5 RBC/HPF) was not possible since in our database only five samples 
had concurrently >5 WBC/HPF, <5 RBC/HPF, USG >1035 and serum creatinine <1.6 
mg/dL. 
 
Statistical	analysis	
 
Statistical analysis was performed with commercially available software (GraphPad Prism 
5.0; GraphPad Software, San Diego, CA, USA) and a P value <0.05 was considered 
statistically significant. Distribution of variables was assessed by Kolmogorov-Smirnov 
test. Mann-Whitney U test was used to compare UP, UPC ratio, between hematuria and 
pyuria groups with the respective control groups. Kruskal-Wallis test and Dunn post test 
were used to compare UP and UPC between groups divided according to the level of 
RBC/HPF. 
 
Results	
 
Two hundred and six complete urinalysis, associated with serum creatinine measurement, 
were retrieved. RBC were <5/HPF in 125 samples, between 5 and 20/HPF in 22 samples 
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and >20/HPF in 59 samples. WBC were <5/HPF in 180 samples, between 5 and 20/HPF 
in 16 samples and >20/HPF in 10 samples.  
Serum creatinine ranged from 0.51 to 10.93 mg/dL (median =1.63 mg/dL), UP ranged from 
1.1 to 480.0 mg/dL (median =23.65 mg/dL), UPC ratio from 0.01 to 10.20 (median =0.15), 
USG from 1007 to 1096 (median=1033).  
 
The case-control analysis revealed significantly higher UP (P=0.0048) and UPC 
(P=0.0433) in “RBC” group compared to “RBC-control” group whereas no significant 
difference were found between “WBC” and “WBC-control” groups (Figure 10). 
In samples without pyuria, USG >1035 and serum creatinine <1.6 mg/dL grouped 
according to the levels of RBC/HPF, UP (median: 45.5 mg/dL; min-max: 12.6-367.8 
mg/dL) and UPC (median: 0.19; min-max: 0.04-1.78) were significant higher (P=0.0035 
and 0.0339, respectively ) in “>20 RBC/HPF” group than in “<5 RBC/HPF” group (UP: 
median: 28.2; min-max: 1.0-352.0; UPC: median: 0.10; min-max: 0.01-1.42), whereas in 
“5-20 RBC/HPF” group neither UP (median: 30.3; min-max:13.4-93.0) nor UPC (median: 
0.06; min-max: 0.05-0.95) were different (Figure 11). According to IRIS staging for 
proteinuria (Elliott and Watson, 2016), in “>20 RBC/HPF group” 4 samples (20%) were 
defined proteinuric (UPC ratio > 0.4) and 9 samples (45%) borderline proteinuric (UPC 
ratio between 0.2 and 0.4). 
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Figure 10 Distribution of urine protein (UP) concentration and urinary protein-to-creatinine (UPC) ratio measured 
in hematuria (83 samples) and pyuria (31 samples) groups and in the respective control groups (83 and 31 
samples, respectively). Box plots represent the interquartile range (IQR), and the horizontal line represents the 
median value. Whiskers extend to the furthest observations within ± 1.5 IQRs of the first or third quartile. Dots 
indicate values > 1.5 IQR. Red asterisks within boxes indicate a significant (P < 0.05) difference compared with 
control group 
 
 
Figure 11 Distribution of urine protein (UP) concentration and urinary protein-to-creatinine (UPC) ratio measured 
in samples grouped according to RBC<5 RBC/hpf (56 samples), RBC between 5 and 20 RBC/hpf (8 samples) and 
>20 RBC/hpf (20 samples) without pyuria, with serum creatinine < 1.6 mg/dL and USG >1035.Box plots represent 
the interquartile range (IQR), and the horizontal line represents the median value. Whiskers extend to the 
furthest observations within ± 1.5 IQRs of the first or third quartile. Dots indicate values > 1.5 IQR. Red asterisks 
within boxes indicate a significant (P < 0.05) difference compared with RBC<5 RBC/hpf group. 
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Discussion	
		
According to the results of this study, the presence of RBC in urine affects UP and in turn 
UPC ratio.  
Higher UPC values were recorded with higher amount of RBC (>20 RBC/HPF). In dogs, 
significant increase of UPC was demonstrated only with gross hematuria (>250 
RBC/HPF). In that study RBC from peripheral blood were added to urine samples and 
were serially diluted whereas in our study field samples were included (Vaden et al., 
2004).  
Although the most probable source of hematuria in our samples were hyatrogenic 
hematuria during cystocentesis, other causes of hematuria such as mucosal bleeding due 
to coagulation disorder or lesions such as neoplasia could not be excluded, albeit unlikely.  
Therefore, the different study design and the different protein patterns present in urine 
could explain the difference between these results and those found in dogs. Further 
studies are necessary in order to determine whether different source of blood change 
differently UPC. Interestingly, in the set of samples without pyuria (and serum creatinine 
<1.6 and USG>1035) grouped according to the level of RBC/HPF, the sample with the 
highest UPC ratio (UPC=1.78) had macroscopic hematuria. Hence, it could be speculated 
that UPC could proportionally increase as RBC increase. 
Conversely to hematuria, pyuria did not increase the UP and UPC ratio. This is in 
accordance to what found in dogs, where UPC was higher in pyuric samples only when 
associated with hematuria (Vaden et al., 2004). Few samples had concurrent pyuria and 
laboratory parameters compatible with adequate renal function (i.e. creatinine within RI 
and USG > 1035). This lack could be due the concurrent presence of CKD and UTI in our 
population, as already reported, (Mayer-Roenne 2007). Moreover, it could be due to the 
tendency to not measure UPC in samples with pyuria and UTI and that bias could be 
considered a limitation of this retrospective study.  Therefore, further prospective studies 
are warranted to better evaluate the effect of pyuria on UP and UPC. 
Although the study was designed to attempt to exclude the main causes of pathologic 
proteinuria except hematuria and pyuria, the presence of renal or prerenal diseases in 
some samples could not completely excluded but was deemed unlikely.  
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Conclusion	
 
In conclusion, hematuria could affect UP and UPC in cats and the effect appeared to be 
proportional to RBC concentration. From a practical point of view, diagnosis of renal 
proteinuria and substaging of proteinuria in patients affected by CKD according to IRIS 
should be avoided in samples with >20 RBC/HPF or interpreted with caution. Further 
prospective studies are necessary to confirm the minor effect of pyuria on proteinuria 
reported in this study. 
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3.	Comparison	between	the	concentration	of	creatinine	and	
symmetric	dimethylarginine	(SDMA)	in	blood	of	Holy	Birman	
cats		
 
Introduction	and	aims	
 
Holy Birman cats have a physiologically high concentration of serum creatinine and urea 
compared with the feline general population (Reynolds et al., 2010; Paltrinieri et al., 2014). 
Moreover, Holy Birman cats have been reported as prone to develop FIP (Pesteanu-
Somogyi et al., 2006), a disease on which renal functions are frequently altered 
(Pedersen, 2014), and may be affected by hereditary polycystic kidney disease (PKD), 
and therefore in this breed clinical and laboratory investigation may be frequently 
performed also in younger cats. In all these clinical scenarios, the presence of renal 
disease risks to be overestimated in Holy Birman cats, due to their physiologically high 
creatinine concentration: the detection of high serum creatinine levels often induces 
owners and vets to perform unnecessary and stressful clinical and laboratory workup to 
exclude the presence of CKD. 
Recently, symmetric dimethylarginine (SDMA) has been proposed as a novel marker for 
an early diagnosis of CKD in cats (Jepson et al., 2008; Braff et al., 2014; Hall et al., 
2014a). As for creatinine, SDMA is excreted by the kidneys and therefore its serum 
concentration increases during CKD and this increase seems to occur earlier than the 
increase of creatinine in cats (Hall et al., 2014a). 
Based on our knowledge on the metabolism of SDMA (Fleck et al., 2003), which is 
different from that of creatinine (Braun et al., 2003), it is very likely that despite the high 
creatinine concentration, in clinically healthy Holy Birman cats SDMA have the same 
concentration than in the general feline population. 
Therefore, SDMA may be proposed as a marker to monitor the health status in this feline 
breed, thus reducing the number of unnecessary samplings and testing to exclude CKD. 
The aim of this study was to assess whether clinically healthy Holy Birman cats (as a 
representative breed with high creatinine concentration) have normal SDMA 
concentrations, thus allowing, in this breed, a better evaluation of renal function compared 
with creatinine, and to define the breed-specific reference interval for SDMA, if needed. 
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Materials	and	Methods	
	
Caseload	
 
This study was done on blood samples collected from clinically healthy Holy Birman cats, 
randomly collected through collaboration with the Italian association of Birman cats 
breeders, that were subjected to regular veterinary visits, that included routine bloodwork, 
urinalysis, abdominal ultrasound and genetic screening for hereditary disorders. The 
inclusion criteria for Birman cats were the absence of any abnormality detected by 
physical examination and diagnostic imaging (see below), and the absence of laboratory 
changes compared with breed specific reference intervals.  
As a control group, blood from cats belonging to breed other than Holy Birman, and 
collected at our Institution during annual wellness visits, before elective surgery (e.g. 
castration, dental scaling) or within clinical examination for diseases not associated with 
decreased glomerular filtration rate (mostly non-metastatic tumors). The inclusion criterion 
for these control cats was a serum concentration of creatinine lower than 1.6 (i.e. the 
threshold value considered as normal by the International Renal Interest Society) (IRIS, 
2015x), the absence of other abnormalities in routine blood and urine analysis.  
The study was approved by the Institutional Animal Care and Use Committee (approval 
number: 2/2016). 
In both groups, samples from cats younger than 6 months or affected by diseases 
potentially influencing the glomerular filtration rate, and samples presenting gross 
abnormalities consistent with hemolysis or lipemia were excluded from the study. 
Samples were collected from the cephalic vein by the referring veterinarians upon 
informed consent from the owners, placed in tubes without anticoagulant, centrifuged and 
frozen at -20°C to be periodically sent to our Department. At our Department, samples 
were thawed, and used to perform a basic panel of biochemical tests to exclude the 
presence of laboratory abnormalities. This panel included the measurement of creatinine, 
urea, total protein, albumin, ALT, GGT, cholesterol, and was performed using an 
automated spectrophotometer (Cobas Mira, Roche, Basel, Switzerland) using reagents 
provided by Hagen Diagnostica (Arezzo, Italy) The remaining serum samples sent to 
IDEXX laboratories to perform SDMA analysis. SDMA was measured in duplicate or, when 
the difference between the two measurements exceeded 2.0 µg/dL, in triplicate. The mean 
values of the replicas recorded in each cat were included in this study. 
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Statistical	analysis	
 
Results regarding age, and creatinine and SDMA recorded in Holy Birman and in from cats 
of other breeds were compared using a non parametric t-test for unpaired samples (Mann 
U Withney) using statistical software (Analyse-it version 2.21, Analyse-it Software Ltd, 
Leeds, UK). The same software was used to assess, using the Pearson’s chi square test, 
the possible differences in the proportion of cats with increased SDMA compared with the 
reference intervals among Holy Birmans and among cats of other breeds. 
In order to assess whether the concentration of SDMA in Holy Birman cats falls within the 
reference intervals for the general population of clinically healthy cats determined by the 
producer of the kit, we applied the method of transference of reference intervals (NCCLS, 
2010), that validates pre-existing reference intervals if less than 10% of 20 randomly 
selected results. A breed-specific reference interval was then established for Birman cats 
using an Excel spreadsheet with the Reference Value Advisor (v. 2.0) set of 
macroinstructions (Geffré et al., 2011), that, according the recommendations of the IFCC-
Clinical and Laboratory Standards Institute (NCCLS, 2010), performs descriptive statistics, 
tests of normality (Anderson–Darling with histograms and Q–Q plots and Box–Cox 
transformation) and outlier analysis. Both Dixon–Reed and Tukey tests were used to 
detect outliers, that were retained unless clear reasons to classify them as aberrant 
observation were found, as recommended by the ASVCP guidelines (Friedrichs et l., 
2012). Reference intervals were calculated using a non-parametric bootstrap method, that 
calculated also the 90% confidence interval of reference limits. Linear regression was 
used to assess the possible influence of age on reference intervals of SDMA in Holy 
Birman cats. 
	
Results	
	
Group	composition	
 
The study population was composed by 101 cats, which fulfilled the inclusion criteria.  
Of these, 50 were Holy Birman cats (21 female, 6 spayed female, 17 male, 6 neutered 
male; age range: 6 months to 13 years, median age: 4 years).  
The remaining 51 cats belong to 8 different breeds (39 domestic shorthair, 3 Persian, 2 
Exotic shorthair, 2 Maine Coon, 2 British shorthair, 1 Devon Rex, 1 Scottish fold, 1 
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Siberian cat). This group was composed by 10 female, 21 spayed female, 4 male, 16 
neutered male (age range: 6 months-17 years, median age: 9 years). 
The age of Holy Birman cats was significantly lower than the age of cats of other breeds 
(P<0.001). 
 
Creatinine	and	SDMA	concentration	
 
Both creatinine (mean ± SD: 1.58 ± 0.36 mg/dL; median: 1.47 mg/dL) and SDMA (12.2 ± 
2.8 µg/dL; 12.0 µg/dL) were significantly higher (P<0.001 for both) in Holy Birman cats 
than in cats of other breeds (1.17 ± 1.16 mg/dL; 1.16 mg/dL for creatinine, and 10.1 ± 2.5 
µg/dL; 9.5 µg/dL for SDMA). However, the distribution of data (figure 12) revealed a higher 
degree of overlapping between groups for SDMA than for creatinine.  
 
 
Figure 12 Distribution of results of creatinine and SDMA recorded in Holy Birman cats and in cats of other 
breeds. Boxes indicate the I-III interquartile interval, the horizontal line corresponds to the median value, the 
vertical lines are the limits of suspected outlier distribution according to the Tukey rule. Each black dot 
corresponds to an individual value. Far outliers are indicated with the open circles. 
 
No significant gender-related differences were found for SDMA for Holy Birman cats 
(P=0.963) or for cats of other breeds (P=0.602). Similarly, no significant differences by age 
were recorded in the two groups (P=0.684 and P=0.560, respectively). 
The analysis of individual data (table 11) revealed that in 20/50 Holy Birman cats (40.0%) 
the concentration of serum creatinine was higher than 1.60 mg/dL, i.e. the threshold 
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recommended to classify cats as affected by CKD stage II (Elliot and Watson, 2016). In 5 
out these 20 cats the deviation from the IRIS threshold was lower than 10%, which may be 
consistent as an acceptable analytical error for creatinine (Ricós et al., 1999) while in the 
remaining 15 cases the deviation from the threshold largely exceeded 10%. However, all 
the values were below the upper limit of the breed-specific reference interval established 
for Holy Birman cats in a previous study (2.5 mg/dL) (Paltrinieri et al., 2014). 
 
Table 9 Individual data recorded in Holy Birman cats and in cats of other breeds. In bold, creatinine values 
higher than the threshold recommended by the international renal interest society (IRIS)4 to classify cats in 
stage II of renal disease, and SDMA values higher than the upper reference limit recommended by the producer 
of the test and included in the new IRIS stagin system.4  
Holy Birman Cats Cats of other breeds 
Cat Age Creatinine (mg/dL) SDMA (µg/dL) Cat Age Creatinine (mg/dL) SDMA (µg/dL) 
1 12 1.89 13.5 1 1 1.05 11.0 
2 4 1.32 10.0 2 0.5 1.26 14.0 
3 8 1.62 13.5 3 0.5 0.92 12.5 
4 1 1.29 14.0 4 12 0.84 6.0 
5 2 1.28 11.0 5 2 0.98 9.0 
6 1 1.12 2.0 6 1 1.01 15.5 
7 5 1.95 15.5 7 1 1.02 9.5 
8 1 1.24 12.5 8 8 1.02 12.5 
9 4 1.37 10.7 9 10 1.03 7.5 
10 2 1.49 13.5 10 12 1.06 8.0 
11 4 1.40 11.0 11 12 1.07 9.3 
12 1 1.01 7.5 12 12 1.09 7.0 
13 2 1.80 15.3 13 9 1.10 15.5 
14 2 1.26 11.0 14 16 1.10 9.5 
15 3 1.42 13.5 15 1.5 1.12 10.0 
16 2 1.47 14.5 16 5 1.12 8.5 
17 8 1.36 9.0 17 2 1.12 4.0 
18 9 2.11 11.0 18 2 1.14 9.0 
19 4 1.57 8.7 19 3 1.15 10.0 
20 6 1.55 9.0 20 7 1.16 8.0 
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21 7 1.26 10.5 21 4 1.16 10.0 
22 11 0.85 8.5 22 9 1.16 10.5 
23 11 1.29 8.5 23 5 1.17 9.0 
24 11 1.43 9.0 24 2 1.17 9.0 
25 10 1.17 16.5 25 14 1.17 9.0 
26 3 2.26 15.0 26 10 1.19 9.5 
27 1 2.12 13.0 27 9 1.20 8.5 
28 5 1.51 13.5 28 10 1.23 13.3 
29 2 1.47 12.0 29 8 1.23 11.0 
30 2 1.73 13.0 30 12 1.23 8.3 
31 1 1.44 11.5 31 6 1.23 10.5 
32 13 1.44 13.0 32 12 1.24 11.5 
33 5 2.22 15.5 33 11 1.24 9.0 
34 1 1.25 11.0 34 2 1.26 14.5 
35 2 2.13 19.5 35 10 1.27 9.0 
36 1 1.75 12.0 36 17 1.31 12.5 
37 1 1.33 15.5 37 13 1.34 10.5 
38 1.5 1.16 12.5 38 10 1.42 12.5 
39 1.5 1.95 12.0 39 4 1.43 9.0 
40 4 2.01 13.5 40 15 1.53 11.0 
41 8 1.81 15.0 41 11 1.29 13.0 
42 6 2.05 13.5 42 11 1.36 9.0 
43 1.5 1.36 12.0 43 14 1.03 9.0 
44 6 2.42 16.0 44 9 1.28 6.0 
45 6 1.61 11.0 45 11 1.39 15.0 
46 7 1.80 11.5 46 7 0.8 12.0 
47 4 2.15 13.5 47 6 1.44 10.0 
48 5 1.31 12.0 48 14 1.08 9.0 
49 5 1.63 12.0 49 10 1.39 8.0 
50 5 1.79 9.0 50 8 0.91 9.0 
 
   
51 14 1.53 13.0 
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The concentration of SDMA was higher than the upper limit of the pre-existing reference 
interval (14 µg/dL) in 10/50 Holy Birman cats (20.0%), and in 4 cats belonging to other 
breeds (7.8%). The proportion of individuals with increased SDMA compared with the 
reference intervals was not significantly different (P=0.100). In 7 of the 10 Holy Birman 
cats with increased SDMA (14.0% of the total number of Birman cats included in this 
study), and in all the 4 cats of other breeds with increased SDMA, the deviation from the 
reference intervals did not exceeded 1.5 µg/dL (approximately the 10% deviation that is 
consistent with the intrinsic variability of the method determined by the CVs recorded in 
duplicate or triplicate measurement). Also in this case the proportion of cats with a 
deviation lower than 10% compared with the reference intervals was not significantly 
different in Holy Birman cats compared with cats of other breeds (P=0.374). A deviation 
higher than 1.5 µg/dL from the upper reference limit was found only in 3 Holy Birman cats 
(6.0% of the total number of Holy Birman cats included in the study), whose SDMA 
concentration was 16.0, 16.5, 19.5 µg/dL, respectively. Two of these 3 cats had also 
creatinine values higher than 1.6 mg/dL. Despite in all the cats of other breeds the 
deviation from the upper reference limit was lower than 1.5 µg/dL, no significant 
differences (P=0.076) were found between Holy Birman cats and cats of other breeds with 
a deviation higher than 1.5 µg/dL from the upper reference limit.  
However, based on these results, the transference method for reference interval did not 
validate, in Holy Birman cats, the reference interval generated in the general feline 
population. Therefore, a breed specific reference interval was generated for SDMA using 
the statistical approach recommended by the ASVCP guidelines. This approach identified 
a single outlier that, however, was in the lower and not clinically significant part of the 
dataset (Figure 12), and defined a reference interval ranging from 3.5 µg/dL (90% 
confidence interval: 2.0-8.5 µg/dL) to 18.7 mg/dL (90% confidence interval: 15.5-19.5 
µg/dL). 
	
Discussion	
 
The results of this study confirmed the physiologically high serum concentration of 
creatinine in Holy Birman cats, already reported in previous studies (Reynolds et al., 2010) 
(Paltrinieri et al., 2014), either in terms of cats with creatinine values higher than the IRIS 
threshold for stage II4 or in terms of magnitude of the increase compared with this 
threshold.  
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Figure 13 Distribution of data regarding SDMA concentration in Holy Birman cats. The bars indicate the 
frequency of each point value. Vertical solid lines indicate the limits of the reference intervals (dotted lines 
represent the 90% CI of each limit). The grey line indicates the fitted distribution, which depicts a Gaussian 
curve. 
 
Also the concentration of SDMA was also increased in some Birman cats. Theoretically, 
cats with increased SDMA should be classified, according to the most recent version of 
IRIS guidelines (Elliot and Watson, 2016) in stage I when creatinine is <1.6 mg/dL or in 
higher stages when creatinine is >1.6. However, in most cases, the increase recorded in 
Holy Birman cats was quantitatively minimal and therefore, this increase may be imputable 
to the analytical variability of the method, determined by the analysis of duplicate analysis 
of SDMA on the samples included in this study (IRIS, 2015x), coupled with the normal 
variability compared with reference intervals, that actually include only 95% of the general 
population (Geffré et al., 2009). An increase of similar magnitude was found also in a 
similar proportion of cats of other breeds, as well as in a previous study in dogs (Nabity et 
al., 2015), on which the maximum values of 16 µg/dL, despite of an upper reference limit 
of 14 µg/dL, was wound in healthy subjects. This confirms that such an increase in 
magnitude is likely non relevant on a biological/diagnostic point of view. In order to exclude 
that these cats have an ongoing CKD, not diagnosed by serum creatinine due to its lower 
sensitivity compared with SDMA (Hall et al., 2014a), repeated measurements over time 
should performed since only persistent increases of SDMA should be considered 
consistent with an ongoing CKD (Elliot and Watson, 2016). However, as a further support 
to the hypothesis that the slight increases recorded in some cats were likely dependent on 
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the intrinsic variability of the method, in both breed groups these changes were found 
either in cats older than 8 years, that are potentially at risk of CKD (Elliot and Watson, 
2016), and on which SDMA may be an earlier marker of CKD than creatinine (Hall et al., 
2014a) (Hall et al., 2014b), or in younger cats.  
Despite the absence of statistical differences in the proportion of cats with increased 
SDMA, it is worth to note that in three cats (6% of Holy Birman cats) increases of SDMA 
concentration not attributable to the analytical variability were found, with an SDMA value 
particularly high in one of these. All these three cats were clinically healthy both at the time 
or sampling and during a follow up of 9 months, and did not have other laboratory 
abnormalities except for a concentration of serum creatinine higher than the IRIS threshold 
in 2 cases. This confirms the risk of overestimation of CKD in Holy Birman cats: although 
the lack of clinical signs over time demonstrate that these cats are likely healthy, based on 
laboratory results alone it is impossible to determine whether these two cats are affected 
by an early phase of CKD or are really healthy but have, in addition to the increased 
creatinine concentration typical of this breed, a physiologically high concentration of SDMA 
or any other condition that induces a transient decrease of GFR. 
 
In any case, the presence of a higher, although non significant, proportion of cats with 
SDMA higher than the reference intervals induced a significant difference between Holy 
Birmans and other breeds of cats in terms of SDMA concentration, as for creatinine, for 
which, however, the overlap between data of the two breed groups was less pronounced. 
Moreover, the transference method did not allow validating the pre-existing reference 
interval. In the generation of the new reference interval a single outlier was found, but it 
was retained in the dataset since low values of SDMA do not have a clinical significance. 
However, the breed-specific reference interval generated in this study for Holy Birman cats 
was largely overlapping with the pre-existing one, and despite the upper reference limit 
was higher than that recommended for the whole population of cats, its huge confidence 
interval, depending on a single cat with very high SDMA value, suggests that the reference 
interval of the general feline population may be used in routine practice, taking into 
account that, occasionally, values higher than this reference interval could be detected. 
Taken together, all these results confirm that, independently on the breed, SDMA, that is 
considered a sensitive marker of CKD, has not an absolute specificity, as reported in 
previous studies (Hall et al., 2014a), and that increased SDMA may be occasionally found 
in Holy Birman cats. However, the comparison of the frequency and magnitude of 
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increased SDMA and increased creatinine in Holy Birman cats, confirms the hypothesis of 
this study, that SDMA is less frequently and less severely increased in Holy Birman cats 
than creatinine. The design of this study was not adequate to investigate the mechanisms 
responsible for this difference. However, the different behavior of the two analytes 
suggests that the high creatinine concentration of  Holy Birman cats does not depend on a 
decreased glomerular filtration rate, which, based on our knowledge on SDMA, would 
more likely induce increases of SDMA than of creatinine (Hall et al., 2014a) (Fleck et al., 
2003) (Braun et al., 2003). It has been demonstrated that SDMA is less affected by body 
mass than creatinine (Hall et al., 2014b) (Hall 2015 et al., 2015), and that in other species, 
physiologically high creatinine concentration are found in breeds with increased muscle 
mass compared with the other breeds (Zaldívar-López et al., 2011). 
However, the muscle mass of  Holy Birman cats is not particularly different from those of 
other cats and it is therefore unlikely that the different behavior of the two analytes 
depends on the muscle mass. Similarly, the differences between Holy Birman cats and 
cats of other breeds cannot be explained by the significant difference recorded for age 
that, if present, would have more likely induced the opposite effect (frequent increases of 
SDMA in the group of older cats, i.e. cats of other breeds rather than in Holy Birman cats). 
Whatever is the mechanism responsible for these differences, to be investigated through 
future studies, on a practical point of view the most important conclusion of this study is 
that SDMA may be a better marker of the health status of the kidney in Holy Birman cats 
compared with creatinine. Based on this study, SDMA could be recommended as a marker 
of choice for routine investigating renal function in this breed (and possibly in any other 
breed with physiologically high creatinine levels) and it should be included in any general 
health screening profile of these cats. The coupled analysis of results of creatinine and 
SDMA would allow to not overdiagnose CKD in Holy Birman cats and to perform additional 
clinical and laboratory investigations only in those cats on which both these analytes are 
outside the breed specific reference intervals or largely outside the reference interval of 
the general feline population. 
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Conclusion	
 
This study supports the idea that SDMA may be less frequently elevated than creatinine in 
apparently healthy Birman cats when non-breed-specific laboratory RIs are used. On one 
hand, this study confirms the importance of using a breed-specific RI for investigating renal 
function in Birman cats; on the other hand, SDMA could be recommended as a marker of 
choice for routine investigation of renal function in this breed (and possibly in other breeds 
with physiologically high creatinine levels) and it should be included in any general health 
screening profile of these cats. The analysis of both creatinine and SDMA would help to 
prevent the over-diagnosis of CKD or errors in staging renal disease in Birman cats. It 
would also help to limit further clinical and laboratory investigations in Birman cats to only 
those that have creatinine concentrations outside of the breed-specific RIs or SDMA 
concentrations that are largely outside of the RI of the general feline population  
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4.	Serum	and	urinary	biomarker	in	cats	
 
General	materials	and	methods:	patients	enrolment	and	sample	
collection	
Client owned cats were prospectively enrolled between November 2014 and September 
2017. All cats were presented for routine health screening at the Internal Medicine unit of 
the Veterinary Teaching Hospital (Department of Veterinary Medicine, University of Milan) 
Informed consent was signed by the owners and, according to the ethical committee 
statements of the University of Milan (number 2/2016), biological samples collected in this 
setting could be used also for research purposes. The study populations included both 
cats at risk to develop CKD and cats already affected by CKD.  
 
Two populations of cats were included in this study: 
- healthy cats older than 8 years of age and healthy cats belonging to breeds potentially 
affected by familiar CKD (i.e. Abyssinian, Persian, Maine Coon) at any age. 
- cats affected by CKD at any age and breed; CKD was diagnosed and staged according 
to criteria listed in Table 1, Table 4 and Table 5. 
Exclusion criteria were the following: cats affected by UTI, pre-renal or post-renal 
proteinuria, cardiovascular diseases, malignant neoplasia, hyperthyroidism or other 
endocrinopathies; treatments with drugs affecting blood pressure (such as glucorticoids, 
ACEi, calcium channel blockers). In case of UTI, the patient (or the urinary sample) was 
included after the resolution of infection. 
 
To identify patients that fulfilled inclusion criteria, a complete physical examination, the 
measurement of SBP and collection of boold and urine samples were performed at each 
cat at the visit,. SBP was measured after a period of acclimatization by the Doppler 
technique (Minidop ES-100VX, Hadeco, Kanagawa, Japan) according to published 
guidelines. (Brown et al., 2007; Taylor et al., 2017) Specifically, the mean values of three 
consecutive and consistent (<20% variability) values were recorded. 
In case of non-collaborative cats or evidences of stress before the measurement of SBP, a 
further clinical visit (within the following 7 days) was proposed to the owner in order to re-
evaluated only SBP and avoid any other stressful clinical procedure.  
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SBP was also evaluated 7 days later in case of abnormal high values, in order to exclude 
the white-coat hypertension (Belew et al., 1999), maintaining the same method of 
measurement (i.e. position, body site and cuff) 
Blood samples were collected by venepuncture from cephalic or jugular vein after 12 
hours fasting. 1 mL of blood was placed in EDTA and the remaining volume (on average 
2,5 mL) was placed in a plain tube to obtain serum. 
CBC was performed with aumated cell counter (Sysmex XT 2000 iV, Sysmex® Co, Kobe, 
Japan). A biochemistry panel (including Sodium, Phosphorous, Calcium, Potassium, Urea, 
Creatinine, Glucose, Total Proteins, Cholesterol, Triglycerides, ALT, ALP, GGT) was 
performed with an automated biochemical analyser (Cobas Mira, Roche® Diagnostic, 
Basel, Switzerland). Serum electrophoresis was performed with Sebia Hydrasis (Sebia 
Italia Srl, Bagno a Ripoli, Firenze, Italia). Fiv/Felv test was performed with rapid immuno-
chromatographic snap test (Feline FIV/FeLV combo test, IDEXX laboratories, IDEXX 
Europe B.V., Hoofddorp, The Netherlands) whenever not previously reported and 
epidemiologic data suggested the execution.  
At least 7 mL of urine were collected by ultrasonographic-guided cystocentesis. In cats 
with CKD or in cats with signs of UTI, an aliquot of urine (1 mL) was sent to the 
microbiologist for bacterial culture.  
A complete urinalysis was performed within 4 hour from collection with the following test: 
macroscopic physical examination of urine; chemical analysis with reagent strips (Combur 
10 test, Roche diagnostics, Risch-Rotkreuz, Switzerland); USG quantification with a 
portable refractometer (Sper scientific, Scottsdale, USA); urinary sediment evaluation 
according as previously described (Rossi et al., 2012); and UPC quantification by 
measuring urinary total proteins with pyrogallol red molybdate (Urine proteins, Sentinel 
diagnostics, Milan, Italy) and urinary creatinine (Creatinina, Real-Time Diagnostics, 
Viterbo, Italy) methods applied to Cobas Mira analyser (Cobas Mira, Roche® Diagnostic, 
Basel, Switzerland) 
Other exams (e.g. abdominal ultrasonography) were performed case by case depending 
on the clinical and laboratory status. 
 
At each visit, cats affected by CKD were staged according to IRIS staging (Elliott and 
Watson, 2016). All patients were monitored over a 18 months period and cats at risk to 
develop CKD (IRIS stage 0) and at IRIS stage 1 were checked every 6 months whereas 
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cats at stage 2-4 were checked every 3 month, unless worsening of the clinical condition 
will recommend additional sampling to assess their health status. 
 
In order to perform the study (biomarker studies) described below, at first visit and at each 
checkpoint, aliquots of serum (100 µL) were stored at -20°C in order to measure the serum 
concentration of big Endothelin-1 (big-ET1, homocysteine and aldosterone. Aliquots of 
urine supernatant (300 µL) were stored to measure the concentration of alpha-1 
microglobulin and big-ET1, and to performer the urinary protein electrophoresis with 
sodium dodecyl sulfate-agarose gel electrophoresis (SDS-AGE). 
Since the volume of serum and urine were not sufficient for all the biomarker studies, not 
all samples were used in each study. 
However, in the studies described below only the samples included in this prospective 
collection were used. 
 
General	results	
 
Forty-eight cats were included in this prospective study which from which it was possible to 
collect 99 serum and urinary samples.   
At the time of inclusion 19 (39.6 %) were staged as At risk, 6 (12.6 %) in stage 1, 16 
(45.2%) at stage 2, 4 (8.3) at stage 3 and 3 (6.3 %) at stage 4. 
Among the 29 cats with CKD (Table 10), 13 were followed over time (5 for three months, 5 
for twelve months, one for fifteen months and 2 for eighteen months). Three cats 
progressed toward higher stage of CKD (one from stage 1 to stage 2, one from stage 2 to 
stage 3 and one from stage 3 to stage 4) and 10 remained in the same IRIS stage. 
Among the 19 cats at risk (Table 11), 17 cats had follow-up available (5 for six months, 5 
for twelve months 2 for fifteen months and 5 for eighteen months). Eight patient 
progressed toward CKD (4 to stage 1 and 4 to stage 2) and 9 remained stable during the 
time monitored. 
Median and interquartile range of the main CBC and biochemistry results obtained from 
the enrolled cats are shown in Table 12. 
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Table 10 Cats with CKD included in the biomarker study. Breed, sex, age (months), presence of symptoms 
related to CKD, duration of the follow-up (months), stage IRIS based on serum creatinine (Stage Crea) with 
progression or stability of CKD with stage reached, sub-stages IRIS based on systolic blood pressure (Stage 
SBP) and sub-stages IRIS based on urinary protein-to-creatinine ratio (Stage UPC) are shown. 
N° Breed Sex Age Symptoms  Follow-up Stage (progression) 
stage  
SBP 
Stage  
UPC 
1 Short air MC 114 H 18 1 (s) AP0 (s) NP 
2 Short air FC 181 S nf 1 n NP 
3 Short air MC 75 H nf 1 AP3 NP 
4 Short air MC 134 S 3 1(P)  AP0 n 
5 Exotic S FC 138 H nf 1 AP0 BP 
6 Persian MC 174 S 12 1 (s) AP2 BP 
7 Short air MC 136 H 12 2 (s) n NP 
8 Short air FC 226 S nf 2 AP3 NP 
9 Siberian FC 84 S 12 2 (s) n BP 
10 Siberian FC 72 H 15 2(P) AP0 NP 
11 Siamese FC 128 H nf 2 n NP 
12 Short air MC 173 S nf 2 AP0 NP 
13 Norwegian FC 106 H 12 2 (s) AP0 (P) NP (P) 
14 Siamese MC 183 S nf 2 n BP 
15 Short air MC 180 S nf 2 AP2 NP 
16 Short air FC 120 S 3 2 (s) AP0** (s) P 
17 Short air FC 144 S 3 2 (s) AP0 NP 
18 Short air MC 190 S nf 2 n NP 
19 Short air FC 176 S 12 2 (s) AP0 (s) NP 
20 Chartreux FC 80 S nf 2 AP0 NP 
21 Birman MC 183 S nf 2 AP1 n 
22 Short air MC 87 S 3 2 (s) AP0 (P) P 
23 Short air FC 171 S nf 3 AP2 NP 
24 Short air MC 195 S 3 3 (P) AP2 (s) P 
25 Short air MC 224 S nf 3 n P 
26 Short air FC 200 S 18 3 (s) AP0 (s) NP 
27 Short air M 210 S nf 4 AP0 P 
28 Norwegian FC 98 S nf 4 AP0 BP 
29 Short air FC 121 S nf 4 n P 
MC: male castrated, M: intact male; FC: female castrated; S: sintomatic, H: healthy; nf: no follow-up P: 
proteinuric, NP: non proteinuric (UPC<0.2), BP: borderline proteinuric (UPC=0.2-0.4); P: proteinuric 
(UPC>0.4); (s): stable. (p): progressive, AP0: SBP<150 mmHg; AP1: SBP=150-160 mmHg; AP2: SBP=160-
180 mmHg; AP3: SBP>180 mmHg; n: not available. ** : presence of white-coat hypertension   
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Table 11 Cats at risk to develop CKD included in the biomarker study. Breed, sex, age (months), duration of the 
follow-up (months), stability or progression toward CKD (with stage reached), sub-stages IRIS based on systolic 
blood pressure (Stage SBP) and sub-stages IRIS based based on proteinuri (UPC, urinary protein-to-creatinine) 
are shown. 
N° Breed Sex Age Follow-up 
Progression 
(stage) 
Stage SBP Stage UPC 
1 Short air FC 169 18 S AP0 BP 
2 Short air FC 103 12 P (1) AP0 NP 
3 Short air FC 88 6 P (2) n NP 
4 Short air FC 133 12 P (2) AP0 BP 
5 Short air FC 137 nf nf n nn 
6 Short air FC 108 6 P (1) AP2 BP 
7 Europeo FC 122 18 P (1) AP2 NP 
8 Exotic S. FC 85 18 P (1) AP0 (wch) NP 
9 Short air FC 131 6 S AP0 BP 
10 Short air MC 131 6 S AP0 BP 
11 Short air MC 162 6 P (2) AP0 NP 
12 Maine Coon MC 71 12 S AP0 NP 
13 Persian MC 67 18 P (2) n NP 
14 Short air MC 167 12 S n BP 
15 Short air FC 101 15 S AP0 NP 
16 Short air MC 164 15 S n NP 
17 Short air M 108 12 S AP0 NP 
18 Short air MC 142 18 S nn NP 
19 Short air FC 133 nf nf nn NP 
MC: male castrated, M: intact male; FC: female castrated; wch: white-coat hypertension; nf: no follow-
up NP: non proteinuric (UPC<0.2), BP: borderline proteinuric (UPC=0.2-0.4); S: stable. P: progressive, 
AP0: SBP<150 mmHg; AP2: SBP=160-180 mmHg. 
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Table 1 Descriptive statistics (median, minimum and maximun values) of the complete celle count (CBC), serum biochemistry parameters, urinary protein-to creatinine 
ratio and urinary specific gravity obtained from the cats included in this study. Results are grouped according to the health status (at risk vs CKD) and according to 
the time of collection (samples collected at time of enrolment in the study vs samples collected at any time during the follow-up). 
 At risk (inclusion) CKD (inclusion) At risk (all samples) CKD (all samples) 
 N° Median Min Max N° Median Min Max N° Median Min Max N° Median Min Max 
Age (months) 19 131 67 169 29 144 72 226 36 133 67 186 63 138 72 228 
SBP (mmHg) 12 130 120 170 21 140 105 230 26 130 100 200 43 140 105 230 
Creatinine* 19 1,29 0,79 1,64 29 1,97 1,22 10,93 35 1,28 0,78 1,64 62 1,95 0,89 10,93 
SDMA 15 12 8 15 17 16 8 25 27 12 7 15 32 16 8 74 
Urea* 19 60 33 101 28 81,5 50 281 35 60 30 107 59 75 6,2 281 
Sodium$ 16 153 141 157 26 151,8 129 163 32 152,5 140 157 57 151,6 129 163 
Potassium$ 17 4 3 4,8 27 4,2 2,7 4,9 33 4,1 3 4,8 58 4,2 2,7 5 
Calcium* 17 10,5 8,9 12 27 10,6 7,2 13 32 10,05 8,8 12 58 10,65 7,2 13,6 
Phosphorous* 18 4,18 2,86 5,35 27 3,64 2,7 26,6 33 4,22 2,86 5,49 57 3,94 2,69 26,6 
Glucose* 19 114 72 157 28 115 81 281 35 117 72 172 60 113 73 281 
Cholesterol* 17 175 64 332 21 179 56 366 33 174 64 332 52 183 56 366 
Triglyceride* 17 36 21 142 19 44 13 99 33 36 21 142 47 40 13 342 
ALT# 19 46 31 115 28 53 25 251 35 47 29 229 60 52,5 25 251 
ALP# 19 55 26 217 28 44 11 113 35 54 24 1176 59 46 11 189 
GGT# 19 1 0 6 28 0 0 4 35 1 0 6 60 0 0 4 
Total Protein* 19 7,54 6,59 8,7 28 7,125 5,94 9,26 35 7,28 5,65 8,7 60 7,115 5,94 9,26 
WBC (x103/µL) 19 8,13 3,06 14,23 27 8,2 3,21 23,56 35 8,13 3,06 14,91 58 8,265 3,21 23,56 
RBC (x106/µL) 19 9,55 7,9 11,89 27 8,2 4,45 11,05 35 9,43 7,34 11,89 58 8,115 4,41 11,17 
Hb (g/dL) 19 13,3 9,3 16,9 27 11,5 5,6 14,8 35 12,9 9,3 16,9 58 10,95 5,6 14,8 
Ht 19 40 30 50,9 27 35 18,6 45 35 40 28 50,9 58 34 18,6 45 
PLT (x103/µL) 19 134 21 555 27 163 1 444 35 145 16 555 58 133 1 444 
UPC 18 0,13 0,04 0,3 27 0,16 0,04 5,63 33 0,14 0,01 0,31 58 0,17 0,02 5,63 
USG 18 1050 1024 1086 26 1027 1008 1066 33 1050 1022 1086 55 1033 1008 1616 
N°: number of samples obtained; SDMA: symmetric dimethylarginine; ALP: alanine transferase; ALP: alkaline phosphatase; GGT: gamma glutamyl tranferase; WBC: 
white blood cells, RBC: red blood cells; Hb: hemoglobin; Ht: hematocrit; PLT: platelets; UPC: urinary protein-to-creatinine ratio; USG: urine specific gravity. *=mg/dL; 
£=µg/dL;$=mmol/L; #=U/L;  
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4.1	Serum	and	urinary	Big	Endothelin-1	
 
Introduction	and	aims	
 
Endothelin-1 (ET-1) is a biological active peptide that in physiologic state it is mainly 
synthetized by endothelial cells and regulates blood pressure.  
In human medicine it was shown that ET-1 is related to many pathologic mechanisms in 
CKD and its production is increased in hypertension and CKD (Kohan, 2010). Although 
circulating concentrations of ET-1 do not accurately reflect ET-1 production, since the 
short-half life and the predominant paracrine and autocrine activity (Dhaun et al., 2006), 
blood ET levels were higher in people with focal segmental glomeruloslerosis (Chen et al., 
2001). Given its potent vasoconstriction activity, the greatest pathophysiological impact of 
ET-1 in hypertension seems to be relates to its effects on vascular remodeling. ET-1 (in 
cooperation with Angiotensin II) promotes vascular cell hypertrophy, hyperplasia, 
inflammatory cell infiltration, and fibrosis (Kohan, 2010). Its deleterious vasocostrictive 
effects (contributing to the systemic HT) seems to be also enhanced by the impairment of 
salt and water homeostasis that could occur in CKD (Boesen, 2015). 
In the kidney ET-1 is over-expressed in both the glomerulus (by podocytes and mesangial 
cells) and the tubulocytes in patients with different nephropaties (Chen et al., 2001; Dhaun 
et al., 2009; Dhaun et al., 2012). In the glomerulus, the enhanced gene transcription 
occurs with a wide range of stimuli (such as angiotensin II, vasopressin, TNF-alpha, ROS, 
hypoxia) and it may be viewed as a common renal stress response (Dhaun et al., 2012). In 
this setting ET-1 cause contraction of podocytes, loss of the slit diaphragm and activation 
and proliferation of mesangial cells with production of pro-inflammatory cytokines and 
matrix proteins (Ohta et al., 1991; Dufek et al., 2016); moreover it contributes to reduction 
of local blood flow (renal blood flow and GFR) by contracting arterioles (Kohan, 2010). On 
the renal tubular system, the pathological expression of ET-1 induces reabsorption of 
water and sodium by renal tubular cells (Kohan, 2010). These ultimately contribute to 
systemic hypertension (Schiffrin, 2005). 
Urinary ET-1 correlates with the severity of renal injury (Dhaun et al., 2009) (Chen et al., 
2001) and with the degree of proteinuria (Lehrke et al., 2001). 
Also in dogs, the increased blood concentration of ET-1, evaluated indirectly by the 
precursor Big Endothelin-1 (big-ET1), seems to be associated with the severity of CKD 
and with hypertensionin (Rossi et al., 2013b). Big-ET1 was used instead of ET-1 because 
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the precursor has longer half-life and the concentration of big-ET1 is proportional to ET-1 
(O’Sullivan et al., 2007). 
In cats, ET-1 was evaluated in cardiomyopathies, showing that plasma ET-1 was a 
significant higher in sick cats compared to healthy cats, (Prošek et al., 2004) and in 
asthma, showing that ET-1 in broncoalveolar lavage fluid was significantly higher in 
asthmatic cats compared to healthy cats (Sharp et al., 2013). 
No information is available regarding ET-1 or big-ET1 in cats with CKD. Therefore, the aim 
of this study was to gain information about the serum and urinary levels of big-ET1 in cats 
with CKD, with and without hypertension and proteinuria, using an enzyme-linked 
immunosorbent assay (ELISA). This is the first work to explore the potential role of big-
ET1 as biomarkers of hypertension associated with CKD. Concentrations were measured 
in cats with staged CKD based on serum creatinine concentration, urinary protein to 
creatinine (UPC) ratio, and systolic blood pressure, as proposed by the International Renal 
Interest Society (IRIS). 
 
Material	and	methods		
 
Measurement	of	big	Endothelin-1	
 
Big-ET1 was measured with a solid phase sandwich ELISA developed for human big 
endothelin-1 by IBL (IBL international GmbH, Hamburg, Germany). According to the 
manufacturer’s instruction, the precoated (captured) antibodies on the plate was a rabbit 
IgG against the C-terminal 22–38 amino acid sequence of human Big-ET1. According to a 
previous study (Biondo et al., 2003) this sequence shows close homology to the feline 
amino acid sequence. The labeled (secondary) antibody was a rabbit IgG is directed 
against a different antigenic site (conjugated with horseradish peroxidase, HRP). The 
declared measurement range was 0.78 – 100 pg/mL. The procedure was performed as 
recommended by the manufacturer  
 
At the time of analysis, selected sera and supernatants were gently thawed by transferring 
tubes at 4°C the day before analysis and then at room temperature one hour before 
analysis. Plates were read using an automatic plate reader (Dasit multiscan, Dasit) at a 
wavelength of 450 nm. 
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Selection	of	the	samples	
 
This study was divided in three session of work. In the first session, 10 serum samples and 
10 samples of urine were selected. These samples were obtained from different cats at 
different IRIS stages (at risk and different severity of CKD) and were firstly run in order to 
subsequently perform a validation study.  
In the second session of the study, the validation of the urinary Big-ET1 was performed; 
the validation of the serum Big-ET1 was not performed since almost all the serum samples 
in the previous session failed to yield results above the detection limit of the test. 
Moreover, further 10 serum samples were evaluated at that time.  
Finally, in the third session 59 urinary and 10 serum samples were assayed. 
In case of urinary tract infection at the time of inclusion and no supernatants available 
within one month after recovery, the T0 of urinary was considered the following 
checkpoint. 
 
Method	validation	
 
Urinary samples tested in the first session of work were refrigerated overnight and were 
used the day after to prepare the reference material for the method validation. Specifically, 
a “high pool” and a “low pool” were prepared by mixing the samples with the highest and 
the lower Big-ET1 concentration, respectively. The intra-assay variability was determined 
by measuring the Big-ET1 concentration of the 2 pools 5 times in the same kit. The mean 
value, the standard deviation (SD) and the coefficient of variation (CV = SD / mean X 100) 
were calculated using Excel spreadsheet. The linearity under dilution test was performed 
by serially diluting the “high pool” by a twofold dilution scheme (i.e 1:2, 1:4, 1:8 and 1:16) 
using distilled water. Dilutions were tested in duplicate. The mean between the two results 
and the expected values corresponding to each dilution were calculated. Linear regression 
between expected and observed results was applied. The percentage of recovery of the 
observed values compared with expected values at each dilution was also calculated as 
follow: recovery = mean observed / expected X 100. 
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Statistical	analysis	
 
A commercially available software (GraphPad Prism 5.0; GraphPad Software, San Diego, 
CA, USA) was used for statistical analysis. A P value <0.05 was considered statistically 
significant. Distribution of variables was assessed by Kolmogorov-Smirnov test. 
The urinary Big-ET1-to-creatinine (Big-ET1:UC) ratio was calculated to normalize the Big-
ET1 concentration to the urine dilution. 
Mann-Whitney U test was used to compare urinary big-ET1 and urinary Big-ET1:UC ratio 
between samples grouped according to the presence of CKD (At risk vs CKD) on the basis 
of SBP (<150 mmHg vs >150 mmHg). Mann-Whitney U test was also used to compare 
urinary big-ET1 and urinary Big-ET1: UC ratio between samples at risk grouped according 
to the stability or progression toward CKD; progression of CKD was identified when at the 
following check-point (6 or 12 months after inclusion) the cat was classified in a higher 
IRIS stage, according to criteria exposed in Table 1. 
Kruskal-Wallis test was used to compare urinary big-ET1, urinary big-ET1:UC ratio 
between samples grouped according to the IRIS staging. Mann-Whitney U test with 
Bonferroni correction was used to perform multiple comparisons between the single 
groups. 
Median, range, I and IV interquartile of all the groups were calculated; mean and SD were 
graphically displayed in figures. 
Correlations between variables (SBP, glucose, urea, creatinine, sodium, potassium, 
calcium, phosphor, cholesterol, triglycerides, ALT, ALP, GGT, total proteins, WBC, RBC, 
HTC, HGB, PLT, USG, urinary protein, urinary creatinine, UPC, age) were evaluated using 
Spearman’s correlation test.  
 
Results	
 
Serum	Big-ET1		
 
Seven patients at risk and 12 cats with CKD were included (one cat were tested two time: 
time zero and after 3 months). Results obtained from the 20 samples were shown in Table 
13. One of the 7 cats at risk (14.3%) and 4 cats of the CKD group (30.8%) had detectable 
Big-ET1. Concentrations were always low, with the exception of a sample in CKD group 
(15.81 pg/mL, IRIS stage 3). 
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Preliminary	validation	in	urine	
 
The mean ±SD of the 5 repeated measurements of the “low pool” was 9.10 ±8.29 pg/mL 
and the corresponding CV was 91.1% (Table 14). The analysis of the values 
(measurement n° 2) shows the presence of a “mild outlier”. This value is higher than 1.3 
times the interquartile range (i.e. 12 pg/dL) (Westgard, 2003).  
 
 
 
Table 13 Samples included in urinary evaluation of Big-ET1. The number of cat (see also Table 16), 
time of sampling (months), the breed, the sex, the age (months), the serum bigET-1 (sBigET1) when 
available, urinary BigET-1 to urinary creatinine ratio (uBigET-1:UC), stage IRIS based on serum 
creatinine (Stage Crea), sub-stages IRIS based on systolic blood pressure (Stage SBP) and urinary 
protein-to-creatinine ratio (Stage UPC) and progression toward IRIS stages based on serum 
creatinine 
Cat sBigET1 IRIS stage SBP Stage UPC 
2 0 A AP0 BP 
3 0 A AP0 NP 
5 0 2 AP2 NP 
6 0 1 AP0 NP 
7 1,86 A AP0 BP 
8 4,02 2 nd BP 
9 2,17 3 AP0 NP 
10 0 3 AP2 nd 
11 0 1 nd NP 
15 0 3 AP2 P 
15 0 4 AP2 NP 
19 0 A AP2 NP 
26 0 2 AP0 P 
27 0 A AP0 P 
30 0 2 AP2 NP 
33 0 A AP0 NP 
35 0 A AP0 NP 
41 15,81 3 nn P 
42 0 3 AP0 P 
43 2,51 4 AP0 P 
nd = not determined; NP = non-proteinic; BP = proteinuria borderline; P = proteinuria; AP0 = <150 mmHg; 
AP1 = 150-159 mmHg; AP2 = 160-179 mmHg; AP3 => 180 mmHg 
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Excluding this value, the mean became 5.50 pg/dL, the SD was than considerably lower 
(2.27 pg/dL) that the previous one and consequently the CV drops to 41.3 %. 
The mean ±SD of the 5 repeated measurements of the “high pool” (Table 14) was 56.74 
±5.60 pg/mL and the corresponding CV was 9.8 %.  
 
Table 14 Results of the 5 within-run (intra-assay) repeated measures of the two pools of urine 
Measurement 
Low pool 
BigET1 (pg/mL) 
High pool 
BigET1 (pg/mL) 
1 6,09 51.99 
2 23,50 65.78 
3 4,92 55.76 
4 8,21 57.83 
5 2,76 52.35 
 
 Linear regression demonstrated an excellent degree of correlation (R2 =0.97; P = 0.002) 
for LUD test (Figure 14).  
 
 
Figure 14 Linearity under dilution (LUD) of “high pool” obtained by mixing two different urine samples. 
Observed values (in pg/dL) were statistically correlated to the expected value according to a linear model.— 
intercept: 20.90 (95% confidence interval [CI]: 23.37 to 1.57); slope: 1.05 (95% CI: 0.90–1.21); recovery test—
intercept: 22.31 (95% CI: 210.27 to 5.64); slope: 1.17 (95% CI: 0.63–1.71). 
 
The mean percentage of recovery compared with expected values was 83.4%. However, a 
very low value was found with the 1:16 dilution (Table 15). The expected Big-ET1 
concentration was very close to the lower limit of detection of the kit and, as shown above, 
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also high imprecision can be found at these levels. Excluding this value the mean recovery 
becomes 110.8%. 
 
Table 15 Results of the linearity under dilution test. The percentage of recovery (O/E) was calculated  
Dilution Observed (pg/mL) 
Expected 
(pg/mL) O/E (%) 
Undiluted 56,74 56,74 
 1:2 36,58 28,37 128,9 
1:4 13,91 14,19 98,1 
1:8 7,47 7,09 105,4 
1:16 0,04 3,55 1,3 
 
 
Urinary	Big-endothelin	1—Population	of	cats		
 
The 69 samples included in urinary evaluation of Big-ET1 belonged to 42 patients, 27 and 
3 of which were also sampled other 2 and 3 times in the follow-up, respectively (Table 16). 
 
At the time of inclusion, 18 were classified as At risk and 24 affected by CKD (IRIS 1: 4 
cats; IRIS 2: 14 cats; IRIS 3: 4 cats; and IRIS 4: 2 cats). 
Mean ±SD of age in At risk group and CKD was 121.9 and 145 months, respectively 
(range 67-169 and 72-226 months, respectively).  
In At risk group were present 7 castrated male, one intact male and 10 neutered female 
whereas in CDK group 10 castrated male and 14 neutered female. 
The majority of cats at risk and cats with CKD were European shortair (15 and 17, 
respectively) 
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Table 16 Samples included in urinary evaluation of Big-ET1. The number of cats, the time of sampling (months), 
the breed, the sex, the age (months), the serum bigET-1 (sBigET1) when available, urinary BigET-1 to urinary 
creatinine ratio (uBigET-1:UC), stage IRIS based on serum creatinine (Stage Crea), sub-stages IRIS based on 
systolic blood pressure (Stage SBP) and urinary protein-to-creatinine ratio (Stage UPC) and progression toward 
IRIS stages based on serum creatinine 
Cat Time Breed Sex Age  sBigET1 uBigET1 uBigET-1 :UC 
Stage 
Crea stage SBP Stage UPC Progression 
1 0 Short air MC 136 Nd 1,07 0,0019 2 Nd NP stable 
1 12 Short air MC 147 Nd 2,03 0,0063 2 Nd NP nf 
2 18 Short air FC 186 0,00 21,68 0,1325 A AP0 BP stable 
2 0 Short air FC 169 Nd 0 0,0000 A AP0 BP nf 
3 0 Short air FC 103 0,00 34,29 0,0854 A AP0 NP progressive 
4 6 Short air FC 92 Nd 31,83 0,1245 2 AP1 NP progressive 
4 0 Short air FC 88 Nd 0,95 0,0045 A Nd NP progressive 
5 0 Short air FC 226 0,00 0 0,0000 2 AP2 NP nf 
6 0 Short air MC 114 Nd 0 0,0000 1 AP0 NP stable 
6 6 Short air MC 121 Nd 0 0,0000 1 AP0 NP stable 
6 18 Short air MC 133 0,00 0,99 0,0029 1 AP0 NP nf 
7 0 Short air FC 133 1,86 6,149 0,0193 A AP0 BP progressive 
7 12 Short air FC 143 Nd 0 0,0000 2 Nd BP progressive 
8 0 Siberian FC 84 4,02 0 0,0000 2 Nd BP stable 
9 0 Siberian FC 72 2,17 14,94 0,0900 2 AP0 NP progressive 
9 15 Siberian FC 87 Nd 34,64 0,5560 3 AP0 NP progressive 
10 0 Short air FC 171 0,00 3,07 0,0188 3 AP2 NP nf 
11 0 Short air FC 108 Nd 0 0,0000 A AP2 BP progressive 
11 6 Short air FC 115 0,00 0 0,0000 1 Nd NP progressive 
12 0 Short air MC 75 Nd 12,49 0,0506 1 AP2 NP nf 
13 18 Short air FC 140 Nd 0 0,0000 1 AP2 NP progressive 
13 0 Short air FC 122 Nd 0 0,0000 A AP2 NP progressive 
14 0 Siamese FC 128 Nd 12,22 0,0339 2 Nd NP nf 
15 3 Short air MC 199 0,00 8,34 0,3022 4 AP2 NP progressive 
15 0 Short air MC 195 0,00 0,69 0,0250 3 AP2 P progressive 
16 0 Norwegian FC 106 Nd 0,73 0,0039 2 AP0 NP stable 
16 12 Norwegian FC 122 Nd 8,11 0,0466 2 AP3 P stable 
17 0 Short air MC 87 Nd 0 0,0000 2 AP0 P stable 
18 0 Norwegian FC 98 Nd 10,02 0,2193 4 AP0 BP nf 
19 0 Exotic S. FC 85 0,00 16,50 0,0819 A AP2 NP progressive 
19 18 Exotic S. FC 102 Nd 0 0,0000 1 AP0 BP progressive 
20 0 Exotic S. FC 138 Nd 38,91 0,2604 1 AP0 BP nf 
21 0 Siamese MC 183 Nd 0 0,0000 2 Nd BP nf 
22 0 Persian MC 174 Nd 16,54 0,1033 1 AP2 BP stable 
23 0 Short air MC 180 Nd 3,15 0,0313 2 AP2 NP nf 
24 0 Short air FC 121 Nd 14,94 0,4640 4 Nd P nf 
25 3 Short air FC 123 Nd 15,26 0,0900 2 AP0 P stable 
26 0 Short air FC 144 Nd 50,67 0,2939 2 AP0 NP stable 
26 3 Short air FC 147 0,00 14,25 0,1307 2 AP0 P stable 
27 0 Short air MC 131 0,00 0 0,0000 A AP0 BP stable 
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27 6 Short air MC 139 Nd 3,85 0,0130 A AP0 NP stable 
28 0 Short air FC 131 Nd 0 0,0000 A AP0 BP stable 
28 6 Short air FC 139 Nd 2,68 0,0098 A AP0 NP stable 
29 0 Short air MC 190 Nd 0 0,0000 2 Nd NP nf 
30 0 Short air MC 162 Nd 0 0,0000 A AP0 NP progressive 
30 6 Short air MC 169 0,00 0 0,0000 2 AP2 NP stable 
31 12 Short air FC 189 Nd 0 0,0000 2 Nd NP stable 
31 0 Short air FC 176 Nd 0 0,0000 2 AP1 NP stable 
32 0 Chartreux FC 80 Nd 0,398 0,0015 2 AP0 NP nf 
33 12 Maine Coon MC 85 Nd 11,92 0,0391 A AP0 NP stable 
33 0 Maine Coon MC 71 0,00 4,91 0,0157 A AP0 NP stable 
34 6 Persian MC 73 Nd 8,42 0,0210 2 Nd NP progressive 
34 18 Persian MC 87 Nd 3,8 0,0112 2 Nd NP progressive 
34 0 Persian MC 67 Nd 0 0,0000 A Nd NP progressive 
35 0 Short air MC 167 Nd 1,77 0,0137 A Nd BP stable 
35 6 Short air MC 173 0,00 0 0,0000 A AP0 NP stable 
35 12 Short air MC 181 Nd 5,1 0,0546 A AP0 BP stable 
36 9 Short air FC 101 Nd 0,35 0,0019 A AP0 NP stable 
36 0 Short air FC 111 Nd 0 0,0000 A AP0 NP stable 
37 0 Short air MC 164 Nd 0 0,0000 A Nd NP stable 
38 6 Short air M 113 Nd 3,02 0,0090 A AP0 NP stable 
38 0 Short air M 108 Nd 0,65 0,0017 A AP1 NP stable 
39 0 Short air MC 142 Nd 10,92 0,0763 A Nd NP stable 
39 3 Short air MC 145 Nd 0 0,0000 A Nd NP stable 
39 18 Short air MC 163 Nd 5,92 0,1175 A AP0 BP stable 
40 0 Short air FC 133 Nd 0 0,0000 A AP2 NP nf 
41 0 Short air MC 224 15,81 13,86 0,3746 3 Nd P nf 
42 0 Short air FC 200 Nd 4,99 0,0465 3 AP0 NP stable 
42 12 Short air FC 213 0,00 14,58 0,2107 3 AP0 P stable 
MC: male castrated; M: male; FC: female castrated; Nd: not determined. NP: non-proteinuric; BP: borderline 
proteinuric; P: proteinuric; nf: no follow-up; AP0: systolic blood pressure (SBP) <150 mmHg; AP1: SBP= 150-
159 mmHg; AP2: SBP=160-179 mmHg; AP3: SBP >180 mmHg 
	
	
Urinary	Big-endothelin	1—Correlation	
 
Urinary Big-ET1 was significantly negatively correlated with RBC (r =−0.263, P= 0.030), 
Hb (r=−0.364, P=0.002) and Ht (r=−0.349,P=0.003) (figure 15), and positively correlated 
with serum creatinine (r=0.241, P=0.046) (figure 16). Also urinary Big-ET1:UC ratio was 
significantly negatively correlated with RBC (r =−0.367, P= 0.002), Hb (r=−0.451, P=0.000) 
and Ht (r=−0.442,P=0.000) (figure 15); positive correlation was found with serum 
creatinine (r=0.321, P=0.007) and urea (r=0.347, P=0.004) (Figure 16) 
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Figure 15 Graphic representation of the correlation between urinary Big-ET1 concentration (on the left) or 
urinary Big-ET1 to creatinine ratio (on the right) with red blood cells (RBC, top), hematocrit (Ht, middle) and 
hemoglobin (Hb, bottom). The brown line represent the regression line.  
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Figure 16 Graphic representation of the correlation between urinary Big-ET1 to creatinine ratio and serum 
creatinine (top) and urea (bottom). The brown line represent the regression line. 
 
Urinary Big-endothelin 1—Comparison in groups according to serum creatinine 
Grouping samples according to the presence of CKD, there was no significantly difference 
for urinary Big-ET1 concentration (P=0.214) and urinary Big-ET1:UC ratio (P=0.128) 
between At risk group and CKD group (Figure 17 and Table 17). However, 8 samples in 
CKD groups had urinary Big-ET1:UC ratio above the higher value obtained in At risk 
group.  
 
Table 17 Descriptive statistics of the groups At risk and CKD. In brackets are shown the number of cats. 
 At risk (n° 28) CKD (n° 41) 
 
BigET1 
(pg/mL) BigET1:UC 
BigET1 
(pg/mL) BigET1:UC 
Minimum 0,0 0,0 0,0 0,0 
25% Percentile 0,0 0,0 0,0 0,0 
Median 0,800 0,003 3,070 0,018 
75% Percentile 5,715 0,034 14,060 0,114 
Maximum 34,29 0,132 50,670 0,556 
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Figure 17 Graphical distribution of urinary Big-ET1 concentration (on the left) or urinary Big-ET1 to 
creatinine ratio (on the right) between group At risk and CKD 
 
When CKD cats were grouped according to IRIS staging, urinary Big-ET1 was not 
significant different (P=0.079) between groups, whereas urinary Big-ET1:UC ratio was 
significantly higher (P=0.001) in IRIS 3-4 group compared to all other groups (Figure 18 
and Table 18). 
 
Table 18 Descriptive statistics of the different groups divided according to IRIS Staging. In brackets are shown 
the number of cats  
 At risk (n° 28) IRIS 1 (n° 9) IRIS 2 (n° 23) IRIS 3-4 (n° 9) 
 
BigET1 
(pg/mL) 
BigET1:
UC 
BigET1 
(pg/mL) 
BigET1
:UC 
BigET1 
(pg/mL) 
BigET1:
UC 
BigET1 
(pg/mL) 
BigET1:
UC 
Minimum 0,0 0,0 0,0 0,0 0,0 0,0 0,690 0,019 
25% Percentile 0,0 0,0 0,0 0,0 0,0 0,0 4,030 0,035 
Median 0,800 0,003 0,0 0,0 1,070 0,004 10,020 0,219 
75% Percentile 5,715 0,034 14,520 0,077 12,220 0,046 14,760 0,419 
Maximum 34,290 0,132 38,910 0,260 50,670 0,294 34,640 0,556 
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Figure 18 Graphical distribution of urinary Big-ET1 concentration (on the left) or urinary Big-ET1 to creatinine 
ratio (on the right) in groups groups divided according to IRIS Staging for creatinine. 
 
 
Both uBig-ET1 (P=0.567) and uBig-ET1:UC ratio (P=0.566) did not significant differed 
between at risk cats that remained stable and at risk cats that developed CKD (stage IRIS 
1 or 2) during the monitored period (Table 19 and Figure 19). 
 
 
Table 19 Descriptive statistic of cats at risk stable or progressive. In brackets are shown the number of cats  
 Stable (n° 9) Progressive (n° 8) 
 
BigET1  
(pg/mL) BigET1:UC 
BigET1 
(pg/mL) BigET1:UC 
Minimum 0,0 0,0 0,0 0,0 
25% Percentile 0,0 0,0 0,0 0,0 
Median 0,0 0,0 0,475 0,002 
75% Percentile 3,340 0,015 13,910 0,066 
Maximum 10,920 0,076 34,290 0,085 
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Figure 19 Graphical distribution of urinary Big-ET1 concentration (on the left) or urinary Big-ET1 to creatinine 
ratio (on the right) in stable and progressive groups 
 
Urinary	Big-endothelin	1—Comparison	in	groups	according	to	SBP		
 
Grouping samples according to SBP, no significant difference was found for uBig-ET1 
(P=0.991) and uBig-ET1:UC (P=0.973) between normotensive cats (AP0) and cats with 
different grade of HT (AP1, AP2 and AP3). In Table 20 and Figure 20 are shown the 
descriptive statistics and the graphical distribution, respectively. 
 
 
Table 20 Descriptive statistics of the normotensive (NT) and hypertensive (HT) groups. In brackets are shown 
the number of cats  
 NT (n° 35) HT (n° 14) 
 
BigET1  
(pg/mL) BigET1:UC 
BigET1  
(pg/mL) BigET1:UC 
Minimum 0,0 0,0 0,0 0,0 
25% Percentile 0,0 0,0 0,0 0,0 
Median 3,020 0,009 3,110 0,025 
75% Percentile 14,250 0,090 13,490 0,087 
Maximum 50,670 0,556 31,830 0,302 
NT: normotensive; HT: hypertensive 
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Figure 20 Graphical distribution of urinary Big-ET1 concentration (on the left) or urinary Big-ET1 to creatinine 
ratio (on the right) in the normotensive (NT) and hypertensive (HT) groups 
 
Given the possible effect of nephropathy on this analysis, each group was further split into 
two sub-groups according to the presence of CKD. Also in this case, no significant 
difference was found nor for Big-ET1 (P=0.419) neither for uBig-ET1:UC ratio (P=0.238). 
(Table 21 and Figure 21) 
 
Table 21 Descriptive statistics of the different groups divided according to systolic blood pressure and 
presence of CKD. In brackets are shown the number of cats  
 At risk NT (n° 17) At risk HT (n° 13) CKD NT (n° 18) CKD HT (n° 10) 
 
BigET1 
(pg/mL) 
BigET1:
UC 
BigET1 
(pg/mL) 
BigET1
:UC 
BigET1 
(pg/mL) 
BigET1:
UC 
BigET1 
(pg/mL) 
BigET1:
UC 
Minimum 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
25% Percentile 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Median 3,020 0,009 0,0 0,0 2,990 0,025 5,630 0,039 
75% Percentile 6,035 0,047 6,345 0,038 15,02 0,213 13,50 0,108 
Maximum 34,290 0,132 17,410 0,081 50,67 0,556 31,83 0,302 
NT: normotensive; HT: hypertensive 
 
Figure 21 Graphical distribution of urinary Big-ET1 concentration (on the left) or urinary Big-ET1 to creatinine 
ratio (on the right) in the different groups divided according to systolic blood pressure and presence of CKD 
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Urinary	Big-endothelin	1—Comparison	in	groups	according	to	proteinuria	
 
Urinary Big-ET1 did not significantly differed (P=0.139) between samples classified 
according to IRIS sub staging of proteinuria. Conversely, uBig-ET1:UC ratio was 
24significantly higher (P=0.026) in P stage compared to NP stage (Figure 22). In Table 22 
the descriptive statistic is shown. 
 
Table 22 Descriptive statistics of the different groups divided according to IRIS sub-staging of proteinuria. In 
brackets are shown the number of cats  
 NP (45) BP (16) P (8) 
 BigET1 (pg/mL) BigET1:UC 
BigET1 
(pg/mL) BigET1:UC 
BigET1 
(pg/mL) BigET1:UC 
Minimum 0,0 0,0 0,0 0,0 0,0 0,0 
25% Percentile 0,0 0,0 0,0 0,0 2,545 0,0304 
Median 0,9900 0,0039 0,8850 0,00685 14,06 0,1104 
75% Percentile 8,380 0,0365 9,052 0,1140 14,85 0,3336 
Maximum 50,67 0,5560 38,91 0,2604 15,26 0,4640 
NP: non-proteinuric; BP: borderline proteinuric; P: proteinuric 
 
 
Figure 22 Graphical distribution of urinary Big-ET1 concentration (on the left) or urinary Big-ET1 to creatinine 
ratio (on the right) in different groups divided according to IRIS sub-staging of proteinuria. 
 
 
Discussion	
 
To our knowledge, this is the first study to explore this peptide in feline serum and urine.  
Among the 13 cats with CKD, 5 cat yielded serum Big-ET1 concentration above the limit of 
detection of the ELISA kit (0.78 pg/mL). It’s worth to note that 3 cats were at the late 
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stages of CKD (IRIS stage 3-4). However other 5 patients were at the same stages but 
Big-ET1 was not detected.  
This absence or low concentration of Big-ET1 in sick cats was unexpected since both 
human (Miyauchi et al., 2012) and dogs (Rossi et al., 2013b) affected by CKD have high 
serum Big-ET1. In these species, the concentration tends to be proportional to the severity 
of the CKD. Specifically, previous studies reported that people at late stages of CKD the 
mean ±SD of Big-ET1 (measured with a sandwich ELISA) was equal to 17 pg/mL ± 0.2 
(Miyauchi et al., 2012), whereas in dogs at IRIS stage 4 of CKD mean ±SD of big-ET1 was 
25.26 ±18.64 pg/mL. (Rossi et al., 2013b).  
In our few positive cats, only one had serum Big-ET1 with concentration (15.81 pg/mL) 
similar to values detected in dogs. 
It is mandatory to consider these results as preliminary and further studies with higher 
number of samples are necessary. However, whether these results will be confirmed, 
different hypothesis could be formulated to explaine the results obtained from serum 
samples using ELISA kit. 
First of all, a possible cause could be the analytical specificity of the ELISA kit. The ELISA 
kit used in this study is produced by IBL for detection of human big-ET1 and was 
previously validated in dogs (O’Sullivan et al., 2007) and evaluated in canine CKD by our 
group of research (Rossi et al., 2013b). In that study the kit was able to detect canine Big-
ET1 in serum samples at different concentrations. According to the manufacturer 
information, the antibodies precoated on the plate of this kit are direct toward the epitope 
corresponding to the 22-38 sequence of Big-ET1whereas the labeled secondary antibody 
is directed toward a different epitopes of the polypeptide. In comparison with dog, the 22-
38 aminoacidic sequence of the feline Big-ET1is identical. For this reason, considering the 
homology between canine and feline sequence in that position and the fact that the same 
kit has been validated successfully for dogs we would expect that the antibody on the plate 
was able to bound Big-ET1 in feline serum.  
Conversely the 1-21 feline sequence differs for an amino acid, as reported by Biondo and 
colleague (Biondo et al., 2003).  
Given this theoretical mild difference in sequence and in turn in structure, and, as 
described below, our results in urine that are consistent with successful detection of Big-
ET1 by the kit, it seems unlikely that the scarce detection of this biomarker in feline serum 
is due to this specific ELISA kit. However, these evaluations are not sufficient to exclude 
that the different sequence in cats could reduce the affinity between of the human 
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antibodies and the feline Big-ET1 and a complete analytical validation of the kit for feline 
serum are warranted. 
To overcome this issue, further investigations using an other ELISA kit or using different 
assays with higher analytical sensitivity and specificity such as western blot or 
chromatography are warranted. Moreover, the interaction between of the human labelled 
antibodies and the feline Big-ET1 could require more time, since the incubation times 
indicated by the manufacture is ideal for human Big-ET1. Therefore it could be interesting 
to adjust the protocol performing different incubation periods and temperatures of the 
labelled antibodies.  
Beyond these possible intrinsic problems of the kit, an other possible explanation could be 
the peculiar metabolism of Big-ET1 in cats. It’s known that Big-ET and ET have autocrine 
and paracrine nature but in other species such as human and dogs it achieve sufficient 
blood concentration to be detected in serum. No specific information is available about the 
physiology of this peptide in cats, therefore it could be possible that concentration of Big-
ET1 is physiologically low, it could have different half-life and it could be normally 
degraded with higher rate in blood compared to other species. In this case, the ELISA 
used in this study would be not enough sensitive to detect big ET in blood and different 
more analytical sensitive methods would be needed 
A further possibility is that only hypertensive patients have detectable Big-ET1. In humans 
and dogs, Big-ET1 was shown to be correlated to HT (Rossi et al., 2013b). Therefore it 
could be possible that only cats with high SBP have increased serum Big-ET1 and ET-1. 
However, the 6 patients with HT were all negative. This hypothesis needs further 
evaluation with inclusion of more cats with high SBP. 
Finally, a last hypothesis could be the presence of other molecules in blood that could 
interfere with the antibody binding. However also this aspect might be investigated more 
deeply with proper validation studies because at the moment there is no evidence in 
literature that support this idea.  
Conversely to serum, both validation tests and samples yielded interesting results. 
Concerning validation, the pool of samples with high Big-ET1 concentration yielded a CV 
slightly higher than the limit considered acceptable (5%) for the most common biochemical 
analytes (Ricós et al., 1999) but widely within the limits considered acceptable for ELISA 
kits. 
The assay was more imprecise with the pool with lower concentrations. This result was not 
unexpected since it is already known that when the concentration of an analyte in a 
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sample is low, the slight shift of a measurement from the mean value determines a more 
profound change of CV compared to a sample with higher concentration (Westgard, 
2003). This result suggests that variability between samples at this concentration should 
be interpreted with caution. Moreover, LUD test showed acceptable recovery, highlighting 
no or slight matrix effect on the assay.  
However, a western blot analysis to confirm the cross-reactivity and a more complete 
validation following the National Committee for Clinical Laboratory Standards guidelines 
(NCCLS, 2010) are advisable. 
In this study we evaluated Big-ET1 instead of ET-1 since it was demonstrated that the 
former have longer half-life in blood compared to the latter and their concentrations are 
proportional (O’Sullivanet al., 2007). No information is available about the metabolic 
pathways of these peptides in urine and further studies are required to confirm that the 
tight proportionality occur also in this biological sample. 
However, assuming that urinary Big-ET1 and ET1 are related as demonstrated in serum, 
the increase of this biomarker at late stage of CKD and the significant (although weak) 
correlation with serum creatinine found in this study are in accordance to previous results 
in humans and rats (Chen et al., 2001; Dhaun et al., 2009).  
In a study in people affected by lupus nephritis, urinary ET-1 production increased as renal 
function declined and was correlated to the renal inflammatory disease activity (Dhaun et 
al., 2009). In an other study in rats affected by focal segmental glomerulosclerosis, urinary 
ET-1 excretion was significantly higher in affected animals compared to controls (Chen et 
al., 2001). ET-1 promotes cell proliferation, hypertrophy, inflammation and extracellular 
matrix accumulation (Kohan et al., 2014). Since also feline CKD is characterized by 
chronic inflammation that affects mainly the tubular-interstitium of the kidney (Chakrabarti 
et al., 2013; Brown et al., 2016), it could be speculated that urinary Big-ET1 in cats could 
reflect the inflammatory activity of the kidney as demonstrated in human.  
Nine cats of the 32 (39.1%) at Stage 2 yielded results under the limit of detection of the 
method. This result could suggest that individual/biological variation of the urinary 
excretion of big-ET1 could be high, limiting the use of this biomarker for diagnostic and 
prognostic purposes and could explain the lack of significant difference between groups.  
The variability could also be enhanced by the higher urinary dilution in CKD cats 
(sometimes present also at early stage of the disease) and the low analytical sensitivity of 
this method compared to the concentration of Big-ET1 detected in this specie. 
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The possible different inflammatory activity at each stage mentioned above could be an 
other possible explanation of the variability between groups and the lack of detectable Big-
ET1 in samples at IRIS stage 2. 
Urinary Big-ET1 was not able to predict the development of CKD in cats at risk. This result 
is coherent with the lack of significant difference between the lower stage of CKD (At risk 
vs IRIS 1 vs IRIS 2) and, according to our results, reflect the clinical importance of ET 
system only at late stage of disease. However, although the study design was not 
appropriate to evaluate the prognostic value and few samples were included the analysis.  
Proteinuric patients had higher Big-ET1 values compare to non proteinuric and borderline 
proteinuric patients. However, a wide overlap between groups was shown. 
In the study of Chen and colleagues cited above, urinary ET-1 was correlated with the 
amount of proteinuria (Chen et al., 2001) whereas in the study of Dhaun and collaborators 
on people with lupus nephritis did not (Dhaun et al., 2009). 
It’s worth to keep in mind that proteinuria in cats frequently occur at late stages of CKD 
(Syme et al., 2006). Therefore, given this relation, the tendency of urinary Big-ET1 to 
increase in proteinuric patients could actually be due to the increased severity of kidney 
injury, as demonstrated above, instead of a direct effect of urinary proteins. Multivariate 
analysis with higher number of samples is necessary to evaluate this hypothesis.  
It is interesting to note that, in a recent study, glomerular lesions in idiopathic CKD 
(specifically increased glomerular volume) correlated with proteinuria (Chakrabarti et al., 
2013). Podocyte injury is the hallmark of glomerular injury and ET-1 was demonstrated to 
by one important mediator (Daehn et al., 2014). Therefore it could be hypothesized that 
urinary ET-1 in cats reflect the glomerular injury. Even more, glomerular lesion are mild 
and variable at all the stage of CKD in cats (Chakrabarti et al., 2013) and markers of 
podocyte injury in cats with CKD were not associated with the degree of renal dysfunction 
(Ichii et al., 2011). Hence these data could be further in accordance with the variability of 
urinary Big-ET1 levels in our population. 
However, to confirm all these hypothesis, further studies including cats with a more strict 
criteria and/or execution of renal biopsy together to Big-ET1 quantification are necessary. 
The lack of significant differences between samples with or without HT suggest that SBP is 
not an important determinant of the urinary big ET level in cats. This is not an surprising 
result, since in human medicine urinary ET-1 is considered to reflect mainly renal 
production (Dhaun, 2006) instead of circulating levels because of its autocrine and 
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paracrine actions. Whether Big-ET1 and ET-1 are mainly associated to intra-glomerular 
hypertension instead of systemic hypertension need to be evaluated. 
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4.2	Serum	Homocysteine	
 
Introduction	and	aims	
 
Homocysteine (Hcy) is a thiol-containing amino acid involved in metabolism of S-adenosyl 
methionine, folate and B vitamins (Ruaux et al., 2001; Stanger et al., 2003; Rossi et al., 
2013a). In people, circulating Hcy is strongly correlated to GFR and increases in CKD 
(Wollesen et al., 1999). It was hypothesized that two mechanisms are responsible of the 
hyperhomocysteinemia in case of chronic kidney injury: the reduction of renal excretion 
due to nephron loss and the impaired extra-renal Hcy metabolism due to the toxic effect of 
retained substances (van Guldener, 2006). Hyperhomocysteinemia in patients affected by 
CKD is linked to a greater decline of GFR and to CKD-associated cardiovascular 
complication (Ninomiya et al., 2004; Levi et al., 2014). 
I was also demonstrated that Hcy linearly related to both systolic and diastolic blood 
pressure (Nygard et al., 1995) and it increases in patients with CKD-associated 
hypertension and/or proteinuria (Stehouwer and van Guldener, 2003). It was suggested 
that the possible linking mechanism between hyperhomocysteinemia and hypertension 
could the effect of the former on arterial walls, by destroying elastin fibers, increasing 
collagen production and stimulating smooth muscle activity (van Guldener et al., 2003). 
Also, it could reduce the bioavailability of nitric oxide due to auto- oxidation of 
homocysteine it may lead to the accumulation of asymmetric dimethylarginine, an 
endogenous inhibitor of nitric oxide synthase (van Guldener, 2006). However, since 
impaired renal function may increase both SBP and Hcy (Long and Nie, 2016), whether 
the causal relationship between the two exists is still debated. Independently on the 
mechanism leading to hypertension, in people hyperhomocysteinemia may works as 
predictor of hypertension (Wang et al., 2014).  
Few information is available about Hcy in veterinary medicine. In dogs, Hcy increase with 
hypocobalaminemia (Heilmann et al., 2016), in cardiac diseases (Rossi et al., 2008) and in 
severe CKD similarly to people (Rossi et al., 2008;Rossi et al., 2013b). However, no 
significant increase of Hcy was found in nephropatic patients with hypertension compared 
to normotensive CKD dogs (Rossi et al., 2013b). No information is available about Hcy 
concentration in cats affected by CKD with or without HT. Therefore, the aims of this study 
were to preliminary validate the enzymatic method in this specie, previously validated in 
human and dogs (Rossi et al., 2008), and to evaluate whether Hcy increase in cats with 
CKD and whether it is a marker of CKD-associated HT as in other species. 
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Material	and	methods		
Selection	of	the	samples	
 
Sixty-five samples obtained from 38 cats were included in this study.  
Analyses of the samples were divided into two session of work, performed approximately 
in the middle and at the end of the study period. In the first phase 30 samples were 
analyzed and the validation study was carried out. In the second session further 35 
samples were analyzed. 
 
Measurement	of	homocysteine	
 
Hcy was determined by spectrophotometry using an automated biochemical analyzer 
(Cobas Mira, Roche, Basilea, Swiss) and a commercially enzymatic method (Demeditec 
Diagnostic GMBH, Rendsburg, Germany). At each session of work, the method was 
calibrated and controlled using the provided materials. Reported lower limit of detection of 
the method was 1,5 µmol/L and manufacture declare that the method is linear until 50 
µmol/L. 
 
Method	validation	
 
Samples tested in the first session of work were used the same day to prepare the 
reference material for the method validation. Specifically, a “high pool” and a “low pool” 
were prepared by mixing 5 samples with the highest and the lower Hcy concentration, 
respectively. The intra-assay variability was determined by measuring the Hcy 
concentration of the 2 pools 20 times in the same run. The mean value, the standard 
deviation (SD) and the coefficient of variation (CV = SD / mean X 100) were calculated 
using Excel spreadsheet. The inter-assay variability was determined by measuring the 
“high pool” in 5 consecutive days, keeping the serum closed in the tube at +4°C. 
The linearity under dilution test was performed by serially diluting the “high pool” by a 
twofold dilution scheme (i.e 1:2, 1:4, 1:8 and 1:16) using distilled water. Dilutions were 
tested in triplicate. The mean between the two results and the expected values 
corresponding to each dilution were calculated. Linear regression between expected and 
observed results was applied. The percentage of recovery of the observed values 
compared with expected values at each dilution was also calculated as follow: recovery = 
mean observed / expected X 100. 
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Statistical	analysis	
 
Commercially available software (Analyse-it, Analyse-it software Ltd, Leeds, UK) was used 
for statistical analysis. A P value <0.05 was considered statistically significant. Distribution 
of variables was assessed by Kolmogorov-Smirnov test. 
Median, range, I and IV interquartile, mean and standard deviation of Hcy for all the 
groups were calculated. 
Mann-Whitney U test was used to compare Hcy between two groups. Kruskal-Wallis test 
was used to compare Hcy between 3 or more groups, followed by Bonferroni correction to 
perform multiple comparison between the single groups. Correlations between variables 
were evaluated using Spearman’s correlation test.  
 
Results	
Validation	
 
Results obtained from the 20 repeated readings on high and low serum pools are showed 
in Table 23. 
The high pool provided a mean value of 25.82 µmol/L ± (SD= 1.67 µmol/L), corresponding 
to a 6.46% CV, slightly above 5%, considered acceptable limit of many analytes commonly 
used in clinical biochemistry (Ricos et al., 1999). However, the analysis of individual 
readings revealed the presence of a "far outlier" (reading No. 10), with a value greater than 
3 times the interquartile range (0.96 µmol/L) (Westgard, 2003). By removing this outlier, 
the mean value remains almost unchanged (26.14 mmol/L) but decreases the standard 
deviation (0.81 µmol/L) and consequently the CV, which is 3.11% and drop below the 
acceptable limit above-mentioned. 
Mean ±SD of the low pool was 9.10 ± 0.67 µmol/L for a CV of 7.36%. Even in this case, 
there is an outlier (reading 2) even if it is a "near outlier" (ie a value less than 1.5 times the 
interquartile range (0.68 µmol/L) (Westgard, 2003). Then, even removing this outlier, the 
mean value, (9.17 µmol/L) the standard deviation (0.61 µmol/L) and CV (6.70%) vary 
slightly, which in this case also remains slightly above the acceptable limit, usually used for 
clinical biochemistry determinations (Ricos et al., 1999). 
The results obtained in the inter-assay repeatability tests carried out by 5 repeated 
readings of the high concentration Hcy pool are showed in Table 24. These results 
correspond to a mean value of 23.92 ± 2.77 µmol/L, and a CV of 11.60% 
In this case no outliers have been detected.   
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Table 23 Results of the 20 within-run repeated measurements on high and low pools 
Measurement 
n° 
High pool 
(µmol/L) 
Low pool 
(µmol/L) 
1 26.28 9.50 
2 26.19 7.82 
3 26.00 8.91 
4 26.23 9.65 
5 25.09 7.97 
6 26.65 8.04 
7 25.45 8.08 
8 27.82 9.50 
9 26.65 8.99 
10 19.58 8.69 
11 25.63 9.79 
12 24.95 8.91 
13 26.51 9.68 
14 24.50 9.43 
15 26.47 9.43 
16 27.59 9.06 
17 26.09 9.98 
18 26.65 9.46 
19 26.00 9.87 
20 26.09 9.35 
 
Table 24 Results of the five between-run repeated measure-ments on high pool 
Measurement 
n° 
High pool 
(µmol/L) 
1 26,28 
2 26,19 
3 26,00 
4 26,23 
5 25,09 
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Linearity under dilution test. The results obtained from the dilution of the high concentrated 
Hcy pool are shown in Table 25. 
 
Table 25 Results from the serial dilution of the pool with high concentration of homocysteine. On each dilution 
the reading was performed three times 
Dilution 
1° reading 
(µmol/L) 
2° reading 
(µmol/L) 
3° reading 
(µmol/L) 
Mean 
(µmol/L) 
SD CV (%) 
0 34.36 34.16 nd 34.26 0.14 0.41 
1:2 17.80 13.14 16.95 15.96 2.48 15.55 
1:4 8.76 9.13 8.59 8.82 0.28 3.13 
1:8 4.04 4.20 3.91 4.05 0.15 3.59 
1:16 <2.65 <2.65 <2.65 <2.65 ND ND 
SD: standard deviation; CV (%): coefficient of variability 
 
The intra-assay variability was overlapping or, in much of the cases, much lower than that 
observed in the above-mentioned imprecision tests, with the exception of 1:2 dilution in 
which the CV was higher.  
Regardless of the repeatability, the analyses of data highlight a progressive decrease of 
the mean by increasing the dilution. When compared to the expected values (Table 26), 
the observed values yielded mean ±SD recovery rate of 96.98 ±5.36%, with recovery 
values slightly below the average in 1: 2 and 1: 8 dilutions and higher in 1:4 dilution. 
Results of the last determination (1:16 dilution) were excluded from this analysis because 
they were lower than the detection limit of the method. 
  
Table 26 Serial dilutions of high concentration homocysteine pool with relative observed value (mean of three 
measurements), expected and recovery rate (O/E recovery) 
Dilution 
Observed value 
(µmol/L) 
Expected value 
(µmol/L) 
O/E recovery 
(%) 
0 34.26 34.26 ND 
1:2 15.96 17.13 93.19 
1:4 8.82 8.56 103.12 
1:8 4.05 4.28 94.63 
 
The linearity of the results obtained after dilution (Figure 23) was excellent (P = 0.001; r2 = 
0.998) 
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Figure 23 Graphic representation obtained from Linearity tests after dilution (LUD).  
 
Population	of	cats	
 
The 65 samples included in urinary evaluation of Hcy belonged to 38 patients 
At the time of inclusion, 17 were classified as At risk and 21 affected by CKD. Number of 
affected cats in each of the four IRIS stage (according to serum creatinine) were: IRIS 1 
were 5, IRIS 2 were 10, IRIS 3 were 4 and IRIS 4 were 2. 
In At risk group were present 7 male and 10 female whereas in CKD group 10 male and 
11 female. The majority of cats at risk and cats with CKD were European Short air (14 and 
14, respectively). The results obtained in the 29 sample of healthy cats at risk of CKD are 
listed in Table 27. Samples obtained from cats at risk showed a relative homogeneity of 
values, with data predominantly distributed between 3.37 and 16.7 µmol/L, with the 
exception of two samples (numbers 11 and 19), showing particularly high values (30.7 and 
40.2 µmol/L). Although both of these cats were clinically healthy at the time of inclusion in 
this study, the 12-month follow-up after sampling revealed, in one case, the appearance of 
CKD 6 months after collection, and in the other the appearance of clinical signs and 
laboratory alterations compatible with hyperthyroidism one year after the sample 
collection. The mean value obtained in the group at risk was 10.58 ± 7.78 µmol/L (median: 
8.44 µmol/L), although this distribution is influenced by the presence of the two outliers 
described above. Indeed, excluding the outliers, the value corresponds to 8.74 ± 3.48 
(median: 7.95 µmol/L).  
The results obtained in the 36 nephropatic cats are shown in Table 28.  
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Table 27 Cats at risk included in the study with collection time, IRIS classification of creatinemia (stage Crea), 
proteinuria (stage UPC) and systolic blood pressure (stage SBP), and value obtained from the measurement of 
homocysteine 
Sample n° Cat n° Time Stage Crea Stage UPC Stage SBP Hcy (µmol/L) 
3 2 T0 A BP AP0 5.42 
4 2 T9 A NP AP0 7.10 
5 2 T18 A BP AP0 6.11 
6 3 T0 A NP AP0 9.61 
7 4 T0 A NP nd 8.49 
11 7 T0 A BP AP0 40.20 
19 11 T0 A BP AP2 30.70 
23 14 T0 A NP AP2 8.86 
24 14 T6 A NP AP3 4.27 
25 14 T12 A NP AP3 7.36 
34 20 T0 A NP AP2 7.95 
35 20 T12 A NP AP1 7.36 
42 25 T0 A BP AP0 10.60 
43 25 T6 A NP AP0 11.40 
44 26 T0 A P AP0 11.70 
45 26 T6 A NP AP0 16.70 
46 27 T0 A NP AP0 14.70 
51 29 T0 A NP AP0 3.37 
52 29 T12 A NP AP0 8.44 
53 30 T0 A NP nd 15.70 
54 31 T0 A BP nd 13.30 
55 31 T6 A NP AP0 7.06 
56 31 T12 A BP AP0 6.69 
57 32 T0 A NP AP0 4.62 
58 33 T0 A NP AP1 9.15 
59 33 T12 A nd AP0 6.29 
60 34 T0 A NP nd 5.35 
61 34 T3 A NP nd 11.60 
62 35 T0 A NP AP2 6.82 
Hcy: Homocysteine; T0: collection time executed at time of inclusion; T3: three months from T0; T6: 6 months 
from T0; T9: 9 months from T0; T12: 12 months from T0; T18: 18 months from T0; A: at risk; nd: not available; 
NP: non-proteinic; BP: borderline proteinuric; P: proteinuric; AP0: systolic blood pressure (SBP) <150 mmHg; 
AP1: SBP= 150-159 mmHg; AP2: SBP=160-179 mmHg; AP3: SBP >180 mmHg 
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Table 28 Cats affected by CKD included in the study with collection time, IRIS classification of creatinemia 
(stage Crea), proteinuria (stage UPC) and systolic blood pressure (stage SBP), and value obtained from the 
measurement of homocysteine 
Sample n° Cat n° Time Stage Crea Stage UPC Stage SBP Hcy (µmol/L) 
1 1 T0 2 NP nd 15,10 
2 1 T12 2 nd nd 17,80 
8 5 T0 2 NP AP3 9,47 
9 6 T0 1 NP AP0 12,60 
10 6 T12 2 NP AP0 4,94 
12 8 T0 2 BP nd 16,70 
13 8 T12 2 nd nd 17,10 
14 9 T0 2 NP AP0 7,20 
15 9 T3 3 NP AP0 9,10 
16 9 T12 3 NP AP0 16,40 
17 9 T15 3 NP AP0 13,80 
18 10 T0 3 NP AP2 7,72 
20 11 T6 1 NP nd 38,50 
21 12 T0 1 NP AP3 16,00 
22 13 T0 4 P AP0 23,40 
26 14 T18 1 NP AP2 6,96 
27 15 T0 3 P AP2 15,00 
28 15 T3 4 NP AP2 17,70 
29 16 T0 1 nd AP0 8,62 
30 17 T0 2 NP AP0 11,30 
31 17 T12 2 P AP3 9,98 
32 18 T0 4 BP AP0 15,80 
33 19 T0 1 BP AP0 10,90 
36 21 T0 2 NP AP2 7,82 
37 22 T0 1 BP AP3 10,80 
38 22 T12 1 nd nd 9,24 
39 23 T0 2 P AP0 11,10 
40 24 T0 2 NP AP0 6,07 
41 24 T3 2 P AP0 11,70 
47 27 T6 2 NP AP3 20,10 
48 28 T0 2 NP AP1 12,10 
49 28 T3 2 BP AP0 17,60 
50 28 T12 2 NP nd 16,70 
63 36 T0 3 P nd 21,10 
64 37 T0 2 nd AP1 8,04 
65 38 T0 3 NP AP0 14,80 
T0 =collection time executed at time of inclusion; T3 = three months from T0; T6 = 6 months from T0; T9 = 9 months 
from T0; T12 = 12 months from T0; T18 = 18 months from T0; nd = not available; NP = non-proteinic; BP = proteinuria 
borderline; P = proteinuria; AP0 = <150 mmHg; AP1 = 150-159 mmHg; AP2 = 160-179 mmHg; AP3 => 180 mmHg 
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Comparison	based	on	serum	creatinine	
 
Descriptive statistics of the Hcy for the At risk and CKD groups are summarized in Table 
29 and shown graphically in Figure 24. Hcy between the two group was statistically 
different (P = 0.002) 
 
Table 29 Descriptive statistics of results obtained in CKD cats and cats at risk. Mean, median and 
Min-Max of homocysteine values are shown.  
Group N Mean (95% CI) ± SD Median (95% CI) 
Min-Max  
(I-III quartile) 
CKD 36 13.59 (11.27-15.91) ± 6,24 12.35 (9.98-16.00) 
4.94-38.50 
(9.16-16.70) 
At risk 29 10.58 (8.00-13.17) ± 7,767 8,44 (6.82-11.40) 
3.37-40.20 
(6.56-11.63) 
SD = standard deviation; CI = confidence interval 
 
 
 
Figure 24 Graphic representation of the comparison between the groups of cats at risk (R) and nephropatic cats 
(N). Hcy = homocysteine concentration. Boxes indicate the I-III interquartile interval, the horizontal line 
corresponds to the median value, the vertical lines are the limits of suspected outlier distribution according to 
the Tukey rule. 
 
The results obtained by dividing the CKD group in the subgroups according to IRIS staging 
based on serum creatinine are shown in Table 30 and summarized in Figure 25. 
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Table 30 Descriptive statistics of results obtained in cats grouped according to IRIS stage. Mean, median and 
Min-Max of homocysteine values are shown. 
Stage N Mean (95% CI) ± SD Median (95% CI) Min-Max (I-III quartile) 
A 29 10,58 (7,99-13,18) ±7,77 8,44 (6,82-11,40) 3,37-40,20 (6,56-11,63) 
1 8 14,20 (9,26-19,15) ±10,19 10,85 (6,96-38,50) 6,96-38,50 (8,88-14,58) 
2 18 12,27 (8,97-15,56) ±4,62 11,50 (8,04-16,70) 4,94-20,10 (8,02-16,73) 
3 7 13,99 (8,70-19,27) ±4,50 14,80 (7,72-21,10) 7,72-21,10 (9,88-16,17) 
4 3 18,97 (10,90-27,04) ±3,95 17,70 (-) 15,80-23,40 (16,12-22,45) 
A = at risk; SD = standard deviation; CI = confidence interval 
 
 
 
Figure 25 Graphic representation of the comparison between the group of cats at risk (R) and CKD cats divided 
based on the IRIS stage. Axis axis = IRIS staging; order axis = amount of homocysteine (Hcy). Boxes indicate 
the I-III interquartile interval, the horizontal line corresponds to the median value, the vertical lines are the limits 
of suspected outlier distribution according to the Tukey rule.  
 
This comparison showed a statistical difference between the groups (P = 0.015), but the 
subsequent post-hoc statistical comparisons between the single groups did not showed 
significant differences, likely due to the excessive fragmentation of the values, especially 
for IRIS groups 3 and 4, which were less numerous. 
Therefore, we decided to group the IRIS stage 3 and IRIS stage 4 together and to repeat 
the analysis. The descriptive statistics of the groups (including the new subgroup IRIS 
3+4) are summarized in Table 31 and the and graphically represented in Figure 26. 
A significant general difference was found (P = 0.013) but, again, there was no significant 
difference between the single groups despite the pooling of IRIS 3 and 4. 
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Table 31 Descriptive statistics of results obtained from cats at risk (R) and cats with CKD grouped according to 
the IRIS staging (IRIS 3 and 4 joined). The mean, median and Min-Max values are reported 
Stage N Mean (95% CI) ± SD Median (95% CI) Min-Max (I-III quartile) 
R 29 10,58 (7,99-13,18) ± 7,77 8,44 (6,82-11,40) 3,37-40,20 (6,56-11,63) 
1 8 14,20 (9,26-19,15) ± 10,19 10,85 (6,96-38,50) 6,96-38,50 (8,88-14,58) 
2 18 12,27 (8,97-15,56) ± 4,62 11,50 (8,04-16,70) 4,94-20,10 (8,02-16,73) 
3-4 10 15,48 (11,06-19,90) ± 4,77 15,40 (9,10-21,10) 7,72-23,40 (13,41-17,98) 
SD = standard deviation; CI = confidence interval 
 
 
 
Figure 26 Graphic representation of homocysteine comparison between the at risk cats group (R) and CKD cats 
sub-grouped according to IRIS stages 1, 2 and 3-4 (labeled 3). Boxes indicate the I-III interquartile interval, the 
horizontal line corresponds to the median value, the vertical lines are the limits of suspected outlier distribution 
according to the Tukey rule.  
 
 
The statistical analysis was repeated by comparing only results obtained from samples of 
CKD cats, in order to verify whether any absence of statistical significance could be due to 
the high dispersion of values in the At risk group, which also included outlier. The 
comparison did not show a significant difference (P = 0.319) and results are shown in 
Table 32 and graphically represented in Figure 27. 
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Table 32 Descriptive statistics of results obtained in CKD cats sub-grouped according to IRIS stage (stage 3 and 
4 joined). Mean, median and Min-Max of homocysteine values are shown.  
Stage N Mean (95% CI) ± SD Median (95% CI) Min-Max (I-III quartile) 
1 8 14,20 (9,70-18,71) ± 10,19 10,85 (6,96-38,50) 6,96-38,50 (8,88-14,58) 
2 18 12,27 (9,27-15,27) ± 4,62 11,50 (8,04-16,70) 4,94-20,10 (8,02-16,73) 
3-4 10 15,48 (11,45-19,51) ± 4,77 15,40 (9,10-21,10) 7,72-23,40 (13,41-17,98) 
 
 
Figure 27 Graphical representation of the comparison between IRIS 1, IRIS 2 and a single group IRIS 3 and IRIS 
4 (IRIS 3). Axis axes = IRIS staging; axis of the ordinates = homocysteine (Hcy) values. Boxes indicate the I-III 
interquartile interval, the horizontal line corresponds to the median value, the vertical lines are the limits of 
suspected outlier distribution according to the Tukey rule.  
 
In order to verify the hypothesis that the lack of statistical differences between groups 
could be due to the treatments received after the first visit, all the above analysis was 
repeated using only the results obtained at time 0. 
However, this analysis did not show significant differences (P = 0.163). Results are shown 
in Table 33 and graphically represented in Figure 28. 
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Table 33 Descriptive statistics of results of cats at risk (A) and CKD cats (N) including only samples collected at 
time zero. Mean, median and Min-Max of homocysteine values are shown.  
Group N Mean (95% CI) ± SD Median (95% CI) Min-Max (I-III quartile) 
A 17 12,15 (8,59-15,71) ± 9,57 9,15 (6,82-13,30) 3,37-40,20 (6,35-13,77) 
N 21 12,46 (9,26-15,66) ± 4,58 11,30 (8,62-15,10) 6,07-23,40 (8,43-15,33) 
SD= standard deviation; CI= confidence interval. A= At risk; N= nephropatic cats 
 
 
 
Figure 28 Graphical representation of the comparison between cats at risk and CKD cats. Axis axes = IRIS 
staging; axis of the ordinates = homocysteine (Hcy) values. Boxes indicate the I-III interquartile interval, the 
horizontal line corresponds to the median value, the vertical lines are the limits of suspected outlier distribution 
according to the Tukey rule.  
 
Similarly, the comparison between groups divided according to IRIS stages, including 
samples collected at time 0 (descriptive in Table 34 and graphical representation in Figure 
29), did not reveal significant differences between the groups (P = 0.168). 
 
Table 34 Descriptive statistics of results of cats grouped according to IRIS stage, including only samples 
collected at time zero. Mean, median and Min-Max of homocysteine values are shown. 
Stage N Mean (95% CI) ± SD Median (95% CI) Min-Max (I-III quartile) 
A 17 12,15 (8,61-15,69) ± 9,57 9,15 (6,82-13,30) 3,37-40,20 (6,35-13,77) 
1 5 11,78 (5,26-18,31) ± 2,75 10,90 (-) 8,62-16,00 (10,07-13,73) 
2 10 10,49 (5,87-15,11) ± 3,46 10,29 (7,20-15,10) 6,07-16,70 (7,77-12,35) 
3-4 6 16,30 (10,34-22,26) ± 5,50 15,40 (7,72-23,40) 7,72-23,40 (14,21-21,29) 
A= at risk; SD= standard deviation; CI= confidence interval 
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Figure 29 Graphic representation of homocysteine comparison between the At risk group (A) and CKD cats sub-
grouped according to IRIS stages 1, 2 and 3-4 (labeled 3). Boxes indicate the I-III interquartile interval, the 
horizontal line corresponds to the median value, the vertical lines are the limits of suspected outlier distribution 
according to the Tukey rule. 
 
The correlation between creatininemia and homocysteinemia (Figure 30) was statistically 
significant (P <0.001), although the correlation coefficient was moderate (r = 0.433).  
 
 
Figure 30 Graphic representation of the correlation between serum creatinine (Crea) and homocysteine (Hcy). 
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This result suggested that the decrease of GFR may play a role in determining the 
increase of concentration of homocysteinemia, despite other factors involved in the onset 
of hyperomocysteinemia could not be excluded. 
 
Comparison	based	on	proteinuria	
 
Descriptive statistics of Hcy in groups divided according to IRIS stage for proteinuria in 
Table 35 and summarized in Figure 31. No statistically significant difference (P = 0.090) 
was found in this comparison. 
 
Table 35 Descriptive statistics of results grouped according to IRIS sub-stage for proteinuria. Mean, median and 
Min-Max of homocysteine values are shown. 
Stage N Mean (95% CI) ± SD Median (95% CI) Min-Max (I-III quartile) 
NP 40 11,01 (8,75-13,26) ± 6,17 9,13 (7,72-12,10) 3,37-38,50 (7,14-14,76) 
BP 13 15,12 (11,16-19,07) ± 10,00 11,70 (6,69-17,60) 5,42-40,20 (9,30-17,00) 
P 6 15,38 (9,55-21,21) ± 5,63 13,35 (9,98-23,40) 9,98-23,40 (11,01-21,29) 
NP= non-proteinuric; BP= borderline proteinuric; P= proteinuric; SD= standar deviation; CI= 
confidence interval 
 
 
Figure 31 Graphic representation of the comparison between the group of cats divided based on the IRIS sub-
stage of proteinuria (BP= borderline proteinuric, NP=non-proteinuric, P= proteinuric). Axis axis = IRIS staging; 
order axis = amount of homocysteine (Hcy). Boxes indicate the I-III interquartile interval, the horizontal line 
corresponds to the median value, the vertical lines are the limits of suspected outlier distribution according to 
the Tukey rule 
 
Repeating the statistical analysis only on cats with CKD (Table 36, Figure 32), the 
difference between the groups was not statistically significant (P = 0.679). 
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Table 36 Descriptive statistics of results grouped according to IRIS sub-stage for proteinuria including only cats 
with CKD. Mean, median and Min-Max of homocysteine values are shown. 
Stage N Mean (95% CI) ± SD Median  
(95% CI) 
Min-Max  
(I-III quartile) 
NP 20 13,22 (10,18-16,26) ± 7,38 12,35 (7,82-16,00) 4,94-38,50 (7,76-16,23) 
BP 5 14,36 (8,28-20,44) ± 3,27 15,80 (-) 10,80-17,60 (10,87-17,00) 
P 6 15,38 (9,83-20,93) ± 5,63 13,35 (9,98-23,40) 9,98-23,40 (11,01-21,29) 
NP= non-proteinuric; BP= borderline proteinuric; P= proteinuric; SD= standar deviation; CI= 
confidence interval 
 
 
 
Figure 32 Graphic representation of the comparison between the group of cats with CKD divided based on the 
IRIS sub-stage of proteinuria (BP= borderline proteinuric, NP=non-proteinuric, P= proteinuric). Axis axis = IRIS 
staging; order axis = amount of homocysteine (Hcy). Boxes indicate the I-III interquartile interval, the horizontal 
line corresponds to the median value, the vertical lines are the limits of suspected outlier distribution according 
to the Tukey rule. 
 
The difference becomes statistically significant (P = 0.011) if the comparison based on the 
UPC values is restricted to samples referred to the cats sampled at time 0. Comparison 
between the single groups revealed significant difference only between BP and NP (P = 
0.025), with higher values obtained in BP group, but not between BP and P and NP and P. 
Results are reported in Table 37 and graphically represented in Figure 33.  
 
 
 
Table 37 Descriptive statistics of results grouped according to IRIS sub-stage for proteinuria including only 
sample collected at the time of inclusion. Mean, median and Min-Max of homocysteine values are shown. 
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Stage N Mean (95% CI) ± SD 
Median 
(95% CI) 
Min-Max 
(I-III quartile) 
NP 22 9,76 (6,93-12,60) ± 3,77 
9,01 
(7,20-12,60) 
3,37-16,00 
(7,17-12,78) 
BP 10 16,61 (12,40-20,82) ± 10,64 
12,50  
(10,60-30,70) 
5,42-40,20 
(10,78-17,87) 
P 4 17,65 (11,00-24,30) ± 5,62 18,05 (-) 
11,10-23,40 
(12,73-22,44) 
NP= non-proteinuric; BP= borderline proteinuric; P= proteinuric; SD= standar deviation; CI= 
confidence interval 
 
 
 
Figure 33 Graphic representation of the comparison between the group of cats divided based on the IRIS sub-
stage of proteinuria (BP= borderline proteinuric, NP=non-proteinuric, P= proteinuric) including only samples 
collected at the time of inclusion. Axis axis = IRIS staging; order axis = amount of homocysteine (Hcy). Boxes 
indicate the I-III interquartile interval, the horizontal line corresponds to the median value, the vertical lines are 
the limits of suspected outlier distribution according to the Tukey rule.  
 
The correlation between UPC and homocysteinemia (Figure 34) was not statistically 
significant (P <0.058) and the correlation coefficient was very low (r = 0.248). 
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Figure 34 Graphical representation of the correlation between urinary protein-to-creatini (UPC) ratio and 
homocysteine (Hcy). 
 
Comparison	based	on	SBP	
 
Hcy was not significantly different between groups of samples classified according to SBP 
(P = 0.988). Descriptive statistics as shown in Table 38 and graphically displayed in Figure 
35. 
 
Table 38 Descriptive statistics of results grouped according to IRIS sub-stage for SBP. Mean, median and Min-
Max of homocysteine values are shown. 
IRIS stage N Mean (95% CI) ± SD Median 
(95% CI) 
Min-Max  
(I-III quartile) 
AP0 32 11,42 (9,02-13,81) ± 6,93 10,75 (7,10-12,60) 3,37-40,20 (6,84-14,33) 
AP1 4 9,16 (2,39-15,93) ± 2,09 8,60 (-) 7,36-12,10 (7,64-10,87) 
AP2 9 12,17 (7,66-16,68) ± 7,95 7,95 (6,96-17,70) 6,82-30,70 (7,47-15,90) 
AP3 7 11,14 (6,02-16,26) ± 5,32 9,98 (4,27-20,10) 4,27-20,10 (7,71-15,13) 
SD= standard deviation; CI= confidence interval; AP0: SBP< 150 mmHg; AP1: SBP= 150-159 mmHg; AP2: 
SBP= 160-179 mmHg; AP3: SBP> 180 mmHg 
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Figure 35 Graphic representation of the comparison between the group of cats divided according to the IRIS 
sub-stage of SBP (AP0: SBP< 150 mmHg; AP1: SBP= 150-159 mmHg; AP2: SBP= 160-179 mmHg; AP3: SBP> 180 
mmHg). Axis axis = IRIS staging; order axis = amount of homocysteine (Hcy). Boxes indicate the I-III 
interquartile interval, the horizontal line corresponds to the median value, the vertical lines are the limits of 
suspected outlier distribution according to the Tukey rule.  
 
Significant differences (P = 0.985) were not observed either by comparing normotensive 
and hypertensive cats, using a cut-off of 150 mmHg, as shown in Table 39 and Figure 36. 
 
Table 39 Descriptive statistics of homocysteine in hypertensive cats (HT) and normotensive cats (NT), using 150 
mmHg as cut-off. Mean, median and Min-Max of homocysteine values are shown. 
IRIS Stage N Mean (95% CI) ± SD Median 
(95% CI) 
Min-Max  
(I-III quartile) 
HT 20 11,21 (8,23-14,19) ± 6,13 9,01 (7,72-12,10) 4,27-30,70 (7,51-13,79) 
NT 32 11,42 (9,06-13,77) ± 6,93 10,75 (7,10-12,60) 3,37-40,20 (6,84-14,33) 
SD= standard deviation; CI= confidence interval. 
 
AP0 AP1 AP2 AP3
0
5
10
15
20
25
30
35
40
45
IRIS	PS
Hc
y	
µm
ol
/L
Near	outliers
Far	outliers
 116 
 
Figure 36 Graphic representation of the comparison between the hypertensive cats (HT) and normotensive cats 
(NT), using 150 mmHg as cut-off. Axis axis = IRIS staging; order axis = amount of homocysteine (Hcy). Boxes 
indicate the I-III interquartile interval, the horizontal line corresponds to the median value, the vertical lines are 
the limits of suspected outlier distribution according to the Tukey rule. 
 
The same statistical analysis were performed only on the group of CKD cats in order to 
exclude the effect on results of the healthy cats, that in turn supposedly do not have 
alteration of Hcy metabolism.  
However, this analysis showed neither significant differences nor comparing the different 
IRIS stages (P = 0.817) (Table 40 and Figure 37) neither classifying the samples as 
normotensive or hypertensive (using the 150 mmHg value as cut-off, P = 0.780) (Table 41 
and Figure 38). 
 
Table 40 Descriptive statistics of results grouped according to IRIS sub-stage for SBP, including only samples 
of cats affected by CKD. Mean, median and Min-Max of homocysteine values are shown.  
IRIS Stage N Mean (95% CI) ± SD Median 
(95% CI) 
Min-Max  
I-III quartile) 
AP0 16 12,21 (9,79-14,63) ± 4,74 11,50 (8,62-15,80) 4,94-23,40 (8,82-15,38) 
AP1 2 10,07 (3,22-16,92) ± 2,87 10,07 (-) 8,04-12,10 (8,04-12,10) 
AP2 5 11,04 (6,71-15,37) ± 4,95 7,82 (-) 6,96-17,70 (7,47-15,90) 
AP3 5 13,27 (8,94-17,60) ± 4,62 10,80 (-) 9,47-20,10 (9,81-17,37) 
SD= standard deviation; CI= confidence interval; AP0: SBP< 150 mmHg; AP1: SBP= 150-159 mmHg; AP2: 
SBP= 160-179 mmHg; AP3: SBP> 180 mmHg 
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Figure 37 Graphic representation of the comparison between the group of cats divided according to the IRIS 
sub-stage of SBP (AP0: SBP< 150 mmHg; AP1: SBP= 150-159 mmHg; AP2: SBP= 160-179 mmHg; AP3: SBP> 180 
mmHg), including only samples of cats affected by CKD. Axis axis = IRIS staging; order axis = amount of 
homocysteine (Hcy). Boxes indicate the I-III interquartile interval, the horizontal line corresponds to the median 
value, the vertical lines are the limits of suspected outlier distribution according to the Tukey rule.  
 
 
Table 41 Descriptive statistics of homocysteine in hypertensive cats (HT) and normotensive cats (NT), including 
only samples of cats affected by CKD. Mean, median and Min-Max of homocysteine values are shown. 
IRIS Stage N Mean (95% CI) ± SD Median  
(95% CI) 
Min-Max  
(I-III quartile) 
HT 12 11,81 (9,08-14,53) ± 4,38 10,39 (7,82-16,00) 6,96-20,10 (7,91-15,58) 
NT 16 12,21 (9,85-14,57) ± 4,74 11,50 (8,62-15,80) 4,94-23,40 (8,82-15,38) 
SD= standard deviation; CI= confidence interval. 
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Figure 38 Graphic representation of the comparison between the hypertensive cats (HT) and normotensive cats 
(NT), using 150 mmHg as cut-off and including only cats affected by CKD. Axis axis = IRIS staging; order axis = 
amount of homocysteine (Hcy). Boxes indicate the I-III interquartile interval, the horizontal line corresponds to 
the median value, the vertical lines are the limits of suspected outlier distribution according to the Tukey rule. 
 
Similarly to the data of proteinuria, even for the systolic blood pressure we performed a 
statistical comparison on the samples obtained at time 0 prior to each therapy. In this 
case, no significant differences were observed neither by comparing the different IRIS 
classes (P = 0.814) (Table 42 and Figure 39) nor classifying the samples as normotensive 
or hypertensive (using the 150 mmHg value as cut-off, P = 0.779) (Table 43 and Figure 
40). 
 
 
Table 42 Descriptive statistics of results grouped according to IRIS sub-stage for SBP, including only samples 
collected at time of inclusion. Mean, median and Min-Max of homocysteine values are shown. 
IRIS Stage N Mean (95% CI) ± SD Median (95% CI) Min-Max (I-III quartile) 
AP0 18 12,33 (8,51-16,15) ± 8,42 11,00 (7,20-14,70) 3,37-40,20 (7,11-14,71) 
AP1 3 9,76 (0,40-19,12) ± 2,10 9,15 (-) 8,04-12,10 (8,23-11,61) 
AP2 7 12,12 (6,00-18,25) ± 8,64 7,95 (6,82-30,70) 6,82-30,70 (7,74-13,98) 
AP3 3 12,09 (2,73-21,45) ± 3,45 10,80 (-) 9,47-16,00 (9,69-15,13) 
SD= standard deviation; CI= confidence interval; AP0: SBP< 150 mmHg; AP1: SBP= 150-159 mmHg; AP2: 
SBP= 160-179 mmHg; AP3: SBP> 180 mmHg 
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Figure 39 Graphic representation of the comparison between the group of cats divided according to the IRIS 
sub-stage of SBP (AP0: SBP< 150 mmHg; AP1: SBP= 150-159 mmHg; AP2: SBP= 160-179 mmHg; AP3: SBP> 180 
mmHg), including only samples collected at time of enrolment. Axis axis = IRIS staging; order axis = amount of 
homocysteine (Hcy). Boxes indicate the I-III interquartile interval, the horizontal line corresponds to the median 
value, the vertical lines are the limits of suspected outlier distribution according to the Tukey rule. 
 
 
Table 43 Descriptive statistics of homocysteine in hypertensive cats (HT) and normotensive cats (NT), including 
only samples collected at time of inclusion. Mean, median and Min-Max of homocysteine values are shown. 
IRIS Stage N Mean (95% CI) ± SD Median  
(95% CI) 
Min-Max  
(I-III quartile) 
HT 13 11,57 (7,23-15,91) ± 6,41 9,15 (7,82-15,00) 6,82-30,70 (7,91-13,07) 
NT 18 12,33 (8,65-16,02) ± 8,42 11,00 (7,20-14,70) 3,37-40,20 (7,11-14,71) 
SD= standard deviation; CI= confidence interval. 
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Figure 40 Graphic representation of the comparison between the hypertensive cats (HT) and normotensive cats 
(NT), using 150 mmHg as cut-off and including only samples collected at time of enrolment. Axis axis = IRIS 
staging; order axis = amount of homocysteine (Hcy). Boxes indicate the I-III interquartile interval, the horizontal 
line corresponds to the median value, the vertical lines are the limits of suspected outlier distribution according 
to the Tukey rule. 
 
Furthermore, no significant correlation (P = 0.964; r = -0.006) was found between BP and 
homocysteinemia levels (Figure 41). 
 
 
Figure 41 Graphical representation of the correlation between systolic blood pressure (PS) and homocysteine 
(Hcy).  
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Disease	progression		
 
Regardless of the mechanism responsible for hyperomocysteinemia in cats with CKD, we 
checked if the Hcy could be an early marker of renal disease despite the inappropriate 
experimental design and the few data available on the follow up of the cats included in the 
study. Therefore, the cats at risk were divided into groups depending on whether or not 
they had developed CKD within 6 to 12 months after the first sample collection. 
This comparison, shown in Table 44 and graphically represented in Figure 42, did not 
reveal a significant difference between the groups (P = 0.384), although mean and median 
values of Hcy were lower in cats that did not develop CKD compared to those found in 
cats that developed kidney disease. 
 
Table 44 Descriptive statistics of homocysteine in samples collected at time of enrolment in cats grouped 
depending on whether or not (“progressive” or “stable”, respectively)they had developed CKD within 6 to 12 
months after the first sample collection. Mean, median and Min-Max of homocysteine values are 
shown.including only samples collected at time of inclusion. 
Group N 
Mean 
(95% CI) ± SD 
Median 
(95% CI) 
Min-Max 
(I-III quartile) 
Progressive 6 
14,84 
(10,13-19,56) ± 8,38 
13,65 
(7,20-30,70) 
7,20-30,70 
(8,72-16,31) 
Stable 12 
10,85 
(7,51-14,18) ± 3,36 
11,05 
(7,95-13,30) 
5,42-16,70 
(8,45-12,80) 
SD= standard deviation; CI= confidence interval. 
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Figure 42 Graphic representation of the distribution of homocysteine in samples collected at time of enrolment 
in cats grouped depending on whether or not (“progressive” or “stable”, respectively) they had developed CKD 
within 6 to 12 months after the first sample collection. Boxes indicate the I-III interquartile interval, the horizontal 
line corresponds to the median value, the vertical lines are the limits of suspected outlier distribution according 
to the Tukey rule. 
 
 
The previous analysis was repeated including only At risk cats. The results, shown in 
Table 45 and represented in Figure 43, showed that although there is no statistical 
significance (P = 0.110). 
 
Table 45 Descriptive statistics of homocysteine in samples collected at time of enrolment in cats at risk grouped 
depending on whether or not (“progressive” or “stable”, respectively) they had developed CKD within 6 to 12 
months after the first sample collection. Mean, median and Min-Max of homocysteine values are shown. 
Group N Mean (95% CI) ± SD Median 
(95% CI) 
Min-Max  
(I-III quartile) 
Progressive 3 18,09 (9,22-26,95) ± 11,31 14,70 (-) 8,86-30,70 (9,83-28,03) 
Stable 6 9,69 (3,42-15,96) ± 2,81 9,88 (5,42-13,3) 5,42-13,30 (7,74-11,83) 
SD= standard deviation; CI= confidence interval. 
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Figure 43 Graphic representation of the distribution of homocysteine in samples collected at time of enrolment 
in cats at risk grouped depending on whether or not (“progressive” or “stable”, respectively) they had 
developed CKD within 6 to 12 months after the first sample collection. Boxes indicate the I-III interquartile 
interval, the horizontal line corresponds to the median value, the vertical lines are the limits of suspected outlier 
distribution according to the Tukey rule. 
 
To verify whether the Hcy values at T0 were predictive of the development of proteinuria 
and hypertension, the comparison between stable and progressive patients was 
performed using this two IRIS sub-staging, irrespective of the degree of CKD (i.e. IRIS 
stage based on serum creatinine),  
 
Regarding proteinuria, there were no significant differences between stable and 
progressive patients (P = 0.304) and no tendencies to increase mean or median Hcy 
values Table 46 and in Figure 44). As previously done for creatinine, it was not possible to 
repeat this comparison only on subjects at risk, because none of them showed a transition 
to a higher stage of proteinuria than that found at T0. 
 
Table 46 Descriptive statistics of homocysteine in samples collected at time of enrolment in cats grouped 
depending on whether or not (“progressive” or “stable”, respectively) they had developed proteinuria within 6 
to 12 months after the first sample collection. Mean, median and Min-Max of homocysteine values are shown.  
Group N Mean (95% CI) ± SD Median  
(95% CI) 
Min-Max  
(I-III quartile) 
Progressive 2 8,69 (0,59-17,96) ± 3,70 8,69 (-) 6,07-11,30 (6,07-11,30) 
Stable 13 12,71 (9,07-16,35) ± 6,23 12,10 (7,95-15,00) 5,42-30,70 (8,56-14,80) 
SD= standard deviation; CI= confidence interval. 
progressivo stabile
5
10
15
20
25
30
progressione	crea
Hc
y	
µm
ol
/L
 124 
 
 
Figure 44 Graphic representation of the distribution of homocysteine in samples collected at time of enrolment 
in cats grouped depending on whether or not (“progressive” or “stable”, respectively) they had developed 
proteinuria within 6 to 12 months after the first sample collection. Boxes indicate the I-III interquartile interval, 
the horizontal line corresponds to the median value, the vertical lines are the limits of suspected outlier 
distribution according to the Tukey rule.  
 
Similarly, no significant difference (P = 0.481) in Hcy values at time 0 was found between 
cats who maintain normal SBP and cats which then showed an increase in the IRIS 
staging of hypertension at subsequent sample collections (Table 47, figure 45). However, 
similar to that found for creatinine-based IRIS, a tendency to increase median and median 
values in progressive patients has been observed. Therefore, it could be interesting to 
perform future studies with multiple sampling and higher sample of patients, in order to 
check whether this preliminary visual difference can play a prognostic role. This type of 
observation could be relevant both in CKD and in at risk subjects, but in this study a 
separate comparison within the two groups was not possible because only a cat with CKD 
and only two of the risk cats showed increasing SBP values.  
 
Table 47 Descriptive statistics of homocysteine in samples collected at time of enrolment in cats grouped 
depending on whether or not (“progressive” or “stable”, respectively) they had developed hypertension within 6 
to 12 months after the first sample collection. Mean, median and Min-Max of homocysteine values are shown.  
Group N Mean (95% CI) ± SD Median (95% CI) Min-Max (I-III quartile) 
Progressive 3 11,62 (7,57-15,67) ± 2,93 11,30 (-) 8,86-14,70 (9,27-14,13) 
Stable 9 9,52 (7,18-11,86) ± 3,20 9,15 (6,07-12,60) 5,42-15,00 (6,82-12,00) 
SD= standard deviation; CI= confidence interval. 
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Figure 45 Graphic representation of the distribution of homocysteine in samples collected at time of enrolment 
in cats grouped depending on whether or not (“progressive” or “stable”, respectively) they had developed 
hypertension  within 6 to 12 months after the first sample collection. Boxes indicate the I-III interquartile interval, 
the horizontal line corresponds to the median value, the vertical lines are the limits of suspected outlier 
distribution according to the Tukey rule.  
 
	
Discussion	
 
The validation tests showed that the determination of Hcy in the cat with the enzymatic 
method had more than acceptable levels of imprecision and accuracy, analogously to 
study performed on other species (Rossi et al., 2008). 
Overall, intra-assay results showed a satisfactory performance, highlighting lower CVs with 
higher Hcy values and higher CV at lower Hcy values. This result is not surprising, since it 
is already known that when the concentration of an analyte in a sample is low, the slight 
shift of a measurement from the mean value determines a more profound change of CV 
compared to a sample with higher concentration (Westgard, 2003). 
Also the inter-assay CV was acceptable, even if it was higher than that found in the intra-
assay tests. Higher variability is expected with inter-assay test since, in addition to the 
intrinsic variability of method, other factors (e.g. the preservation of the sample) can affect 
results (Kale et al., 2012). 
The results of the LUD test showed that the method, applied on feline serum, had 
excellent accuracy, similar to that observed in other species (Rossi et al., 2008).  
The most diluted sample has always showed values below the detection limit of the 
method, suggesting that even at low values the test seems to be very repeatable and on 
the other hand that the dilution accuracy is high. 
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A more complete assessment of accuracy would require a comparison of results with 
those obtained using a gold standard, which is not available for the feline species, and the 
performance of the spiking tests. This last test should be carried out by measuring the 
concentration of Hcy in the serum before and after the addition of purified feline Hcy (not 
available on the market) or more commonly, by quantifying the analyte in a serum with low 
concentration, supplemented with increasing volume of another serum in which the 
concentration of the analyte is higher. In our study, this test could have been done by 
adding high Hcy concentration pools (used in imprecision and LUD tests) to the low-
concentration Hcy pool used in the imprecision test. However, in cats this kind of 
evaluations is conditioned by the low volumes of serum that can be collected from each 
animal and in the majority of cases available volume is not sufficient to perform all the 
tests required in routine method validation (Kjelgaard-Hansen and Jensen, 2010). Given 
that, our good dilutions test results and the necessity to prepare other serum pool for the 
spiking recovery tests with the risk of decreasing the number of samples useful for 
subsequent analyzes, we decided to not "consume" other serum aliquots to perform this 
additional test. For the same reasons, other tests commonly included in validation studies, 
such as the evaluation of quantification and detection limits (Kjelgaard-Hansen and 
Jensen, 2010), conservation analysis at different time and temperature conditions, or 
evaluation of the interference of substances such as lipids, hemoglobin and jaundice, were 
not performed. 
However in dogs, although some interferers had statistically significant variations on the 
expected values, no clinically relevant variations were observed neither in the presence of 
interferents at concentrations commonly found in clinical practice or after conservation for 
medium to long time (Rossi et al., 2008). Therefore, it could be axpected that this also 
could occur in the cat. 
Given this, the method provides results that are easily interpretable also in case of small 
differences between the groups. When samples exhibit macroscopic alterations due to 
severe hemolysis, jaundice or lipemia, or samples with extreme conservation conditions 
are used, results should be interpreted with caution. 
Overall, the results obtained from the comparison of the groups classified basing on 
creatinine and on the IRIS stage showed an increase in CKD cats in comparison with the 
cats at risk. Moreover, in the CKD group, a progressive increasing trend comparable to the 
IRIS stage was shown, although not always the observed differences appeared to be 
significant. This result could be due to a certain degree of overlapping results between the 
 127 
different groups, and to the number of samples in groups, not always sufficiently high, that 
could have masked significant differences. 
From a pathogenetic point of view, the increase of Hcy in nephropatic cats could have 
difference causes. Since Hcy is mainly excreted by the kidney, the reduction of GFR could 
reduce the excretion of this amino acid (Selhub, 1999). Also, it was hypothesized that Hcy 
metabolism is directly or indirectly affected by CKD (van Guldener, 2006). 
The trend of Hcy to increase only at late stage of CKD represents a difference with what 
previously found in dogs. Indeed Rossi and colleagues showed that Hcy was higher early 
at stage 2 compared to control dogs and IRIS stage 1, whereas no significant differences 
were found between IRIS 2 and the higher values (Rossi et al., 2013b). A possible 
explanation of this different behavior of Hcy in cats compared to dogs could be due to its 
different metabolic features in this specie. Indeed, Hcy in cats is not affected by 
enteropaties (McMichael et al., 2000) and by cobalamin deficiency (Ruaux et al., 2001). 
An other possible explanation is the different characteristics of the healthy patients in the 
two studies: in the study in dogs young healthy patients were included (Rossi et al., 
2013b) whereas in our study old cats were selected. Whether age affect Hcy concentration 
have to be determined in cats. Moreover, since slow progressive CKD is common in 
elderly cats, it is not possible to exclude that  
The value obtained from cats At risk (mean ±SD: 8.74 ±3.48 µmol/L) can to be considered 
"normal" for healthy cats at risk to develop CKD. However, it should be considered that 
this result cannot be extended to the entire feline population at risk, due to the small 
dimension of the population considered in this study, also to the not comparable collection 
times and also to the application of not strictly selection criteria of well-defined statistical 
approaches, which are based on the observed distribution of values, as recommended by 
the guidelines for the definition of reference ranges elaborated by the American Society of 
Veterinary Clinical Pathology (Friedrichs et al., 2012). Therefore in the future, we will focus 
the study using the reference range in accordance with the above guidelines. 
Despite these considerations, these results suggested that normal levels in cat are slightly 
superior to those found in normal dogs (mean ±SD: 5.72 ±3.26 µmol/L) in a previous study 
(Rossi et al., 2008). However, it is interesting to note that dogs included in control group 
had lower mean age (mean ±SD of age: 5.7 ±2.3 years) compared to healthy cats in our 
study (11.1 ±2.7 years, data not shown). This higher values in healthy cats could have 
affect statistical significance in comparison with CKD cats. Since CKD is common in 
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elderly cats, it is not possible to exclude that a mild slow-progressive CKD was present in 
some of cats at risk.  
 
Preliminary data obtained from our study suggested that high Hcy in a cat without any 
signs of pathologies that can potentially induce hyperomocysteinaemia may be predictive 
of the occurrence of CKD pathologies. However, this study is not designed to determine 
the prognostic value of Hcy in feline CKD and sampling number of the groups was 
particularly small. 
It is also important to note that some patients who developed CKD in the following months 
after the sample collection yielded Hcy concentration similar to stable patients. 
Overall, results obtained in the analysis based on degree of proteinuria showed a modest 
increasing trend similar to the IRIS stages increment.  
This tendency was evident in the whole case and in particular, in the samples 
corresponding to time of inclusion where a significant difference was found between NP 
and BP patients. This result could be interesting since the pathological importance of 
borderline proteinuria in CKD cats is still debated and the presence of hyperhocysteinemia 
in these patients could suggest to not underestimate borderline proteinuria in CKD cats. 
Despite this significant difference that needs further evaluation, these findings, together 
with the low level of correlation between the degree of proteinuria and homocysteinemia, 
represented a further difference between dog and cat in the behavior of Hcy during CKD. 
However, this difference is not surprising in the light of the different pathogenesis of canine 
kidney disease, which is predominantly associated with immunocomplex 
glomerulonephritis, compared to feline CKD, which rarely glomerular injury is predominant 
in the pathogenesis (Polzin, 2017). Hypertension and proteinuria in the cat seem to be 
less associated with each other and the absence of correlation between homocysteinemia 
and proteinuria, together with the possible different Hcy metabolism hypnotized in other 
study (McMichael et al., 2000), could be a further confirmation to this assumption. 
The serum Hcy concentration in the cat did not seem dependent to the SBP, unlike what 
happens in humans (Stanger et al., 2004). This finding was in accordance with the 
hypothesis of McMichael and colleagues (McMichael et al., 2000), which suggested that in 
the cat the serum Hcy concentration depends mainly on the peculiar metabolism in this 
specie. Moreover, the lack of correlation between homocysteinaemia and SBP and the 
absence of significant differences between groups confirmed what was already found in 
the dog. Specifically, a study showed no significant differences in Hcy concentration 
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between non-hypertensive animal or with minimal increases in SBP compared to dogs 
with hypertension, both considering the total number of nephropathic dogs, irrespective of 
the IRIS stage and within the individual IRIS stages (Rossi et al., 2013b).  
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4.3	Serum	aldosterone	
 
Introduction	and	aims	
 
The RAAS is one of the main control system of the systemic hypertension (Mishina et al., 
1998; Syme, 2011). Increased secretion of aldosterone is considered a link among renal 
disease, sodium retention, volume expansion, peripheral vascular resistance, and 
systemic hypertension (Syme, 2011). In cats, high aldosterone concentration was 
demonstrated with CKD and even higher values were found with concurrent CKD-related 
hypertension (Jepson et al., 2014). Systemic hypertension is an important potential 
complicating factor of CKD (Syme, 2011) and is common in cats with this disease. (Syme 
et al., 2002a; Kobayashi et al., 1990; Brown et al., 2007;Taylor et al., 2017). The 
persistence of high SBP can lead to severe clinical consequences due to target organ 
damage (TOD), affecting the eyes, heart, brain and the kidney itself (Sansom et al., 
2004;Taylor et al., 2017). Determination of systolic blood pressure (SBP) is therefore 
mandatory to correctly stage and treat cats with CKD. However, diagnosis of hypertension 
could be challenging in cats since white coat hypertension is reported to occur frequently, 
with increase of SBP on average around 22 mmHg during clinical examination, but with a 
highly unpredictable interindividual effect and SBP increasing by as much as 75 mmHg in 
some cats (Belew et al., 1999).  
Therefore, a biomarker of hypertension not affected by white-coat hypertension could be 
useful in cats, although previous studies failed to demonstrate diagnostic utility of a group 
of biomarkers (i.e. plasma N-Terminal probrain natriuretic peptide, vascular endothelial 
growth factor and cardiac troponin I) in cats to this aim (Bijsmans et al., 2017).  
The aim of this study was to evaluate the value of aldosterone in cats at risk of developing 
CKD and in subjects with CKD. The analysis of the results will allow us to evaluate how 
aldosterone varies in different stages. In addition, in the case of white-coat hypertension, 
serum aldosterone was evaluated in hypertensive and normotensive subjects in order to 
evaluate its utility in distinguishing this type of hypertension from the true HT that needs 
treatment. 
	
 	
 131 
Material	and	methods	
 
Selection	of	samples	
 
Fifty-seven samples obtained from 35 cats were included in this study (of 22 subjects the 
samples at 12 months or, if not available, at 6 months were also selected). 
Sample analysis was subdivided into three work sessions: 
• In the first session, 10 samples (3 healthy and 7 nephropathy) with a serum volume 
between 1 and 1.5 mL were tested, with the aim of validate the test. 
• In the second session (that was performed the following day), the intra-assay 
repeatability test and the linearity under dilution test were performed. These tests were 
considered a first validation of the ELISA kit. Moreover, the analysis of 28 additional 
samples was performed in this session. The intra-assay repeatability test was performed 
using the samples of the first session, kept refrigerated for not more than 12 hours. 
Specifically, based on its results and using residual serum volume, samples with lower 
aldosterone concentrations were mixed to form a pool (labelled "low pool") while those 
with higher concentrations were mixed to form a second pool (called "high pool"). Each of 
these two pools has been tested 5 times. The perform linearity under dilution test; a third 
pool with very high aldosterone concentration (using the two pool with the highest values) 
was prepared. This pool was serially diluted by a twofold dilution scheme (i.e 1:2, 1:4, 1:8 
and 1:16) using distilled water. The expected values corresponding to each dilution were 
calculated. The percentage of recovery of the observed values compared with expected 
values at each dilution was also calculated as follow: recovery = mean observed / 
expected X 100. 
• In the last session, 19 further samples were tested. 
 
Measurement	of	Aldosterone	
 
A commercially available ELISA kit ("Parameter Aldosterone Assay", R & D System, 
Minneapolis, MN, USA) was used for the determination of aldosterone. This is a 
competitive type of ELISA designed to measure serum, plasma, urine and cell culture 
supernatants. The ELISA plate was coated with anti-mouse goat IgG and the competitor 
aldosterone was conjugated to horseradish peroxidase. The reported minimum detectable 
dose was 15.2 pg/mL.  
At the time of analysis, selected sera were gently thawed by transferring tubes at 4°C the 
day before analysis and then at room temperature one hour before analysis.  
 132 
Analytical procedures were performed following the manufacturer’s instruction, setting at 
each run standard solutions (six solutions between 6000 pg/mL and 24.7 pg/mL). 
Plate was washed with an automatic washing instrument (BioRad Microtech, Segrate, 
Milan, Italy), aspirating and applying the wash buffer solution for a total of 4 consecutive 
times.  
The optical density of each well was determined at 450 nm and 540 nm within 30 minutes 
after the addition of the stop solution. For this process a spectrophotometer (Labsystem 
Multiscan MS, Labsystems Helsinki, Finland) was used. A standard curve was set using 
commercially available software (CurveExpert Professional, 2.3.0) and results were 
calculated accordingly. 
	
Statistical	analysis	
 
Statistical analysis was performed with software (GraphPad Prism 5.0, GraphPad 
Software, San Diego, CA, USA). For each test, a p-value of less than 0.05 indicated 
statistical significance. The normality of the distributions was evaluated by the Shapiro-
Wilk test. 
The correlation between aldosterone and serum creatinine or SBP was tested with the 
Spearman test, examining all the samples at all times. 
Mann-Whitney's non-parametric test was used to compare aldosterone concentration 
among the following pairs of groups: 
• Cats at risk ("At risk") vs nephropathic cats (independently of the IRIS stage, "CKD" 
group). 
• A group of "stable" subjects vs. group of defined "progressive" subjects, based on the 
information obtained in the months following the inclusion; Progression was defined as 
passing to a higher IRIS stage. 
• Group of normotensive ("NT") vs. Hypertensive ("HT") subjects; For the purposes of 
this study, hypertension has been defined as cats with a constant pressure of more than 
150 mmHg. 
The non-parametric test of Kruskal-Wallis has been used to compare aldosterone 
concentration in three or more groups: 
•  Groups divided by IRIS classification. 
• Cats normotensive at risk vs. normotensive nephropathy cats ("CKD NT") and 
hypertensive nephropathy cats ("CKD HT"). 
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Using the data obtained in subjects with more than one sampling over time, the 
nonparametric Wilcoxon signed ranks test was used to compare the concentration of 
aldosterone obtained at inclusion ("T0") and after 6 or 12 months ("T6-12") for both at risk 
and for nephropathic (CKD) subjects. 
For each group median, range, I, and IV interquartile, mean, and standard deviation were 
calculated.  
 134 
Results	and	discussion	
 
Intra-assay	imprecision	
 
The results of the 5 repeated readings on the two serum pools are shown in Table 48. 
 
Table 48 Values obtained from the intra-assay test on the “low” pool and on the “high” pool 
N° of Reading “Low Pool” (pg/mL)  “High Pool” (pg/mL) 
1 133.2 223.7 
2 145.9 305.3 
3 129.9 314.5 
4 138.4 301.7 
5 144.4 247.6 
 
The “low pool” provided an mean value of 138.2 ± 6.7 pg/mL, corresponding to a 4.8% CV. 
The “high pool” provided an average value of 278.6 ± 40.3 pg / mL, for a CV of 14.5%.  
Linearity under dilution test demonstrated poor recovery results, yielding mean 
percentages of recovery compared with expected values equal to 9.6% (Table 49) and 
failing to linear distribution (figure 46) 
 
Table 49 Serial dilutions of aldosterone pool with relative observed value (mean of three measurements), 
expected and recovery rate (O/E recovery) 
Dilution Observed (pg/mL) 
Expected 
(pg/mL) O/E (%) 
Undiluted 4476,6 4476,6  
1:2 alto1 328,06 2238,3 14,66 
1:4 alto 100,1 1119,15 8,94 
1:8 alto 38,55 559,575 6,89 
1:16 alto 22,25 279,7875 7,95 
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Figure 46 Graphic representation obtained from linearity under dilution tests. 
 
Excluding the first dilution and considering the 1:2 dilution as the starting point, better 
recovery (mean = 84.5%) (Table 50) and an almost linear distribution were found (Figure 
47). 
 
Table 50 Serial dilutions of aldosterone pool with relative observed value (mean of three measurements), 
expected and recovery rate (O/E recovery), excluding the first dilution and considering the 1:2 dilution as the 
starting point 
Dilution Observed (pg/mL) 
Expected 
(pg/mL) O/E (%) 
Undiluted    
1:2  328,06 328,06  
1:4  100,1 164,03 61,03 
1:8  38,55 50,05 77,02 
1:16 22,25 19,28 115,43 
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Figure 47 Graphic representation obtained from linearity under dilution tests, excluding the first dilution and 
considering the 1:2 dilution as the starting point 
 
Overall, these results show a discrete precision of the ELISA method used in this study. 
The value obtained from the "low pool” is excellent, while the CV obtained from the "high 
pool”, although higher than 5%, considered as the limit of acceptability of many of the 
analytes commonly used in clinical biochemistry, for the ELISA test can be considered 
reliable (Westgard, 2003). Linearity under dilution test showed poor reliability at high 
concentration of aldosterone whereas with lower concentration (at least below 300 pg/mL) 
results can be considered valid. 
	
Population	of	cats	
 
The 57 samples included in this study were collected by 35 cats (16 at risk and19 with 
CKD at the time of inclusion). The list of cats, staging and aldosterone concentration are 
shown in Table 51 whereas data of samples of the same cats collected after 6-12 are 
shown in table 52. 
The majority of them were domestic shorthair cats and 16 (45.7%) were males (1 intact 
male) and 19 (54.3%) females (all castrated). 
At the time of inclusion, cats aged between 7 and 20 years (mean 12.5 years). The 34%, 
the 46% and the 20% of them aged between 5-10, 11-15 and 15-20 years, respectively. 
The mean age in the “At risk” group and in the CKD group was 10.8 and 12.3 years, 
respectively. IRIS staging and aldosterone concentration of cats included in this study are 
shown in Table 51, whereas in Table 52 IRIS staging and aldosterone concentration of 
cats followed for 6-12 months. 
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Table 51 Cats included in the study with breed, age (years), serum creatinine (Crea, mg/dL), IRIS classification 
based on creatinemia (stage Cr), UPC value, IRIS sub-staging based on proteinuria (stage UPC), systolic blood 
pressure (SBP, mmHg), IRIS sub-staging based on SBP (stage Pr) and aldosterone concentration (pg/mL) 
N° Breed Age Crea Stage Cr. UPC Stage UPC SBP  Stage Pr. Aldost. 
1 Shorthair 13 2.21 2 0.05 NP nv nv 12.2 
2 Shorthair 16 1.08 A 0.27  BP 120 AP0 1683.8 
3 Shorthair 10 1.04 A 0.07  NP 130 AP0 55.4 
4 Shorthair 8 1.52 A 0.11 NP nv nv 43.5 
5 Shorthair 20 1.87 2 0.08 NP 230 AP3 5402.1 
6 Shorthair 12 1.5 1 0.04 NP 130 AP0 68.3 
7 Shorthair 13 1.39 A 0.20 BP 120 AP0 128.8 
8 Siberian 9 1.67 2 0.30 BP nv nv 52.7 
9 Siberian 8 1.97 2 0.10 NP AP0 AP0 117.3 
10 Shorthair 14 2.59 2 0.15 NP 160 AP2 18 
11 Shorthair 11 0.79 A 0.24 BP 160 AP2 111.9 
12 Shorthair 8 1.51 1 0.09 NP 200 AP3 148.3 
13 Shorthair 19 6.67 4 0.66 P 130 AP0 1229.9 
14 Shorthair 12 1.04 A 0.06  NP 170 AP2 300 
15 Siamese 12 1.81 2 0.09 NP nv nv 86.2 
16 Shorthair 18 2.88 3 0.39  BP 160 AP2 42 
17 Norwegian 10 1.97 2 0.06 NP 140 AP0 37 
18 Shorthair 8 2.48 2 0.78 P 145 AP0 664.3 
19 Exotic S. 14 1.22 1 0.34 BP 130 AP0 168.3 
20 Siamese 18 1.96 2 0.26 BP nv nv 8.4 
21 Shorthair 15 1.9 2 0.16 NP 160 AP2 46.7 
22 Shorthair 10 4.44 2 0.10 NP 145 AP0 90.4 
23 Shorthair 10 1.64 A 0.25 BP 120 AP0 223.8 
24 Shorthair 13 1.36 A 0.26 BP 130 AP0 30 
25 Shorthair 15 1.99 2 0.18 NP 140 AP0 163.7 
26 Shorthair 14 1.54 A 0.05 NP 140 AP0 22.6 
27 Chartreux 7 2.14 2 0.07 NP 120 AP0 101.6 
28 Maine Coon 7 1.44 A 0.04 NP 130 AP0 100.9 
29 Persian 8 1.48 A 0.06 NP nv nv 924.8 
30 Shorthair 8 1.02 A 0.30 NP nv nv 63.6 
31 Shorthair 8 0.91 A 0.07 NP 120 AP0 6.2 
32 Shorthair 11 1.28 A 0.14 BP 130 AP0 178 
33 Shorthair 14 1.29 A 0.16 NP nv nv 269.5 
34 Shorthair 13 1.16 A 0.16 NP nv nv 608.4 
35 Shorthair 19 3.19 3 0.06 NP 130 AP0 253.4 
nv: not available; A: at risk; NP: non-proteinuric; BP: borderline proteinuric; P: proteinuric; nf: no follow-up; AP0: systolic 
blood pressure (SBP) <150 mmHg; AP1: SBP= 150-159 mmHg; AP2: SBP=160-179 mmHg; AP3: SBP >180 mmHg 
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Table 52 Cats included in the study with breed, age (years), serum creatinine (Crea, mg/dL), IRIS classification 
based on creatinemia (stage Cr), UPC value, IRIS sub-staging based on proteinuria (stage UPC), systolic blood 
pressure (SBP, mmHg), IRIS sub-staging based on SBP (stage Pr) and aldosterone concentration (pg/mL) 
N° Breed Age Crea Stage Cr. UPC Stage  UPC SBP Stage Pr Aldost. 
1 Shorthair 13 2.04 2 0.12 NP nv nv 76.4 
2 Shorthair 16 1.17 A 0.20 BP 120 AP0 3940.6 
6 Shorthair 12 1.62 2 0.15 NP 130 AP0 71.7 
7 Shorthair 13 1.64 2 0.32 BP nv nv 90.7 
8 Siberian 9 1.99 2 nv nv nv nv 100.5 
9 Siberian 8 3.45 3 0.04 NP 140 AP0 831.4 
11 Shorthair 11 1.28 1 0.11 NP nv nv 139.5 
14 Shorthair 12 1.39 A 0.06 NP 200 AP3 396.6 
16 Shorthair 18 5.31 4 0.16 NP 160 AP2 33.1 
19 Exotic S. 14 0.8 A 0.19 NP 150 AP1(wch) 2073 
23 Shorthair 15 2.53 2 0.69 P 110 AP0 114.9 
24 Shorthair 10 1.58 A 0.04 NP 140 AP0 137.2 
25 Shorthair 10 1.4 A 0.09 NP 130 AP0 71.5 
26 Shorthair 13 1.8 2 0.18 NP 190 AP3 29 
27 Shorthair 15 2.55 2 0.36 BP 125 AP0 84.2 
29 Maine Coon 7 1.5 A 0.01 NP 110 AP0 93.3 
30 Persian 7 1.73 2 0.03 NP nv nv 409.9 
31 Shorthair 8 1.03 A 0.24 BP 140 AP0 243.6 
32 Shorthair 8 0.78 A 0.06 NP 110 AP0 33 
33 Shorthair 8 1.07 A nv nv 130 AP0 124.1 
34 Shorthair 11 1.37 A 0.17 NP nv nv 1298.5 
35 Shorthair 13 3.86 3 0.57 P nv nv 196.1 
nv: not available; A: at risk; NP: non-proteinuric; BP: borderline proteinuric; P: proteinuric; nf: no follow-up; 
AP0: systolic blood pressure (SBP) <150 mmHg; AP1: SBP= 150-159 mmHg; AP2: SBP=160-179 mmHg; 
AP3: SBP >180 mmHg; wch: whithe-coat hypertension 
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Comparisons	based	on	serum	creatinine	
 
Grouping all samples (irrespective of time of collection) according to the presence of CKD, 
there was no significantly difference for urinary aldosterone concentration (P=0.192) 
between At risk group and CKD group (Figure 48 and Table 55). 
 
Table 53 Descriptive statistics of the groups At risk and CKD 
     At risk (n=26) CKD (n=13) 
Minimum 6,2 8,4 
25% Percentile 61,5 46,7 
Median 133,0 90,7 
75% Percentile 449,6 168,3 
Maximum 3941,0 5402,0 
 
 
 
Figure 48 Graphical distribution of aldosterone concentration in cats At risk and cats with CKD 
 
Using samples collected at the time of enrollment in the study, no significant difference 
was found for the concentration of aldosterone (P = 0.632) comparing the at risk cats with 
CKD-affected cats. The results obtained are shown in Table 54 and graphically 
summarized in Figure 49. 
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Table 54 Descriptive statistics of the cats At risk and cats with CKD using samples collected at the time of 
enrollment 
 At risk (n=16) CKD (n=19) 
Minimum 6,2 12,2 
25% Percentile 55,4 49,7 
Median 111,9 101,6 
75% Percentile 300,0 210,9 
Maximum 1684,0 5402,0 
 
 
 
Figure 49 Graphical distribution of aldosterone concentration in cats At risk and cats with CKD using samples 
collected at time of inclusion  
 
These data suggested that the presence of nephropathy may not induce significant 
changes in the concentration of aldosterone in the cat. This hypothesis will be verified 
subsequently in statistical control between IRIS stage groups, where it will be assessed 
whether the distribution is also dependent on the severity of nephropathy. 
It is important to underline that some subjects included in “At risk” group showed signs of 
nephropathy in the months following the enrollment in the study (6 to 12 months later). 
Therefore, it was considered useful to repeat the analysis in group of samples collected at 
T0 and exclude the cats whose evolution after the collection was unclear (e.g. by refusing 
the owner to participate in the monitoring). The aim of this analysis was to include in the 
"At Risk" group only the actually healthy subjects and perform a better comparison with the 
CKD cats. Also in this case, the statistical comparison between the two groups did not 
show any significant difference (P = 0.598). The descriptive statistics of the "At risk" group 
and the graphical view of the new comparison are shown in Table 55 and Figure 50, 
respectively.  
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Table 55 Descriptive statistics of the cats At risk collected at the time of enrollment excluding the cats whose 
evolution after the collection was unclear. 
 At risk (n=11) 
Minimum 6,2 
25% Percentile 38,3 
Median 86,2 
75% Percentile 189,5 
Maximum 1684,0 
 
 
 
Figure 50 Graphical distribution of aldosterone concentration in cats At risk and cats with CKD  using samples 
collected at time of inclusion and the cats whose evolution after the collection was unclear 
 
With this latter analysis, although the mean and median of the "At risk" group have been 
reduced, the distribution remains still influenced by an "outlier", corresponding to Cat No. 
2, having aldosterone concentration of 1683.8 pg/mL. In a recent study, the median value 
obtained in healthy non-hypertensive cats was 45.4 pg/mL (interquartile range: 19.6-65.0) 
(Jepson et al., 2014). The concentrations obtained in our clinically healthy cats seemed to 
be slightly higher and could justify the absence of significance among the two groups in 
our study. However, a different method has been used in the study of Jepson and 
collaborators (i.e. radio-immunoassay) and intrinsic analytical differences could justify this 
difference, which can only be investigated performing a method comparison study 
between the two methods.  
 
The reason for the presence of high level of aldosterone in one cat in the “at risk” group is 
difficult to explain. The same subject produced a similarly high aldosterone value in the 
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second sampling after 12 months, therefore it is unlikely that this result is an analytical 
outlier but it is probable that aldosterone was actually high. In veterinary literature, high 
aldosterone values were recorded in primary hyperaldosteronism. Cats with primary 
hyperaldosteronism are generally adults or elderly, and clinical examination shows 
weakness, cervical ventroflexion and dysphagia (Schulman, 2010). Although this cat did 
not show any particular clinical symptoms at the time of sampling and the other laboratory 
parameters were normal and not compatible with hyperaldosteronism, it was not possible 
to exclude the presence of an early stage of this disease, which is normally rare in the cat.  
In addition, previous studies reported the influence of diet on aldosterone concentration. 
Cats fed with a poor sodium diet tend to have aldosterone values higher than those taking 
normal sodium and in a previous study it was shown that the increase could be of 30-fold 
(Yu and Morris, 1998). In our study, the diet was not considered but it is interesting to note 
that the sodium level was low at the time of sampling collection (data not shown). Despite 
that, in subsequent controls (with high aldosterone concentration still present) sodium 
returned within the reference range. Therefore, it is not possible to exclude that the diet 
may have contributed to the variability of serum aldosterone concentration but it is 
considered unlikely. 
 
Considering the CKD group (both for samples at T0 and irrespective of collection time), 
aldosterone concentration had a homogeneous distribution of values with the exception of 
a subject (Cat No. 5) with a significantly higher concentration than the other cats under 
study. This cat was classified as IRIS 2 stage and the SBP was very high (230 mmHg). 
However, no follow-up data was available and white-coat hypertension could not be 
excluded.  
These values are similar to those obtained in the recent study mentioned above, where 
the median values of 84.1 pg/mL (interquartile range: 33.6-137.8 pg/mL) was found in 
nephropatic and normotensive cats, and the median values of 149.8 pg / mL (interquartile 
range: 103.1-228.7 pg/mL) was found in nephropatic and hypertensive cats (Jepson et al., 
2014). 
 
Cats classified according to the IRIS stages on serum creatinine, showed no significant 
difference (P = 0.238) between groups, including samples collected at different times in 
the analysis. Results are shown in Table 56 and graphically summarized in Figure 51. In 
this analysis the cats in IRIS stage 3 and 4 were few in number (2 IRIS 3 cats and 1 cat in 
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IRIS 4 stage), therefore, we grouped them in a single group (IRIS 3-4 group) in order to be 
dimensionally comparable to other groups. 
 
Table 56 Descriptive statistics of the cats grouped  according to IRIS staging for serum creatinine. Results of 
cats at IRIS stage 3 and 4 are joined.  
 At risk (n=26) IRIS 1 (n=4) IRIS 2 (n=21) IRIS 3-4 (n=6) 
Minimum 6,2 68,3 8,4 33,1 
25% Percentile 61,5 86,1 41,8 39,8 
Median 133,0 143,9 86,2 224,8 
75% Percentile 449,6 163,3 116,1 931,0 
Maximum 3941,0 168,3 5402,0 1230,0 
 
 
 
Figure 51 Graphical distribution of aldosterone concentration in cats grouped according to IRIS staging based 
on serum creatinine (cats at IRIS stage 3 and 4 are joined) 
 
It is possible to note a tendency of aldosterone to have greater concentrations in the 
advanced stages of CKD (IRIS 3 and 4 stages), although the higher median in IRIS 2 is 
attributable to the presence of single cases with a significantly higher concentration in one 
cat and few number of samples were included in IRIS 3-4.  
 
In this study, the correlation between creatinine and aldosterone (Figure 19) was not 
statistically significant (P = 0.166, r= -0.14), confirming the absence of effect of 
nephropathy on the concentration of aldosterone. 
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Figure 52 Graphical representation of the correlation between serum creatinine and aldosterone 
 
In summary, the absence of correlation between serum creatinine and aldosterone and the 
absence of significant differences in aldosterone levels between "A" risk and CKD 
suggested that, at least in our population of study, the serum aldosterone concentration is 
not influenced by the presence of nephropathy. 
 
Comparison	based	on	the	progression	of	CKD	
 
We verified whether the few available data on cats follow-up included in the study could be 
useful in identifying a possible role of aldosterone as an early marker of renal disease. 
To this aim, cats at risk were subdivided into groups depending on whether they had 
developed or not renal failure in 6-12 months after the first sample collection. 
This comparison, shown in Table 57 and graphically represented in Figure 53, did not 
reveal a significant difference between the groups (P = 0.330). 
 
 
Table 57 Descriptive statistics of cats at risk that remained stable or progressive over time (6-12 months) 
 Stable (n=8) Progressive (n=4) 
Minimum 6,2 55,4 
25% Percentile 33,4 73,7 
Median 82,2 214,4 
75% Percentile 161,5 768,6 
Maximum 223,8 924,8 
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Figure 53 Graphical distribution of aldosterone values obtained at time of inclusion in cats at risk that remained 
stable or progressive over time (6-12 months) 
 
Moreover, we verified the progression of aldosterone concentration in those subjects 
where a second sampling was obtained. Specifically, values obtained in zero time and 
after 6 months or 12 months were compared.  
A first analysis was performed with subjects that were classified as At Risk at the time of 
enrolment. The results showed no significant differences (P = 0.547) as shown in Table 58 
and Figure 53. Figure 54 shows the same results but focusing on aldosterone values 
below 300 pg/dL. 
 
Table 58 Descriptive statistics of results obtained at time zero (T0) and after 6 or 12 months (T6-12) in cats at 
risk 
 T0 (n=8) T6-T12 (n=8) 
Minimum 6,2 8,0 
25% Percentile 38,4 76,9 
Median 106,4 130,7 
75% Percentile 212,4 217,6 
Maximum 1684,0 4575,0 
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Figure 54 : Graphical distribution of aldosterone values obtained at time zero (T0) and after 6 or 12 months (T6-
12) in cats at risk 
 
 
 
Figure 55 Graphical distribution of aldosterone values obtained at time zero (T0) and after 6 or 12 months (T6-
12) in cats at risk (focused on aldosterone <300 pg/ml) 
 
In this group of subjects there was a cat (No. 2) that has developed nephropathy in 12 
months. Excluding this subject, the absence of statistical difference between the two times 
(P = 0.937) remains and the findings are described in Table 59 and shown graphically in 
Figure 56, focusing on aldosterone charts minus 300 pg/dL 
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Table 59 Descriptive statistics of results obtained at time zero (T0) and after 6 or 12 months (T6-12) in cats at 
risk after exclusion of subject No. 2 
 T0 (n=7) T6-T12 (n=7) 
Minimum 6,2 8,0 
25% Percentile 30,0 71,5 
Median 111,9 124,1 
75% Percentile 223,8 139,5 
Maximum 1684,0 4575,0 
 
 
 
Figure 56 Graphical distribution of aldosterone values obtained at time zero (T0) and after 6 or 12 months (T6-
12) in cats at risk after exclusion of subject No. 2 (focused on aldosterone <300 pg/ml) 
 
 
The trend of aldosterone concentrations that can be appreciated by observation of this last 
graph could be considered an estimate of biological variability in healthy cats. However, 
with the data available, it is not possible to calculate a coefficient of variation applicable to 
other future studies since evaluation of the biological variability was not one of the 
objectives of this study and further studies with more specific study design and criteria of 
inclusion are needed to evaluate this type of variability. 
 
The subjects who were classified as CKD at the time of enrolment were also examined. 
There was no significant difference (P = 0.966) between the concentration of aldosterone 
measured at inclusion and after 6-12 months, as shown in Table 60 and in Figure 57.  
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Table 60 Descriptive statistics of results obtained at time zero (T0) and after 6 or 12 months (T6-12) in cats with 
CKD 
 T0 (n=11) T6-T12 (n=11) 
Minimum 12,2 29,0 
25% Percentile 52,7 76,4 
Median 128,8 100,5 
75% Percentile 300,0 409,9 
Maximum 924,8 831,4 
 
 
 
Figure 57 Graphical distribution of aldosterone values obtained at time zero (T0) and after 6 or 12 months (T6-
12) in cats with CKD 
 
Also in this group there was a subject (n ° 9) who, in 12 months, experimented an 
worsening of the disease, moving to a subsequent IRIS stage (from Stage 2 to Stage 3). 
Excluding this subject, there is no statistical difference between the two times (P = 0.556) 
and the results are described in Table 61 and shown graphically in Figure 58. 
 
Table 61 Descriptive statistics of results obtained at time zero (T0) and after 6 or 12 months (T6-12) in cats with 
CKD after exclusion of subject No. 9 
 T0 (n=10) T6-T12 (n=10) 
Minimum 12,2 29,0 
25% Percentile 45,2 75,2 
Median 146,3 95,6 
75% Percentile 422,4 399,9 
Maximum 924,8 475,0 
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Figure 58 Graphical distribution of aldosterone values obtained at time zero (T0) and after 6 or 12 months (T6-
12) in cats with CKD after exclusion of subject No. 9 
 
 
Comparing the graph in Figure 55 with the one in Figure 56, and the chart in Figure 57 and 
Figure 58, it is worth to note that the only two cases with worsening of health status (one 
for the population at risk, moving from " At risk” to Stage 2 and one for CKD group, moving 
from Stage 2 to 3) showed a marked increase in aldosterone concentration over time, with 
greater variation compared with the other stable cases. Based on these two individual 
cases it is not possible to provide definitive conclusions, however it is likely that these 
increases over time in cats with active nephropathy are consistent with what was observed 
in the previous analysis, where, although not significant, a tendency to have higher 
aldosterone concentration in subjects with more severe CKD was found.  
It is also not possible to exclude analytical outliers that could be affected this specific 
analysis and could be avoided by double measurements. Therefore, more assessments 
are needed with more case with progressive disease to further evaluate these preliminary 
results. 
 
Comparisons	based	on	SBP		
 
Aldosterone was not significant different grouping samples according to the presence of 
CKD and HT (P = 0.142) (using a cut-off of 150 mmHg) as shown in Table 62 and shown 
in Figure 59. 
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Table 62 Descriptive statistics of the different groups divided according to systolic blood pressure (SBP) and 
presence of CKD. 
 
 At risk NT 
(n=22) 
At risk NT 
(n=4) 
CKD HT 
(n=14) 
CKD HT  
(n=7) 
Minimum 6,2 111,9 37,0 18,0 
25% Percentile 52,4 158,9 81,1 29,0 
Median 126,5 348,3 116,1 42,0 
75% Percentile 354,2 1654,0 356,1 148,3 
Maximum 3941,0 2073,0 1230,0 5402,0 
NT: normotensive (SBP<150 mmHg); HT: hypertensive (SBP>150 mmHg) 
 
 
Figure 59 Graphical distribution of aldosterone in cats grouped according to the health status (At risk vs CKD) 
and the presence of hypertension (lower or higher 150 mmHg). NT: normotensive; HT: hypertensive 
 
Such results suggest the absence of any relationship between hypertension and serum 
aldosterone in the cat. As a further confirmation of this hypothesis, no significant 
correlations (P = 0.213, r = 0.168) between systolic pressure values and aldosterone 
levels were found (Figure 60). 
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Figure 60 Graphic representation of the correlation between systolic blood pressure (SBP) values and 
aldosterone  
 
One of the goals of this study was to use aldosterone to differentiate white-coat 
hypertension from true hypertension. According to results of our population, this biomarker 
do not have any utility for such aim. 
In a recent study, it is reported that in some hypertensive cats ACE inhibitors did not cause 
aldosterone (and renin) changes after the onset of therapy. This goes to support the fact 
that hypertension in the nephropathic cat might not be directly (or completely) caused by 
the activation of the RAAS system (Jepson et al., 2014), and the results of our study seem 
to be in accordance with this hypothesis. 
 
Comparisons	based	on	Proteinuria		
 
Aldosterone did not significantly differed (P=0.227) between samples classified according 
to IRIS sub staging of proteinuria (figure 61). In table 63 the descriptive statistic is shown. 
Table 63 Descriptive statistics of the different groups divided according to proteinuria. 
 
 NP (n = 37) BP (n = 14) P (n = 4) 
Minimum 6,2 8,4 114,9 
25% Percentile 45,1 50,1 135,2 
Median 93,3 120,4 430,2 
75% Percentile 284,8 228,8 1089,0 
Maximum 5402,0 3941,0 1230,0 
NP: non-proteinuric; BP: borderline proteinuric; P: proteinuric 
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Figure 61 Graphical distribution of aldosterone cats grouped according to IRIS staging for proteinuria (NP: non-
proteinuric; BP: borderline proteinuric; P: proteinuric) 
 
No significant correlation (P=0.533) was found between UPC and aldosterone (Figure 62) 
 
 
Figure 62 Graphic representation of the correlation between urinary protein-to-creatinine (UPC) ratio and 
aldosterone 
 
These results, again, confirm that the pathogenicity of proteinuria in cat is different from 
that of other species, in particular to the dog where this alteration is mainly depends on 
glomerulopathy, which not only results in loss of proteins with the urine, but also triggers a 
pathophysiologic mechanism that induces RAAS activation and hypertension. The kidney 
disease in the cat has a prevalent tubule-interstitial component and this makes the 
proteinuria not particularly frequent and severe as demonstrated in the case study  
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4.4	Urinary	alpha-1	microglobulin	
 
Introduction	and	aims	
 
Feline CKD is mainly characterized by interstitial inflammation and tubular injury 
(McLeland et al., 2015). Several markers of tubular damage have been evaluated urine of 
cats with CKD. N-acetyl-beta-D-glucosaminidase (NAG) index (Sato et al., 2002) and 
retinol-bonding protein (RBP) (van Hoek et al., 2008; van Hoek et al., 2009; Jepson et al., 
2009) have been correlated to the development of azotemia and tubular damage, 
respectively; lower levels of uromodulin (Ferlizza et al., 2015) and cauxin (Miyazaki et al., 
2007; Jepason et al., 2010; Ferlizza et al., 2015) and higher cystatin C (Ghys et al., 2014) 
were also demonstrated in cats with CKD. Alpha-1 micorglobulin (A1MG) is a protein that 
is produced by the liver as alpha-1-microglobulin/bikunin precursor (AMBP) and, due to 
the low molecular weight (that is 26.000 Da), is able to freely pass the glomerulus 
(Akerström et al., 2000). 
In people, urinary A1MG is a valuable tool to estimate tubulointerstitial damage and it may 
precede albumin excretion (Penders and Delanghe, 2004). It was shown that high urinary 
A1MG have predictive value for both remission and progression of certain types of CKD 
(Pfleiderer  et al., 1992; Bazzi et al., 2001; Shore et al., 2010; Robles et al., 2013)  
Also in dog A1MG was shown to increase as the CKD progress (Vinge et al., 2010) bu 
there are no studies evaluating A1MG in cats with CKD 
The aim of this study was to validate a commercially available ELISA kit for quantification 
of A1MG in feline urine by investigating intra-assay variability, linearity under dilution, 
spiking recovery and to evaluate this biomarker in a group of cats with or without tubular 
damage and CKD  
 
Material	and	methods	
Selection	of	the	samples	
 
Thirty-four urine samples belonging to cats were included. These patients were selected 
among the cats evaluated with sodium dodecyl sulfate-agarose gel electrophoresis (SDS-
AGE) study described above.  
The results of SDS-AGE preliminary evaluation were used to identify 2 samples without 
and one sample with tubular bands (TBs). These samples were deemed to be useful to 
the validation purpose because the presence of TBs could be theoretically suggestive of 
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tubular damage and in turn likely suggestive of presence low molecular weight proteins 
and likely of alpha1-microglobulin (A1M); conversely the absence of such bands could 
suggest the absence of A1M. 
 
Measurement	of	alpha1-microglobulin	and	validation	of	ELISA	kit	
 
The ELISA kit evaluated in this study (Cat α1-Microglobulin ELISA Kit – Mybiosource, San 
Diego, CA, USA) was a quantitative sandwich ELISA. As stated by the manufacturer, 
ELISA stripplate wells were coated with purified anti-A1MG antibodies, the detection range 
was from 3,12 µg/mL to 100 µg/mL and the analytical sensitivity was 1 µg/mL. No 
information was available regard the target epitopes. 
The day before analysis aliquots were gently thawed overnight at +4°C and were warmed 
at room temperature one hour before the procedures.  
Intra-assay variability was assessed by testing one sample with TBs and one sample 
without TBs 5 times (5 wells each) and both samples were distributed in 2 different strips 
in order to evaluate also the variability due to pipetting. Mean, standard deviation and 
coefficient of variation (CV) were calculated.  
Linearity under dilution (LUD) test was performed by serially diluting the sample with TBs 
and one sample without TBs by a twofold dilution scheme (i.e 1:2, 1:4, 1:8 and 1:16) using 
the ELISA kit diluent. Also two other dilution protocols were evaluated, diluting the sample 
with TBs 20, 40, 60 and 80% using the ELISA kit diluent and distilled water. Spiking 
recovery test (SRT) was performed by adding to the samples without TBs the ELISA kit 
diluent, the standard 1 (3,12 µg/mL), the standard 3 (12,5 µg/mL) and the standard 6 (100 
µg/mL ) by a 1:10 ratio (90 µL of sample + 10 µL of spike). 
In the second session of work, all the remaining samples (32 samples) were than assayed. 
In each run, the diluent (used as blank solution) and the six standards (ranging from 3,12 
µg/mL to 100 µg/mL) provided by the manufacturer were set in duplicate to calibrate the 
ELISA kit. Plate was washed with an automatic washing instrument (BioRad Microtech, 
Segrate, Milan, Italy), suctioning and applying the wash buffer solution for a total of 4 
consecutive times. Absorbance was measured within 30 minutes by an automatic 
spectrophotometer reader (Labsystem Multiscan MS, Labsystems Helsinki, Finland). The 
best calibration curve was obtained by setting the absorbance of calibrators in 
commercially available software (CurveExpert Professional, 2.3.0). Results were 
expressed as µg/mL and calculated with the equation of calibration curve using Excel 
software.   
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Results obtained by the LUD and SRT tests were evaluated by linear regression analysis. 
Also, the percentage of recovery of each dilution n both tests was calculated according to 
the formula:  
recovery (%) = mean observed / expected X 100. 
For samples results, the ratio between the A1MG concentration (µg/mL) and the urinary 
creatinine (mg/dL) measured at the time of inclusion (“uA1MG/uC”) was calculated in order 
to normalize the A1MG concentration to the urine dilution. 
	
 
Statistical	analysis	
 
Difference in urinary A1MG concentration and uA1M/uC between the group of cats with 
TBs and groups of cats without the TBs (identified by SDS-AGE) were calculated with 
Mann-Whitney test  
 
Results	and	discussion	
 
Among the 34 samples, 10 had TBs (6 in a mixed pattern and 4 in a tubular pattern).  
The sample with and the sample without TBs resulted in a mean ±SD A1MG of 25.67 
±5.31 µg/mL and 34.32 ±7.13 µg/mL, respectively. CVs were 20.7 for the sample with TBs 
and 20.8 for the sample without. 
LUD tests failed to fit linearity in all dilution protocols and with both types of diluent (Figure 
63). Specifically, the dilution protocol from 1:2 to 1:16 yielded recovery from 29.8% to 
207.2% (mean: 101.4 %) for sample with TBs and from 29.9% to 240.1% (mean: 108.0%) 
for sample without TBs (table 6664 the dilution protocol from 20% to 80% with ELISA 
diluent yielded 12.4% to -44.4% recovery (mean: -3.0%) and the dilution protocol from 
20% to 80% with bi-distilled water yielded 78.4% to 131.3% recovery (mean: 256.7%) 
(Table 65).  
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Figure 63 Linearity under dilution results. Top left: the dilution protocol from 1:2 to 1:16 for sample with TBs. 
Top right: dilution protocol from 1:2 to 1:16 for sample without TBs. Bottom left: dilution protocol from 20% to 
80% with ELISA diluent yielded. Bottom right: dilution protocol from 20% to 80% with bi-distilled water yielded  
 
 
Table 64 Serial dilutions of the samples with tubular bands (TBs) and sample without TBs. Measured values, 
expected values and recovery rate (O/E recovery) are shown 
 
 TBs 
 
 No TBs 
 
Dilution 
Measured 
(µg/mL) 
Expected 
(µg/mL) 
O/E  
(%) 
Measured 
(µg/mL) 
Expected (µg/mL) 
O/E  
(%) 
Undiluted 46,70 46,7 
 
55,44 55,44 
 
1:2 6,96 23,3 29,8 8,31 27,72 29,9 
1:4 6,47 11,8 54,8 7,48 13,86 53,9 
1:8 6,71 5,9 113,7 7,48 6,93 107,9 
1:16 6,01 2,9 207,2 8,31 3,46 240,1 
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Table 65 Serial dilution of the sample with tubular bands (TB) from 20% to 80% with ELISA diluent and distilled 
water yielded. Measured values, expected values and recovery rate (O/E recovery) are shown 
 
ELISA diluent Distilled water 
Dilution Measured Expected O/E (%) Measured Expected O/E (%) 
100% 45,30 45,30 
 
42,08 42,08 
 
80% 5,62 36,24 15,50 32,98 33,66 97,9 
60% -0,96 27,18 -3,5 36,97 25,24 146,4 
40% -1,23 18,12 -6,7 48,53 16,83 288,3 
20% -1,68 9,6 -17,5 47,43 9,6 494,1 
 
Also SRT showed lack of linearity (Table 66 and Figure 64).  
 
Table 66 Spike recovery test results. Measured and expected values are shown 
 Measured Expected 
NoTB + Diluent 18,34 56,40 
NoTB + Standard 1 13,74 56,71 
NoTB + Standard 3 17,01 57,65 
NoTB + Standard 3 18,45 66,40 
 
 
  
Figure 64 Graphical representation of spiking recovery test. 
 
No significant differences was found between samples with TBs and samples without TBs 
(Figure 65 and Table 67), nether with urinary A1MG concentration (P=0.164) nor with 
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A1M/uC (P= 0.622). Given the validation test results, these results were considered 
unreliable. 
 
Table 67 Descriptive statistics (median and min-max range) of alpha-1 microglobulin (a1MG) and alpha-1 
microglobulin-to-creatinine ratio (a1MG/uC) in samples without tubular bands (No TBs) and with tubular bands 
(TBs) 
	 a1MG	(μg/mL)	 a1MG/uC	
Group	 Median	(μg/mL)	 Min-max	(μg/mL)	 Median		 Min-max	
No	TBs	 40.83	 27.48-62-67	 0.21	 0.08-1.54	
TBs	 35.19	 25.57-59-43	 0.16	 0.06-1.32	
 
 
 
Figure 65 Graphical representation of distribution of alpha-1 microglobulin (left) and alpha-1 microglobulin-to-
creatinine ratio (right) in samples without tubular bands (No TBs) and with tubular bands (TBs). Box plots 
represent the interquartile range (IQR), and the horizontal line represents the median value of each group. 
Whiskers extend to the minimum and maximum values. 
 
In order to investigate the possible reasons of the failure in all the validation tests, the 
content of standard of the kit with the higher A1MG concentration (standard n° 6) was 
assayed with SDS-AGE (see SDS-AGE study below for method description). The standard 
yielded a strong band with a molecular weight corresponding to that of albumin and two 
weak bands in the high molecular weight area of the gel but any bands were detected in 
the low molecular weight area of the gel where A1MG was expected (Figure 66). A band 
with the MW of A1MG was not detected in our standard. Therefore it was suspected that 
the A1MG ELISA kit purchased and used in this study was not correctly produced or the 
specifications declared from the manufacturer did not correspond to the real 
characteristics.This possibility was demonstrated in an other published study in dogs, 
where the presence of albumin instead of the right biomarker (procalcitonin) was 
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demonstrated in the standard of the ELISA kit evaluated by the authors (Floras et al., 
2014). However, the evaluation with SDS-AGE could not be sensitive enough to detect 
A1M, which could be present in a lower concentration than the limit of sensitivity of SDS. 
Moreover the addition of other proteins in standard solution is allowed in order to mimic 
the content of the original matrix. 
 
 
Figure 66 SDS-AGE of control sample (“C”, with indication of molecular weight) and the standard 6 (S) of the 
ELISA kit 
 
Therefore, a preliminary evaluation with Western-blot analysis was performed. The same 
standard (standard n° 6) was run and the secondary antibody provided with the ELISA kit 
(rabbit anti-cat A1MG antibody) was used to detect. Than an antibody toward the FC 
portion of rabbit antibody (human anti-rabbit FC), labeled with fluorescence was used to 
detect. No visible fluorescent bands were detected on the gel. However, the lack of results 
from this western-blot analysis could be due to incorrect dilution protocol of the antibodies 
or also the improper use the antibody provided by the ELISA kit manufacturer in the 
western-blot method. Therefore, further assays are required to evaluate in depth the 
analytical performance of the ELISA kit used in this study.  
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4.5	Urinary	SDS-AGE		
 
Introduction	and	aims	
 
Qualitative evaluation of proteinuria in patient affected by CKD with protein electrophoresis 
allows identification of specific protein patterns which in turn reflect renal injury at various 
segment of the nephron. By this method is possible to identify glomerular, tubular or mixed 
proteinuria. Glomerular proteinuria occurs when the selective permeability of the 
glomerulus is altered, leading to filtration of proteins with middle molecular weight (MMW, 
60–80 kDa) to high molecular weight (HMW; >80 kDa). The presence of only MMW 
proteins in urine, such as albumin, is defined as “selective” glomerular proteinuria, 
whereas HMW proteins, such as IgG indicate “nonselective” glomerular proteinuria (Yalcin 
and Cetin, 2004). Tubular proteinuria is characterized by the presence of low molecular 
weight (LMW; <60 kDa) proteins which normally freely pass the glomerulus and are 
reabsorbed in the proximal tubule (Nabity et al., 2011). When both glomerular filtration and 
tubular reabsorption are disturbed, mixed proteinuria can occur (Zini et al, 2004).  
In dogs, good sensitivity of urinary electrophoresis for the identification of tubular damage 
was shown (Zatelli et al., 2003; Zini et al., 2004; Zaragozza et al., 2003). Specifically when 
compared to histopathology, sensitivity for both glomerular and tubular damage was 100% 
and 92%, respectively, whereas the specificity was lower (40-62%) (Zatelli et al., 2003). In 
addition, the presence of proteins with very low MW (12-15 kDa) was associated with 
higher grade of tubular damage on histopathology (Zini et al., 2004). 
The sodium dodecyl sulphate agar gel electrophoresis (SDS-AGE) is easy and relatively 
inexpensive electrophoretic method for qualitative urinary protein investigation.  
It was recently validated at our institution in dogs (Giori et al., 2011) and valuated cats with 
suspected amyloidosis (Paltrinieri et al., 2015) but no information is available about the 
electrophoretic protein patterns in naturally occurring feline CKD. The aim of this study is 
to describe the electrophoretic patterns of proteinuria in cats with CKD using a 
commercially available SDS-AGE method. 
	
Materials	and	methods  
70 samples obtained from 39 cats were included in this study. SDS-AGE was performed 
on urinary supernatants using a commercially available semi-automated analyzer was 
used (Hydrasis, Sebia Italia SRL, Bagno a Ripoli, Firenze, Italy). Electrophoretic gels are 
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supplied by the manufacturer (Hydragel 5 Proteinuria, Sebia Italia SRL, Bagno a Ripoli, 
Firenze, Italy). Five wells were available in each gel and in each run two gels can by load. 
Samples were analyzed after a maximum of 12-months storage at -20°C. The day before 
analysis aliquots were gently thawed overnight at +4°C and were warmed at room 
temperature one hour before the run.  
In each run 9 samples and a control samples were loaded in the two gels. The control 
material was purchased by the manufacturer (Molecular mass control, Sebia Italia SRL, 
Bagno a Ripoli, Firenze, Italy ) and contained proteins with known molecular weight 
(lysoxyme, 14.3 had; triosephosphate isomerase, 26.6 kDa; bovine albumin 66 kDa; and 
human IgG, 150 kDa). 
Procedures were performed according to the manufacture’s instruction. Specifically, after a 
brief vortex of the supernatant, each urine sample was mixed with the diluents included in 
the kit containing SDS and bromophenol blue. The instrument was then prepared by 
mounting the sponges embedded with the appropriate buffer (pH 8.5) on the electrodes 
and by placing two gels on the migration chamber after removal of excess buffer.  
Five µl of urine diluted as above were placed into wells of the gel and the procedure was 
started using the specific program (Proteinuria 1*5).  
The gel was then transferred to the staining module and automatically stained with acid 
violet and washed. After that, gels were manually treated with a solution of glycerin (1:8 in 
distilled water) and dried.  
Gels were then scanned with a commercially available scanner and acquired on the 
computer as JPEG images.  
Gels were visually analyzed and electrophoretic bands of the samples were identified 
comparing with bands of the control sample.  
For each sample, one of the following patterns were assigned: 
• Negative: no bands. 
• Albuminuria: only a band of MW equal to albumin (Figure 67, lane “A”). 
• Glomerular selective: bands with MW lower than IgG and higher or equal to albumin 
(Figure 67, lane “GS”). 
• Glomerular non-selective: bands with MW equal to IgG and higher or equal to 
albumin (Figure 67, lane “Gns”). 
• Tubular: bands with MW lower to albumin with or without albumin bans (Figure 67, 
lane “T”). 
• Mixed: bands lower and higher than albumin (Figure 67, lane “M”). 
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Figure 67 SDS-AGE of urine samples. Lane C: control; lane A: albuminuric; lane Gs: glomerular selective 
pattern; lane Gns: glomerular non selective pattern; lane T: tubular pattern; lane M: mixed pattern 
 
 
Statistical	analysis	
 
Fisher’s exact test was used to verify the null hypothesis that the tubular bands (i.e. 
tubular or mixed patterns) were equally distributed in samples grouped according to the 
healthy status (At risk vs CKD in all samples) and grouped according to proteinuria (NP vs 
BP+P). Commercially available software was used and a P-value of 0.05 was considered 
significant. 
 
Results	
 	
Distribution of IRIS sub-stage for proteinuria in the IRIS staging group (based on serum 
creatinine) were shown in table 68. 
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Table 68 Distribution of IRIS sub-stage for proteinuria in the IRIS staging group (based on serum creatinine) 
 NP BP P total 
At risk 17 9 - 26 
IRIS 1 8 4 - 12 
IRIS 2 15 3 5 23 
IRIS 3 4 1 3 8 
IRIS 4 1 1 - 2 
total 81 18 8  
NP: non-proteinuric; BP: borderline proteinuric; P: proteinuric 
 
Descriptive statistics of urinary protein, UPC ratio and USG in the different IRIS stages are 
shown in table 69. 
 
Table 69 Descriptive statistic of urinary protein, UPC ratio and USG in the different IRIS stages. Median (range) 
are shown. Number of samples are indicated in brackets. 
 IRIS 1 (12) IRIS 2 (23) IRIS 3 (7) IRIS 4 (2) 
UP 35.7 (5.2-61.4) 28.0 (6.1-171.3) 
18.5 
(2.8-39.1) 
7.7 
(4.4-11.0) 
UPC 0.13  (0.04-0.34) 
0.17  
(0.03-0.78) 
0.17 
(0.02-0.71) 
0.20 
(0.16-0.24) 
USG 1048 (1028-1060) 
1034 
(1016-1066) 
1013 
(1008-1025) 
1012 
(1010-1013) 
NP: non-proteinuric; BP: borderline proteinuric; P: proteinuric 
 
In “At risk” group, 3 samples were negative (2 NP, 1 BP), 2 with albuminuria (1 NP, 1 BP), 
18 glomerular selective (11 NP, 7 BP), 2 glomerular non-selective (2 NP), 1 tubular (NP). 
In “CKD group”, 2 samples were negative (1 NP, 1 P), 8 with albuminuria (7 NP, 1 BP), 15 
with glomerular selective pattern (12 NP, 1 BP, 2 P), 1 with glomerular non-selective (NP), 
5 with tubular pattern (1 NP, 2 BP, 2 P) and 13 with mixed pattern (6 NP, 4 BP, 3 P). 
 
The tubular bands were significantly more frequent (P=0.0006) in cats with CKD than in 
cats at risk (figure 68). 
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Figure 68 Distribution of data regarding number of samples with or without tubular bands in cats at risk and cats 
with CKD 
 
Number of samples with tubular bands (tubular or mixed pattern) in the different groups 
dividend according to IRIS staging (including only CKD cats) is graphically displayed in 
figure 69. In figure 70, the distribution of UP, UPC ratio and USG in the same sub-groups 
is shown. 
 
 
 
 
Figure 69 Distribution of data regarding number of samples with or without tubular bands in groups divided 
according to IRIS staging based on serum creatinine 
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Figure 70 Distribution of urinary protein (top), UPC ratio (middle) and USG (bottom) groups divided according to 
IRIS staging and presence of tubular bands (noT: no tubular bands; T: presence of tubular bands 
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Considering all the samples, the tubular bands were also significantly more frequent 
(P=0.025) in proteinuric patients than in non-proteinuric (figure 71). 
 
 
Figure 71 Distribution of data regarding number of samples with or without tubular bands in non-proteinuric 
(NP) group and in the group with UPC>0.2 (BP + P). 
 
This different distribution was also significant (P= 0.0003) taking into account only CKD 
patients (Figure 72).  
 
Figure 72 Distribution of data regarding number of samples with or without tubular bands in non-proteinuric 
(NP) group and in the group with UPC>0.2 (BP + P), including only CKD cats 
 
Distribution of the tubular bands in the different groups divided according to IRIS stage for 
proteinuria (only CKD cats) is graphically displayed in figure 73. 
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Figure 73 Distribution of data regarding number of samples with or without tubular bands in non-proteinuric 
(NP), borderline-proteinuric (BP) and proteinuric (P) group.  
 
 
Discussion	
Proteinuria was not so common in our population of cats with CKD. When present, it was 
mild in magnitude and never exceeded UPC =1. This is in accordance with a previous 
study in which 90% and 49% of cats with CKD had a UPC of <1.0 and <0.25, respectively 
(Syme et al., 2006). 
The presence of proteins with MW equal or higher than albumin was frequent in our 
population. These were found even in the absence of proteinuria (i.e. UPC>0.2) or the 
absence of CKD, suggesting that the specificity is moderate in cats. 
Since the majority of cats at risk having this pattern remained healthy for months after 
urine collection, the presence of these proteins and these patterns should be considered 
normal in cats, at least in the elderly cats at risk to develop CKD. 
It is not possible to exclude early glomerular damage in our population but it is mild and 
uncommon in cats with CKD, especially at early stages (Brown e tal., 2016). 
The presence of proteins with MW higher than albumin is already described in healthy cats 
(Ferlizza et al., 2015). The most abundant are cauxin (Miyazaki  et al., 2003) and 
uromodulin  (Ferlizza et al., 2015) and it is possible that these proteins are responsible of 
these findings in our population. 
The tubular pattern, together to the mixed pattern, was significantly more frequent in CKD 
cats. It is also possible to note that tubular bands were identified at any stage of CKD in 
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our population and it could suggest that tubular damage occurs since the beginning of the 
disease in cats (Chakrabarti et al., 2013). 
In addition, although few samples were included in IRIS stage 3 and 4, low MW proteins 
were relatively more frequent at late stages. Assuming that that the progression of CKD is 
strictly related to the worsening of the tubule-interstitial damage in cats (Brown et al., 
2016), this latter results is in accordance to what found in in dogs with CKD, where the 
presence of low MW proteins (tubular bands) was significantly associated with the grade of 
tubule-interstitial damage (Zini et al., 2004) 
Moreover, the higher frequency of tubular bands detected in proteinuric patients support 
the theory that proteinuria in nephropatic cats is mainly secondary to tubule-interstitial 
damage (Brown et al., 2016). As further confirmation, at any stage the UPC tended to be 
higher in samples with tubular bands compared to samples without tubular bands in the 
same IRIS stage. 
Finally, it is interesting to note that the frequency of tubular damage in borderline-
proteinuric and proteinuric cats is similar. This result suggests that BP in CKD cats need to 
receive more attention.  
However, few samples are included in these groups and further statistical evaluations are 
needed to confirm this hypothesis.  
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General	conclusions	
 
This study had the aim to assess serum and urinary biomarkers usefulness in cats with 
CKD with or without proteinuria and hypertension. 
Evaluation of big-ET1 in serum of cats did not show satisfying results, since very low 
concentration was found in both healthy cats and cats with CKD, but further evaluations 
are needed. Conversely, results in urinary samples were encouraging and, to our 
knowledge, this is the first study validating and detecting this biomarker in urine of cats 
with CKD. The evaluated ELISA method yielded satisfying validation results, supporting its 
introduction in this specie. The association between the urinary levels of Big-ET1 and the 
severity of CKD and proteinuria revealed that it could be a promising aid in nephropathic 
cats, especially at early stages. Moreover, it could shed light on the pathogenesis of 
tubulo-interstitial and glomerular damage in cats with CKD. Hence, it could reflect the 
inflammatory activity of the kidney as demonstrated in humans (Dhaun et al., 2009). 
The enzymatic method for Hcy measurement, previously validated in dogs in our institution 
(Rossi et al., 2013), can be considered reliable also in cats according to the good precision 
and accuracy detected with the validation tests. From a diagnostic point of view, the 
results were however less encouraging in cats with hypertension and CKD when 
compared to other species, since no direct relationship with hypertension was found, 
suggesting that Hcy is not a valuable biomarker for hypertension in these patients. The 
progressive increase of Hcy concentration associated with the progressive increase in 
severity of CKD and the detection of high Hcy in some non-azotemic patients with CKD 
could add a new marker to those currently available for the identification and staging of the 
kidney disease of the cat, even though serum creatinine may provide superimposable 
information and may continue to be preferred to this new test. 
Aldosterone was not associated with CKD and hypertension, although a tendency to 
increase in aldosterone in the most advanced stages of nephropathy was observed. These 
results were partially in accordance with previous studies performed on cats, where RAAS 
activation appeared to be not completely dependent on kidney injury (Steele et al., 2002; 
Jepson et al., 2014). The lack of a relationship with systemic blood pressure confirms that 
the pathogenesis of CKD-associated hypertension is multifactorial and is not caused solely 
by the activation of RAAS (Javadi et al., 2005). Therefore, Aldosterone cannot be 
considered an indicator of hypertension in cats affected with CKD and it is not useful in 
distinguishing real hypertension from white-coat hypertension. However, in the light of our 
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results and results of previous studies, aldosterone quantification can still be considered in 
patients with advanced CKD or in patients with non-responsive hypertension, given the 
possible high concentration in some of these patients. 
The ELISA kit for A1MG measurement failed all the validation tests, therefore results were 
considered unacceptable. Accordingly, this commercially available ELISA could not be 
used, and further studies are needed in order to investigate the presence of A1MG in cats 
with CKD and tubular damage.  
SDS-AGE showed the presence of bands corresponding to proteins with MW higher than 
albumin but lower than IgG in elderly healthy cats. Although an early glomerular damage 
could not be excluded in our population, this pattern appeared to be normal in this specie 
and has to be taken into account in the evaluation of proteinuria in cats. Tubular bands 
were common in patients with CKD at any stage confirming the predominant tubule-
interstitial damage typical of this disease in cats. The presence of this pattern also at early 
stages (such as IRIS 1 and/or non-proteinuric and borderline proteinuric sub-stages) is 
promising and therefore SDS-AGE can be considered a valuable aid in the diagnostic 
approach to feline CKD. However, further studies including higher number of patients with 
early CKD and different urinary tract diseases are necessary to better evaluate the 
diagnostic utility of this test. 
 
 
  
 171 
Scientific	activities	
 
International peer reviewed papers:  
• Giraldi M, Paltrinieri S, Zatelli A. Evaluation of the analytical variability of protein pads 
on canine urine. Veterinary Clinical Pathology. IN PRESS  
• Giraldi M, Rossi G, Paltrinieri S, Bertazzolo W, Scarpa P. Evaluation of the analytic 
variability of urine protein-to-creatinine ratio in cats. Veterinary Clinical Pathology. 
SUBMITTED 
• Paltrinieri S, Giraldi M, Prolo A, Scarpa P, Beccati M, Graziani B, Bo S. Serum 
symmetric dimethylarginine (SDMA) and creatinine in Holy Birman cats compared with 
cats of other breeds. Journal of feline medicine and surgery. IN PRESS 
• Hernandez A, Bilbrough GEA, DeNicola DB, Myrick C, Edwards S, Hammond JM, 
Myers AN, Heseltine J, Russell K, Giraldi M, Nabity MB. Comparison of the 
performance of the IDEXX SediVue Dx® with manual microscopy for detection of cells 
and crystals in urine sediments. Journal of veterinary internal medicine. SUBMITTED 
 
Abstracts:  
- Giraldi M, Rossi G, Scarpa P, Bertazzolo W, Paltrinieri S. Evaluation of proteinuria in 
cats: comparison between Coomassie Brilliant Blue and Pyrogallol red Molybdate. 25th 
ECVIM-CA / 17th ECVCP Congress – Lisbon (Portugal); 9th–12th September 2015  
- Giraldi M, Paltrinieri S, Zatelli A. Evaluation of analytical variability of dipstick in 
identification of proteinuria. 26th ECVIM-CA Congress – Goteborg (Sweden); 8th–10th 
September 2016  
- Giraldi M, Scarpa P, Paltrinieri S. Frequency of electrophoretic changes in urine of old 
cats with or without CKD. 18th ECVCP / ESVONC congress – Nantes (France); 20th–22nd 
October 2016  
- Giraldi M, Rossetti P Vitiello T, Scarpa P. Reproducibility of urinary sediment 
examination: stain versus bright-field and phase-contrast. 27th ECVIM-CA congress – St. 
Julian’s (Malta); 14th–16th September 2017 
- Ruggerone B, Scarpa P, Giraldi M, Paltrinieri S. Reference intervals in Shetland 
sheepdogs: is primary hyperlipidemia a real features in this breed? 26th ECVIM-CA 
Congress – Goteborg (Sweden); 8th–10th September 2016  
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- Scarpa P; Palestrini C; Marelli SP; Giraldi M; Ghiringhelli M; Raja M; Fusi E. How Does 
the Nutritional Assessment of Dogs Vary in a Veterinary Staff? 26th ECVIM-CA Congress 
– Goteborg (Sweden); 8th–10th September 2016  
- Borromeo V, Ocar O, Berrini A, Faverzani S, Rizzi R, Giraldi M, Scarpa P. Development 
and validation of a single blood sampling method of iohexol plasma clearance for the 
assessment of glomerular filtration rate (GFR) in dogs. 71th Convegno SISVET – Napoli 
(Italy); 28th June –1st July 2017 
- Zambarbieri J; Giraldi M, Ruggerone B, Faverzani S; Scarpa P. Symmetric 
dimethylarginine (SDMA) and nephropathy in dog: diagnostic utility in clinical practice. 27th 
ECVIM-CA congress – St. Julian’s (Malta); 14th–16th September 2017 
 
Oral presentations:  
- Giraldi M, Scarpa P. Case report. SIMIV congress – Cremona (Italy); March 7th-8th, 
2015  
- Giraldi M, Patrinieri S, Rossi G, Bertazzolo W, Scarpa P. Evaluation of proteinuria in 
cats: comparison between Coomassie Blue and Pyrogallol Red-Molybdate. Veterinary and 
Animal Science Days – Milan (Italy); 16-17th July 2015  
- Giraldi M, Patrinieri S, Scarpa P. Evaluation of a commercial ELISA for measurement of 
feline urinary alpha1-microglobulin. Veterinary and Animal Science Days – Milan (Italy); 9-
10th June 2016  
 
Lecturer:  
- Participation as speaker in 3 webinars for Farmina pet foods® lecturing about diagnosis 
and treatment of canine and feline chronic kidney diseases  
 
Co-supervision of Degree thesis 
- Stefano Negri: Rosso pirogallolo e blu di coomassie:due colorazioni a confronto per la 
determinazione del rapporto proteinuria/creatininuria (UPC) nel gatto. Thesis 
supervisor: Prof. Paola Scarpa; Thesis co-supervisor: Marco Giraldi. February 2016 
- Paola Rossetti: Riproducibilitá dell’esame del sedimento urinario nel cane: confronto tra 
diversi metodi per la valutazione semiquantitativa di eritrociti e leucociti. Thesis 
supervisor: Prof. Paola Scarpa; Thesis co-supervisor: Marco Giraldi. July 2016 
 173 
- Carola Curcio: Omocisteinemia nel gatto: validazione analitica di un metodo enzimatico 
e indagini preliminari sull’iperomocisteinemi  in gatti nefropatici Thesis supervisor: Prof. 
Saverio Paltrinieri; Thesis co-supervisor: Marco Giraldi. October 2017 
- Alessia Bellintani: Aldosterone nel gatto nefropatico: Osservazioni preliminari Thesis 
supervisor: Prof. Paola Scarpa; Thesis co-supervisor: Marco Giraldi. October 2017 
- Camilla Piazza Thesis supervisor: Prof. Paola Scarpa; Thesis co-supervisor: Marco 
Giraldi. October 2017 
 
Awards: 
Best poster presentation at the 27th ECVIM-CA congress in the section clinical pathology 
(St. Julian’s, Malta; 14th–16th September 2017). 
 
Externship  
I spent two months (June-July 2017) at the department of Veterinary Pathobiology at 
Texas A&M University (Texas, USA) under the supervision of Dr. M. Nabity (dipl. ACVP), 
where I was involved in a research project about the analytical validation of an automated 
analyser of canine and feline urine sediment. I took also part in weekly journal clubs of 
veterinary clinical pathology, seminaries and cytology-histology slide review rounds. 
 
Other activities  
During the three years I spent time in daily practice at the DIMEVET, under the supervision 
of Prof. Paola Scarpa, performing clinical consultations and laboratory works. In this 
period, I managed 186 primary clinical cases (both dogs and cats). I also had the 
opportunity to perform and interpret 636 haematological samples, 176 biochemical panels 
and 91 urine samples of feline and canine patients presented for clinical consultations at 
the DIMEVET, under the supervision of Prof. Saverio Paltrinieri. I also followed veterinary 
students which attended small animal internal medicine clinic and clinical pathology 
laboratory during my PhD period, tutoring them in their clinical and laboratory training.  
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